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Abstract of a thesis submitted in partial fulfilment of the requirements for 
the Degree of Doctor of Philosophy 
 
A study of C-type natriuretic peptide in cerebrospinal fluid and related 
tissues of sheep, and its regulation by dexamethasone 
 
By Michele Odile Wilson 
 
C-type natriuretic peptide (CNP) has high abundance in cerebrospinal fluid (CSF) and central tissues, 
and has been implicated in the regulation of important processes in the central nervous system 
(CNS) including the stimulation of neuronal branching, regulation of blood-brain barrier 
permeability and neuroprotection. Despite the many important putative roles that have been 
attributed to CNP during development and in adult life through in vitro studies, little is known about 
the regulation of CNP in vivo — and its usefulness in clinical settings of pathophysiological CNS 
disorders remains untapped. The aim of this PhD project was to explore the regulation of CSF 
concentrations of CNP and the amino-terminal fragment of proCNP (NTproCNP) in sheep, and 
relate this to central sources. 
 
To determine whether CSF concentrations of CNP peptides are affected by altered levels in plasma, 
concurrent CSF and plasma samples were collected from 15 pregnant sheep throughout the 
gestation period (days 4, 87 and 116) — a time when plasma concentrations become markedly 
increased. Compared with non pregnant sheep (n = 15), plasma concentrations of CNP peptides 
were elevated by 30-fold at days 87 and 116 in pregnant sheep, yet CSF concentrations of CNP and 
NTproCNP did not differ between the groups — which indicated that central levels of CNP peptides 
were independently regulated from those in plasma in sheep. As there were no known compounds 
or physiological setting capable of acutely affecting CSF concentrations of CNP peptides, a series of 
pilot studies was carried out to screen a number of candidate drugs in sheep, and to examine the 
effect of changes in live weight and appetite in red deer stags. Despite the dramatic changes in 
appetite and live weight that occurred throughout the breeding season in red deer stags (> 30 kg 
live weight gain), CSF concentrations of CNP peptides remained stable. Similarly, CNP and 
NTproCNP concentration in CSF of sheep remained unchanged following administration with all 
compounds (including anaesthetics, morphine, a pyrogen and l-deprenyl) except for one; a single 
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i.v. dose of dexamethasone (0.25 mg/live weight) was shown to reliably induce a marked increase 
in CNP and NTproCNP concentration in CSF within 8 h. 
 
Following the successful identification of a secretagogue for CNP, subsequent studies were carried 
out to examine the increases in CNP peptide concentration in CSF and plasma following different 
doses of dexamethasone (0, 0.025, 0.063, 0.125, 0.25 mg/kg live weight), and to associate 
dexamethasone-stimulated increases in peptide levels in CSF with changes in peptide 
concentration and gene expression of NPPC, NPRB and NPRC in tissues sampled from the brain and 
anterior and posterior pituitary glands. Whereas plasma concentrations of CNP peptides were 
increased following all doses of dexamethasone, concentrations in CSF were elevated only at the 
two highest doses. Compared with saline-treated sheep, CNP and NTproCNP content in nervous 
tissue of dexamethasone-treated sheep (0.25 mg/kg, i.v.) was significantly higher throughout the 
brain in 6 and 11 of the 14 tissues considered, respectively. 
 
Gene expression of NPPC was upregulated in several tissues (anterior pituitary gland, posterior 
pituitary gland, hypothalamus, hippocampus and pons), which is supportive of increased synthesis 
of CNP following dexamethasone.  The pituitary gland (anterior and posterior), which is known for 
its enriched levels of CNP content — had a similar concentration of NTproCNP when compared with 
most tissues sampled from the brain. Furthermore, the NTproCNP:CNP concentration ratio in 
pituitary gland (1:1) differed from brain (5:1 to 10:1), suggesting that little CNP degradation occurs 
in the pituitary gland — however the expression of NPRC did not differ between pituitary and brain 
tissue. Gene expression of NPPC was upregulated in both the anterior and posterior pituitary gland 
following dexamethasone, despite no significant increase in CNP or NTproCNP concentration in 
these tissues.  
 
Analysis of the molecular forms present in various fluids and tissues using size-exclusion high 
performance liquid chromatography revealed similar profiles for anterior pituitary gland and 
plasma extracts, whereby proCNP was present, CNP-53 was the prevalent form and CNP-22 was 
virtually absent. Together, these findings suggest that CNP processing differs between brain, 
anterior and posterior pituitary glands and supports the possibility that CNP is secreted directly 
from the anterior pituitary gland into the circulation. The widespread increase of CNP secretion in 
multiple tissues across the brain in response to dexamethasone implicates CNP in glucocorticoid 
actions — possibly related to inflammation or local fluid dynamics mediated by glial cells. These 
findings pave the way for future studies designed to establish the role of CNP in the CNS in normal 
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health in vivo, and to establish a clinical application for this peptide in central settings of 
pathophysiological disorders in the CNS. 
 
Keywords: C-type natriuretic peptide, CNP, NTproCNP, cerebrospinal fluid, CSF, sheep, central 
nervous system, CNS, dexamethasone, glucocorticoids, brain, pituitary  
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Chapter 1. General Introduction 
 
C-type natriuretic peptide (CNP) is a member of the natriuretic peptide family, a group of 
structurally related but functionally distinct peptides. While the heart is the main site of 
production for the cardiac natriuretic peptides (atrial natriuretic peptide: ANP, and brain 
natriuretic peptide: BNP), sources of CNP are widespread. Unlike the other natriuretic peptides, 
CNP circulates at very low concentrations in the blood, leading to the conclusion that CNP acts 
locally in a paracrine/autocrine manner. Indeed, CNP has been shown to be a local regulator of 
bone growth and vasodilation. 
 
Interest in the role of CNP in the central nervous system (CNS) has been growing since CNP was 
discovered in the porcine brain (Sudoh et al. 1990). The widespread distribution of CNP in the rat 
and human brain (Komatsu et al. 1991) and high concentration in cerebrospinal fluid (CSF), which 
exceeds that of other natriuretic peptides and its own concentration in the plasma (Kaneko et al. 
1993), are suggestive of a homeostatic role in the brain. Indeed, in vitro studies have shown a role 
for CNP in several neuroregulatory processes, including nervous system development (Kishimoto 
et al. 2008) and neuroprotection (Ma et al. 2010). In 2011, Schouten et al. reported concurrent 
measurements of CNP and the stable amino-terminal fragment of proCNP (NTproCNP), where it 
was reported that CSF and plasma concentrations of the two peptides were independently 
regulated – suggestive that central and peripheral sources of CNP were separate. 
 
Little is known about the regulation of CNP synthesis and secretion in vivo and its actions in adult 
life are poorly understood. Understanding CNP physiology may be useful in settings of central 
pathological disorders, however study of CNP in CSF is limited in human studies given the 
unlikelihood of obtaining healthy human CSF samples. Consequently, this PhD project was 
initiated to advance our knowledge about central dynamics, sources and regulation of CNP, using 
a large animal model where CSF samples could be obtained from healthy individuals. 
 
To facilitate repeated CSF sampling from healthy sheep, a method was developed for cannulation 
of the cisterna magna (Chapter 3). To test the hypothesis that CNP peptides are independently 
regulated in CSF and plasma in sheep – as in humans – CNP peptides were measured in a unique 
ruminant setting where circulating CNP peptide concentrations are markedly elevated, i.e. 
throughout gestation (Chapter 4). In order to identify central site(s) of CNP synthesis, pilot studies 
were conducted to identify a stimulus or suppressant capable of altering CNP concentrations in 
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CSF (5.1). Following reports of a possible central role of CNP in energy balance and appetite – and 
in the context of identifying factors capable of influencing central levels of CNP peptides – 
temporal changes in CNP peptides were characterised in CSF and plasma of red deer stags, which 
undergo major seasonal changes in live weight and appetite (5.2). Having identified a potential 
candidate stimulus – dexamethasone – changes in CNP peptide concentration were formally 
characterised by use of a dose-response study (Chapter 6). Hypothesising that dexamethasone-
induced increases in CNP concentration in CSF were due to increased peptide release from central 
tissue to CSF, the concentration of both peptides was measured in dexamethasone-stimulated 
and non-stimulated brain and pituitary tissues. Gene expression of the CNP precursor, receptor, 
and clearance receptor was also measured in a selection of tissues to provide further insight into 
the possible synthesis, action and clearance of CNP in specific tissues after dexamethasone 
stimulation. Specific molecular forms of CNP peptides were characterised in CSF, plasma, 
hypothalamus, anterior and posterior pituitary glands and results are presented in Chapter 7. The 
novel findings and main contributions of this work are discussed in Chapter 8, as well as potential 
avenues for further study. 
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Chapter 2. Literature Review 
2.1 Introduction to CNP 
2.1.1 The natriuretic peptide family 
 
The natriuretic peptide (NP) family consists predominantly of the three hormones; atrial 
natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP). 
Due to their crucial role in blood pressure and plasma volume homeostasis (Nishikimi et al. 2006), 
and consequential diagnostic value in the identification of chronic heart failure (Burnett et al. 
1986, Mukoyama et al. 1991, Falcão et al. 2004, Bettencourt 2005), ANP and BNP are arguably 
the best known and most widely studied of these NPs (returning close to 20,000 and 15,000 
PubMed search returns, respectively, compared with approximately 1600 for CNP — March 2017, 
using text in full e.g. ‘atrial natriuretic peptide’). 
 
ANP and BNP are referred to as the ‘cardiac NPs’ (Rademaker & Richards 2005) and are released 
into the circulation in response to hypervolaemia-induced stretch of the atria and ventricles, and 
act in an endocrine fashion to regulate blood volume by antagonising the renin-angiotensin-
aldosterone system and by enhancing natriuresis, diuresis and vasodilation (Richards 1996, Ito et 
al. 2003, Nishikimi et al. 2006). Other NPs have been identified, including dendroapsis natriuretic 
peptide in snake venom, human plasma and atrial myocardium (Schweitz et al. 1992, Shirger et al. 
1999) and ventricular natriuretic peptide in cardiac tissue in eels (Takei et al. 1994), however in 
mammals, ANP, BNP and CNP are considered to be the major members of this family. In the 
literature, the acronym ‘CNP’ is used to refer to the originally discovered 22-residue form (CNP-
22, Figure 2.1) as well as CNP-53, the peptide from which the former is putatively cleaved from 
(discussed below). 
 
NPs contain an obligatory C-terminal 17-residue disulphide ring structure (Potter 2011a), of which 
11 residues are conserved across the family (Figure 2.1). These peptides are expressed in a broad 
range of tissues (Minamino et al. 1988, Sudoh et al. 1990, Ruskoaho 1992, Chrisman et al. 1993, 
Chen & Burnett 1998, Stepan et al. 1999, Woodard et al. 2002, Kalra et al. 2003, Horio et al. 2003, 
Kalra et al. 2004, Prickett et al. 2005, Zhao & Ma 2009, Del Ry et al. 2011), although the main sites 
of NP production are the atria and ventricles for ANP and BNP, and vasculature and central 
nervous system for CNP. 
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Figure 2.1 Primary structure of human natriuretic peptides. 
Black circles represent amino acids that are conserved across the natriuretic peptide family and 
grey circles represent amino acids that differ. (ANP: atrial natriuretic peptide, BNP: brain 
natriuretic peptide, CNP: C-type natriuretic peptide, figure adapted from Potter 2011b). 
 
 
The process of mature peptide formation is similar for each of the NPs, as all are derived from a 
preprohormone which is converted to a prohormone by removal of a signal peptide (Wu et al. 
2003). The prohormone is then cleaved by various enzymes (Table 2.1) to produce two fragments 
which are either stored or immediately released: the respective natriuretic peptides (‘mature 
forms’), as well as an amino-terminal fragment which is presumed to be bio-inactive. Of the 
prohormones, only proBNP has been identified in the circulation (Seferian et al. 2007). 
 
ANP is stored in granules in the atria, where it is primarily expressed, and its release is stimulated 
by atrial wall stretch which results from increased blood volume (de Bold et al. 1986, Edwards et 
al. 1988). BNP is not stored in granules in the ventricles where it is primarily expressed – although 
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it is stored in atrial granules with ANP (Potter et al. 2006) – and is synthesised and released in 
proportion to the degree of left ventricular dysfunction, and following acute myocardial infarction 
and in chronic heart failure (Omland et al. 2002, Richards et al. 2003). CNP has been identified in 
small vesicles in pinealocytes described as being similar to ANP-containing atrial granules 
(Middendorf et al. 1996) and in human aortic endothelial cells staining with granularity (Stingo et 
al. 1992) – the latter of which was consistent with CNP-53. However, the extent to which CNP is 
stored and released, as opposed to synthesised de novo is largely unknown for many tissues, 
including those of the central nervous system.  
 
Differing features of NPs include the location of genes which encode the preprohormone, 
cleavage enzymes, and size/sequence of preprohormones, prohormones, mature forms and 
amino-terminal fragments. Despite close structural similarities, NPs differ largely in their 
biological function (reviewed extensively by Potter et al. 2006, 2009). A comparison of general 
characteristics of NP biology is discussed below and summarised in Table 2.1. 
 
Table 2.1 A comparison of general characteristics of the main natriuretic peptides. 
 
 ANP BNP CNP References 
Location of gene 
which encodes 
for precursor 
Chromosome 
1 (human), 
chromosome 
4 (mouse) 
Chromosome 1 
(human), 
chromosome 4 
(mouse) 
Chromosome 2 
(human, mouse, 
sheep) 
Lima et al. 2008, 
Tamura et al. 1996, 
NCBI database 
Gene name NPPA NPPB NPPC  
Number of 
residues in 
preprohormone 
151 134 126 Itoh et al. 1988, 
Seilhamer et al. 
1989, Tawaragi et 
al. 1991 
Number of 
residues in 
prohormone 
126 108 103 Itoh et al. 1988, 
Seilhamer et al. 
1989 
Number of 
residues in 
mature protein 
28 Varies across and 
within species as 
several truncated 
forms are known to 
circulate, e.g.: 
32 (human, pig, 
dog) 
45 (rat, mouse) 
22, 53 
(two forms) 
Potter et al. 2006, 
Seilhamer et al. 
1989, Sudoh et al. 
1988, Ogawa et al. 
1994, Kojima et al. 
1990, Yandle & 
Richards 2015 
Enzyme 
responsible for 
cleavage of 
prohormone 
Corin Furin or corin Furin Sawada et al. 1997, 
Yan et al. 2000 
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Mode of action Endocrine, 
paracrine and 
autocrine 
Endocrine, 
paracrine and 
autocrine 
Presumed to be 
paracrine and 
autocrine 
Nishikimi et al. 
2006 
Receptor 
responsible for 
mediating effects 
Guanylyl 
cyclase A (GC-
A), also 
known as 
natriuretic 
peptide 
receptor A 
(NPR-A) 
Guanylyl cyclase A 
(GC-A), also known 
as natriuretic 
peptide receptor A 
(NPR-A) 
Guanylyl cyclase B 
(GC-B), also known 
as natriuretic 
peptide receptor B 
(NPR-B or NPR2) 
Potter et al. 2006 
Half-life 2 minutes 
(humans), 0.5 
– 4 minutes 
in mice, rats, 
rabbits, dogs 
and monkeys 
Varies for different 
components, from 
3.9 – 20.7 minutes 
2.6 minutes 
(humans), 1.6 
minutes (sheep) 
Nakao et al. 1986, 
Ruskoaho 1992, 
Mukoyama et al. 
1991, 
Yandle et al. 1986, 
Hunt et al. 1994, 
Charles et al. 1995 
Primary roles Reduction of 
blood volume 
and pressure 
Reduction of blood 
volume and 
pressure, 
prevention of 
cardiac fibrosis 
Stimulation of 
endochondral bone 
growth, reduction of 
cardiac fibrosis, 
dilation of blood 
vessels 
Tamura et al. 2000, 
Horio et al. 2003, 
Nishikimi et al. 
2006 
Current 
diagnostic/ 
therapeutic uses 
Indicator of 
heart failure 
Detection of 
ventricular 
dysfunction and 
likely heart failure 
Clinical trial 
underway using CNP 
analogue to treat 
achondroplasia 
Falcão et al. 2004, 
Bettencourt 2005, 
Lorget et al. 2012 
 
2.1.2 CNP and NTproCNP secretion 
 
First discovered in the porcine brain in 1990, CNP (as it is most commonly known) is composed of 
22 amino acid residues (Sudoh et al. 1990, Figure 2.1) and differs from ANP and BNP in that it 
terminates in the second cysteine residue, lacking a further C-terminal extension (Sudoh et al. 
1990). The CNP precursor peptide gene (NPPC) is located on chromosome 2 in humans, mice 
(Ogawa et al. 1994) and sheep (NCBI database) and contains two exons separated by an intron, 
which encode prepro-CNP, a 126 residue CNP precursor (Ogawa et al. 1994). 
 
The precursor peptide is converted to a 103-amino acid prohormone that is processed 
intracellularly by furin to yield NTproCNP (amino acids 1-50) and CNP-53 (amino acids 51-103) 
(Wu et al. 2003). Both of these forms should occur in equal proportions intracellularly and must 
be secreted from cells in equimolar amounts, assuming the theoretical models of CNP processing 
described by Prickett et al. (2001) and Wu et al. (2003) are true. NTproCNP is not considered to 
have any biological function but it is a stable product of CNP gene expression that is simply co-
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secreted with CNP (Prickett et al. 2001). Aitken et al. (1999) reported that the ovine amino acid 
sequence of NTproCNP differs only slightly from that of the human and pig (92 and 98 % 
homology, respectively).  
 
CNP-53 is further cleaved to produce CNP-22 (Figure 2.2), the latter of which has been described 
as the mature and most biologically active form of the CNP fragments (Baxter 2004), since the 22-
amino acid sequence was found to be carried in CNP-53 in porcine brain extracts (Minamino et al. 
1990). However, labelling CNP-22 as the ‘mature form’ is misleading as it may imply that CNP-53 
is ‘immature’ and potentially inactive. Furthermore, there are no data to suggest that CNP-22 is 
more potent than CNP-53, in fact in vitro data demonstrates equi-potency between the two 
forms (Yeung et al. 1996a). 
 
In fact, Yasoda et al. (2009) suggested that CNP-53 may be more potent than CNP-22, as a higher 
plasma CNP concentration from systemically administered synthetic CNP-22 was required to 
rescue a mouse model of achondroplasia (fibroblast growth factor receptor (3) mutation which 
results in the inhibition of chondrocyte hypertrophy), than the same model of achondroplasia 
crossed with a transgenic mice with liver-specific CNP overexpression (that raised plasma 
concentrations of CNP – presumably CNP-53 and CNP-22). However, it is likely that this difference 
is largely explained by the fact that increased levels of circulating CNP in transgenic mice were 
apparent just after birth, whereas peripheral infusions of CNP began three weeks after birth. 
 
The mechanism for the cleavage of CNP-53 to CNP-22 is unknown, although it is likely to take 
place extracellularly and after secretion, given the predominance of CNP-53 in endothelial cells 
(Stingo et al. 1992), the absence of CNP-22 in the ovine pituitary gland (Pemberton et al. 2002) 
and the predominance of CNP-22 in the circulation (Stingo et al. 1992). In contrast, Yandle et al. 
(1993) showed that similar amounts of CNP-53 and CNP-22 existed in the ovine hypothalamus, 
indicating that processing of CNP may differ between tissues.  
 
There have been conflicting reports about which CNP form is dominant in CSF; Togashi et al. 
(1992) reported CNP-22 as the main form (and that CNP-53 was the dominant form in brain 
tissue), whereas Schouten et al. (2011) reported the main form to be CNP-53. In the former study, 
it was also noted that CNP-53 was present, and, consistent with models of intracellular processing 
of proCNP 1-103 (Prickett et al. 2001, Wu et al. 2003), there was no evidence of proCNP 1-103 in 
CSF.  
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Despite the minor differences in exon sequences between species, CNP-22 has a high degree of 
homology across species – it is identical in sheep, humans, pigs and rats and is the most highly 
conserved natriuretic peptide in vertebrates (Aitken et al. 1999), having been identified in fish 
(Inoue et al. 2003), snake brain (Hayashi et al. 2003) and snake venom (Soares et al. 2005). In 
contrast, human CNP-53 differs slightly from the pig and rat forms, as it has two amino acid 
substitutions (Tawagari et al. 1991).  It has not been sequenced in the sheep. However, Aitken et 
al. (1999) reported that the translated region of exon 1 (encodes the signal peptide and the first 7 
amino acids of NTproCNP) and exon 2 (encodes the remainder of NTproCNP and the entire 
mature hormone) in sheep showed a strong sequence identity (93-98 %) with the human and pig 
sequences.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Schematic diagram of the processing of the CNP prohormone to smaller fragments. 
ProCNP (1-103) is cleaved to form NTproCNP (1-50) and CNP-53 (51-103), which contains the 
CNP-22 fragment (82-103). 
2.1.3 CNP receptors and its clearance 
So far three distinct natriuretic peptide receptors have been identified: natriuretic peptide 
receptors A and B (NPR-A and NPR-B, also termed GC-A and GC-B, respectively), which are 
approximately 1030-amino acid transmembrane guanylyl cyclases, and NPR-C, a 496-amino acid 
transmembrane protein with a short 37-amino acid cytoplasmic tail (Koller et al. 1991) which is 
also a guanylyl cyclase (GC-C). ANP and BNP are ligands for NPR-A (Potter 2011a), whereas NPR-B 
(which is homologous to NPR-A) is potently and selectively activated by CNP which has a binding 
affinity for NPR-B 50- or 500-fold higher than ANP or BNP, respectively, in humans (Koller et al. 
1991).  
ProCNP (1-103) 
NTproCNP (1-50) CNP-53 (51-103) 
CNP-22 (82-103) 
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Guanylyl cyclases exist in two forms – particulate (membrane bound) and soluble  – and both 
forms catalyse the conversion of guanosine triphosphate (GTP) to cyclic guanosine 
monophosphate (cGMP), a secondary intracellular messenger that is presumed to be responsible 
for almost all effects of particulate guanylyl cyclases. The resulting increase in cGMP 
concentration triggers a signalling cascade which involves activation of protein kinases, regulation 
of cGMP-gated cation channels and cGMP-regulated phosphodiesterase – thereby mediating a 
range of downstream effects, including ion channel conductance, smooth muscle relaxation, and 
neurotransmission (Denninger & Marletta 1999).  
 
NPR-A, NPR-B and NPR-C are particulate guanylyl cyclases which are involved in a range of 
physiological processes, including the regulation of gut ion/water transport, phototransduction, 
olfaction and thermosensation (Kuhn 2016). Soluble guanylyl cyclases were traditionally 
considered to belong exclusively to the cytoplasm, however it has been reported that they may 
translocate to the plasma membrane after ligand binding, potentially with the assistance of 
molecular chaperones (Agullo et al. 2005). Regardless, soluble guanylyl cyclases are likely to be 
mostly cytoplasmic, and are receptors for gaseous ligands, which are primarily nitric oxide (NO) 
and carbon monoxide (Evgenov et al. 2006). Soluble guanylyl cyclases contain a haem moiety 
which is essential for NO-binding (Martin et al. 2005). It is known that NPs and NO elicit cGMP 
synthesis and activate common downstream pathways, however many aspects of the interaction 
between CNP, NO and cGMP as regulators of endochondral ossification remain to be explored 
(reviewed by Teixeira et al. 2008). There is evidence to suggest that cGMP-independent functions 
are mediated by some specific protein-protein interactions (Kuhn 2016), although none have 
been reported for NPR-B or NPR-C. 
 
In keeping with the autocrine/paracrine action of CNP, NPRB expression closely matches that of 
NPPC, with major sites of expression in endothelial cells and cardiomyocytes (Del Ry et al. 2011), 
osteoblasts (Hiroyuki et al. 2008), kidney (Canaankuhl et al. 1992) and in neural tissues such as 
the dorsal root spinal and cranial ganglia during embryonic development (DiCicco-Bloom et al. 
2004). NPR-B has been identified in many brain regions, including throughout the brainstem of 
non-human primates (Abdelalim & Tooyama 2011), as well as in the rat and mouse pituitary gland 
(McArdle et al. 1994).  
 
NPR-C (also known as NPR3) comprises   ̴95 % of the NPR population (Maack 1992) and has a 
major functional role as the clearance receptor for the natriuretic peptide family as it is able to 
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bind, internalise and target the peptides for lysosomal ligand hydrolysis (Maack et al. 1987, Potter 
2011b) and the ligand-free receptor is recycled back to the plasma membrane (Potter 2011b). 
Although most of the physiological effects of natriuretic peptides are mediated by NPR-A and 
NPR-B, there is evidence which supports the hypothesis that NPR-C has functional roles — other 
than clearance. The unique intracellular tail of NPR-C contains a pertussis toxin-sensitive G-
binding domain (Anand-Srivastava et al. 1996, Murthy & Makhlouf 1999). Consequently, NPR-C 
may have a signalling role through G-protein coupling, such as the inhibition of adenylyl cyclase 
activity (Pagano & Anand-Srivastava 2001) and stimulation of phosphoinositide hydrolysis 
(Murthy et al. 2000). Furthermore, NPR-C activation is linked to the smooth muscle 
hyperpolarisation induced by CNP in resistance arteries where CNP acts as an endothelium-
derived hyperpolarising factor (Chauhan et al. 2003). Recently, Egom et al. (2015) studied the 
effects of NPR-C ablation on aspects of cardiac functioning using a knockout mouse model. Mice 
lacking in NPR-C were more susceptible to atrial fibrillation and had slower electrical conduction 
in the sinoatrial node and atrium (and also exhibited long bone growth). Atrial fibrillation was 
associated with enhanced collagen expression and deposition in the atria, suggesting a protective 
role for NPR-C in the heart. 
 
Unlike NPR-B, NPR-C has a similar affinity for all the natriuretic peptides and is the most widely 
and abundantly expressed natriuretic peptide receptor. It is highly expressed in many tissues that 
express guanylyl cyclase receptors (Matsukawa et al. 1999); for example, kidney glomeruli (Maack 
et al. 1987). NPR-C distribution includes most of the major endocrine glands, lungs, kidneys and 
the vascular wall where it is the most represented NPR in endothelial cells (Leitman et al. 1986). 
The expression of NPRC is also widespread throughout the brain in rats (Herman et al. 1996a) 
with its mRNA shown to be present in deep layers of the neocortex and limbic cortex, posterior 
cortical amygdala, ventral subiculum, amygdalohippocampal area, and dentate gyrus.  
 
In addition to specific receptor-mediated degradation, natriuretic peptides are also degraded by 
extracellular proteases (Potter 2011b), neprilysin (Kenny et al. 1993) and insulin degrading 
enzyme (IDE, Ralat et al. 2011). Enzymatic degradation may be as important as NPR-C clearance 
and it is responsible for the steady state level of CNP in endothelial cells (Komatsu et al. 1996). 
Neprilysin is a zinc-containing, membrane-bound, ectoenzyme (Kerr & Kenny 1974) that binds 
and degrades CNP as it does with other similar peptide hormones such as angiotensin II 
(Stephenson & Kenny 1987). Although neprilysin cleaves CNP at multiple sites, the primary site of 
hydrolysis occurs between cysteine6 and phenylalanine7 residues (Watanabe et al. 1997). IDE also 
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cleaves CNP (and ANP, but not BNP) at multiple sites, and inactivates the ability of CNP to raise 
intracellular cGMP (Ralat et al. 2011). Conversely, reduced IDE expression enhanced the 
stimulation of NPR-B by CNP which is consistent with IDE-dependent degradation and inactivation 
of CNP (Ralat et al. 2011).  
 
2.1.4 NTproCNP: a marker of CNP production 
Due to its rapid receptor-mediated and enzymatic clearance, CNP has the shortest circulating 
half-life (2.6 min) of all the natriuretic peptides in humans (Hunt et al. 1994) and a similarly short 
half-life (1.6 min) in sheep (Charles et al. 1995). The short half-life of CNP has made it a 
particularly difficult peptide to study, as circulating levels may not reflect tissue concentrations 
near the site of production (Kalra et al. 2003). Therefore, NTproCNP may be considered as a long-
lived surrogate for CNP, so its levels in body fluids can provide an index of CNP secretion/activity 
(Prickett et al. 2001). NTproCNP has been established as a stable product of CNP gene expression 
and its concentration in plasma is highly correlated with CNP concentration (Prickett et al. 2001). 
It is unlikely that NTproCNP is hydrolysed by neprilysin or cleared from the circulation by NPR-C 
(Charles et al. 2006, Schouten et al. 2011), therefore its prolonged half-life makes it a more 
reliable indicator of CNP activity in vivo than measurement of CNP itself (Prickett et al. 2001). 
 
Different clearance rates explain why the plasma concentration ratio of the two peptides 
(NTproCNP:CNP) is consistently high across different species; 31:1 in adult humans (Schouten et 
al. 2011), 26:1 in 4-week-old lambs (Prickett et al. 2009), and 28:1 in adult ewes (Prickett et al. 
2010). This ratio is even higher for CSF concentrations; i.e. 144:1 in human CSF (Schouten et al. 
2011). This may be due to the abundance of neprilysin (Facchinetti et al. 2003) and the 
widespread distribution of NPR-C in the brain and spinal cord tissues (Herman et al. 1996a) which 
depletes the concentration of CNP relative to NTproCNP (Schouten et al. 2011).  There is one 
study which reported that the NTproCNP:CNP ratio in human CSF increased with age (Schouten et 
al. 2011). 
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2.2 Function and regulation of CNP in central and peripheral tissues 
2.2.1 Peripheral roles for CNP 
Although the focus of these studies are of CNP in the central nervous system, CNP is involved in 
the regulation of many important peripheral roles which are discussed below. Given the potent 
natriuretic effects of the cardiac natriuretic peptides, similar roles for CNP have been 
investigated, however it has been established that CNP is significantly less potent for inducing 
natriuretic (Hunt et al. 1994), diuretic or hypotensive effects in vivo than the cardiac natriuretic 
peptides (ANP and BNP, Sudoh et al. 1990). Although CNP appears to have some involvement in 
the regulation of blood pressure – it is produced by the vascular endothelium and causes 
vasodilation in vitro (Wei et al. 1993) – this is through local regulation of vascular tone (Chauhan 
et al. 2003) in an autocrine or paracrine manner.  Also, CNP circulates at much lower 
concentrations than ANP so it appears to have little function in common with the classic 
natriuretic peptides. However, it is becoming clear that CNP is involved in the regulation of a 
much wider range of physiological mechanisms, which is reflected by the many peripheral sites 
which express NPPC, including the vascular endothelium (Chen & Burnett 1998), vascular smooth 
muscle cells (Woodard et al. 2002), myocardial tissue (Kalra et al. 2003, Del Ry et al. 2011), 
cardiac fibroblasts (Horio et al. 2003), reproductive tissues (Chrisman et al. 1993), bone (Prickett 
et al. 2005), kidney (Kalra et al. 2004) and heart (Vollmar et al. 1993). 
 
Trans-organ sampling in anaesthetised sheep revealed that multiple organs contribute to 
circulating levels of CNP and NTproCNP (heart, liver, kidney, hind limb) in ewes, as demonstrated 
by a positive arterio-venous gradient (Charles et al. 2006). Positive arterio-venous gradients of 
CNP forms across the head and neck in trans-organ regional sampling studies have raised the 
possibility that cerebral tissues could be an important source of CNP in the systemic circulation in 
humans (Palmer et al. 2009) and sheep (Prickett et al. 2009). Unlike ANP and BNP, no significant 
net extraction of CNP across any tissue bed has been measured. However, a negative veno-
arterial gradient between both the inferior vena cava and carotid artery, and the jugular vein and 
carotid artery, may implicate the lung in extraction of CNP from the circulation (Charles et al. 
2006).  
 
CNP is known to perform major functions in these tissues through the binding of NPR-B or by 
signalling through NPR-C, and stimulates growth of bone explants in tissue culture by acting on 
proliferative and hypertrophic zones (Yasoda et al. 1998). CNP transcripts and NPR-B are 
expressed in chondrocytes of growth plates (Hagiwara et al. 1994) and there are many reports 
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which demonstrate that the CNP signalling pathway is crucial for normal bone growth in vivo — in 
particularly, the regulation of endochondral ossification (Yasoda et al. 2004a, Yasoda et al. 
2004b). NPPC-knockout mice have a dwarfed phenotype and experience early death (Chusho et 
al. 2001), and a loss-of-function mutation in NPR-B in humans also results in acromesomelic 
dysplasia (Marateaux type) and as a result, also have a dwarfed phenotype (Bartels et al. 2004). 
Similarly, mice with targeted disruption of cGMP-dependent kinase II, a downstream mediator of 
cGMP, also have compromised endochondral ossification and show a dwarfed phenotype (Pfeifer 
et al. 1996). Individuals with mutations in the NPRC gene display skeletal overgrowth/gigantism, 
as has been shown in mice (Jaubert et al. 1999, Matsukawa et al. 1999). Skeletal overgrowth 
results from NPPC overexpression in humans (Ko et al. 2015) and rodents (Fujii et al. 2010). It is 
clear that proper regulation of natriuretic peptide levels is crucial for normal development – and 
that improving our understanding of NP regulation may lead to promising clinical applications 
(reviewed by Peake et al. 2014). 
 
CNP has been shown to rescue a mouse model of achondroplasia, whereby CNP inhibited 
proliferation and induced hypertrophy of chondrocytes when overexpressed in the liver, or 
infused into the circulation (Yasoda et al. 2004b). The use of a CNP analogue in treatment of 
achondroplasia in children is under investigation following reports that BMN 111, a 39-amino acid 
CNP analogue, was capable of inhibiting fibroblast-growth-factor-mediated MAPK activation 
(mitogen-activated protein kinases), and improving aspects of skeletal development (Lorget et al. 
2012).  
 
Several studies have investigated the role of CNP in appetite and energy expenditure, following 
observations that NPPC-knockout mice are typically leaner (Chusho et al. 2001, Tamura et al. 
2004). It was unclear whether this phenotype was due to CNP playing a role in energy balance, or 
an indirect result of the NPPC-knockout mice featuring a misalignment of their teeth and jaws 
from skull and cervical spine deformities – causing mice to have difficulty with eating (Tamura et 
al. 2004). Inuzuka et al. (2010) addressed this dilemma by breeding NPPC-knockout mice with 
chondrocyte-targeted expression (CNP-Tg/NPPC-/-) – i.e. rescuing the skeletal deformities and 
growth retardation, while maintaining an absence of CNP elsewhere. CNP-Tg/NPPC-/- mice had 
reduced body fat accumulation and better insulin sensitivity, suggesting that CNP may be a 
positive regulator of energy balance – either via reducing energy expenditure in brown adipose 
tissue and/or increasing food intake (Inuzuka et al. 2010). However, there is also evidence to 
support an opposite role for CNP; Yamada-Goto et al. (2013) reported that 
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intracerebroventricular administration of CNP suppresses food intake in mice via activation of the 
melanocortin system (Yamada-Goto et al. 2013), suggesting CNP as a negative regulator of energy 
balance.  
 
The involvement of CNP in regulating aspects of reproduction is also unclear, however several 
lines of evidence from a range of species imply that it has a many-faceted role (Walther & Stepan 
2004) and the expression of NPPC is altered in the rat ovary and uterus during the oestrous cycle 
(Dos Reis et al. 1995, Huang et al. 1996). In addition, CNP is involved in the regulation of erectile 
tissue and testicular function (Middendorff et al. 2000, Küthe et al. 2003), male mouse fertility 
(Sogawa et al. 2014) and is produced by trophoblast binucleate cells in the ruminant placenta 
during pregnancy – resulting in plasma CNP concentrations that are approximately 30-fold higher 
than non pregnant values (McNeill et al. 2011). CNP maintains oocyte meiotic arrest in early 
antral follicles of many species including mice (Zhang et al. 2010, Tsuji et al. 2012), cats (Zhong et 
al. 2016), pigs (Hiradate et al. 2014) and goats (Zhang et al. 2015) and this inhibitory effect is 
relieved by the luteinising hormone (LH) surge in vivo (Zhang et al. 2015). This action of CNP may 
be beneficial to infertility treatments, i.e. in in vitro maturation of oocytes whereby the 
synchronisation of nuclear and cytoplasmic maturation can be influenced by CNP to improve 
fertility outcomes (Wei et al. 2017).  
 
CNP exerts a myriad of effects on local vasculature which extend beyond simply promoting 
vasodilation and controlling blood flow in the resistance vessels (Chauhan et al. 2003). Other 
effects include inhibition of vascular smooth muscle cell proliferation and migration (Morishige et 
al. 2000), and the stimulation of re-endothelialisation (Doi et al. 2001, Ohno et al. 2002). Scotland 
et al. (2005a) demonstrated that CNP dose-dependently reduces leukocyte rolling and platelet 
activity, during basal conditions and also under acute inflammatory conditions (induced by 
interleukin1-β and histamine). It was found that these effects were dependent on NPR-C activity, 
specifically via suppression of the expression of P-selectin, a surface adhesion molecule found on 
endothelial cells and platelets. Although the mechanisms for effects of CNP on the vasculature 
are not all understood, such as its ability to protect against against myocardial ischemia/ 
reperfusion injury (Hobbs et al. 2004, Soeki et al. 2005) and prevention of cardiac hypertrophy 
(Wang et al. 2007, Tokudome et al. 2004), there is certainly enough evidence to warrant further 
research into these mechanisms as potential therapeutic targets for cardiovascular diseases 
(reviewed by Scotland et al. 2005b and Lumsden et al. 2010).  
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2.2.2 CNP in cerebrospinal fluid 
It has been established that the concentration of CNP in human CSF is the highest of any 
natriuretic peptide, and that the concentration of CNP peptides in CSF is substantially higher than 
in plasma (Togashi et al. 1992, Kaneko et al. 1993, Ikeda et al. 2001, Schouten et al. 2011). The 
concurrent measurement of CNP in CSF and plasma in healthy patients revealed a concentration 
of 2.13 pmol/L in CSF, and a CNP concentration that was too low to be detected in plasma (assay 
sensitivity < 0.2 fmol/mL, Kaneko et al. 1993). Ikeda et al. (2001) measured CNP concentration as 
6.10 pmol/L in CSF, which was about 2.6 times higher than the concomitant plasma CNP 
concentration (2.37 pmol/L). 
 
Schouten et al. (2011) reported the concentration of CNP peptides in CSF of human patients 
undergoing spinal anaesthesia (age 51-90). Consistent with previous reports, levels in CSF were 
markedly higher than in plasma (nearly 10-fold). In addition, this publication provided the first 
report of NTproCNP concentration in CSF, whereby NTproCNP concentration in CSF was 1045 ± 
359 pmol/L which is 67 times higher than the value for plasma (Schouten et al. 2011). Further, the 
NTproCNP:CNP concentration ratio was greater in CSF (145:1) compared with plasma (31:1); 
indicating that degradation of CNP is more rapid in the CNS than in peripheral tissues. This also 
highlights the diagnostic importance of NTproCNP measurement in CSF, as an indicator of CNP 
release which would have been grossly underestimated by measurement of CNP alone. 
2.2.3 Sources, targets and roles of CNP in the central nervous system 
Several studies of neuroendocrine functions of natriuretic peptides (Doczi et al. 1987, Samson 
1987) were carried out prior to the discovery of CNP in the porcine brain (Sudoh et al. 1990). 
However, it has since been established that CNP is the most abundant natriuretic peptide in the 
CNS and is widely distributed in the brain, e.g. of the rat (Minamino et al. 1991), sheep 
(Pemberton et al. 2002) and human (Ueda et al. 1991, Totsune et al. 1994). Furthermore, the 
expression of NPPC in the CNS has been described for the mouse (Stepan et al. 1999, Mirczuk et 
al. 2014) and rat (Minamino et al. 1991, Stepan et al. 1999). Komatsu et al. (1991) published the 
first report of markedly high levels of CNP in the rat pituitary gland, compared with other cranial 
structures.  This finding was confirmed in sheep (Pemberton et al. 2002) and was shown to be 
unique to CNP; ANP and BNP were present in the pituitary gland at levels similar to those in brain 
tissue. Also, CNP is found in higher concentrations in the rat anterior pituitary gland than in the 
posterior pituitary gland (Komatsu et al. 1991) indicating some differentiation of its roles in 
glandular versus neural tissue. Collectively, these studies have paved the way for investigations of 
potential roles of CNP in the central nervous system. 
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There is evidence to suggest that both neuronal and glial cells are sources and targets of CNP 
(reviewed by Prado et al. 2010). In the dorsal root entry zone of the spinal cord, CNP-induced 
cGMP production via NPR-B was shown to be essential for sensory axon bifurcation (Schmidt et 
al. 2009). In agreement with this, Abdelalim et al. (2013) reported that NPR-B is expressed in 
neuronal cell bodies and processes in dorsal root ganglia (DRG) of the rat. Glial cells of the retina 
(Müller cells) showed a strong presence of CNP, particularly in their endfeet which closely enwrap 
blood vessels, suggesting involvement in the regulation of blood flow and intraocular pressure 
(Fernández-Durango et al. 1999). This is consistent with prior findings from Mori et al. (1997) who 
confirmed the vasodilator effects of CNP on cerebral arterioles in rats. NPPC expression has been 
reported in mouse astrocytes and rat glioma cells (Yeung et al. 1996b), and the ability of CNP to 
stimulate cGMP has been demonstrated in cultures of rat (Kobayashi et al. 1993) and mouse 
(Yeung et al. 1992) glial cells. NPRB is expressed in rat microglia (Moriyama et al. 2006), although 
the level of expression was lower than was found for NPR-A. Consistent with widespread NPR-B 
distribution, CNP-stimulated cGMP accumulation has been established in astrocytes (Deschepper 
& Picard 1994) and neurons (Xia et al. 2013). In summary, there is evidence for CNP-related 
physiology in both neurons and glial cells, including microglia and astrocytes. 
 
Samson et al. (1993) demonstrated that central administration of CNP to conscious rats resulted 
in a decrease in circulating plasma LH concentration, which was mediated via NPR-B. This was a 
follow-up from observations whereby ANP had produced the same effect, however it was 
established that this ANP effect was due to competitive binding and displacement of CNP from 
NPR-C; increased ANP concentration decreased NPR-C availability, which in turn accentuated the 
reduction of LH by CNP. 
 
Given that the presence of NPR-B has been confirmed in the rat anterior pituitary gland, it is 
possible that CNP is an autocrine/paracrine regulator of gonadotrope function. CNP has been co-
localised with immunoreactive LH/FSH (follicle-stimulating hormone) cells; McArdle et al. (1994) 
reported that the majority of CNP-containing cells in the rat anterior pituitary gland were 
gonadotropes. Furthermore, when cultures of rat anterior pituitary cells were exposed to a toxin 
targeted to GnRH (gonadotropin-releasing hormone) receptor-expressing cells, there was a 
significant reduction in CNP-stimulated cGMP production and GnRH-stimulated LH release 
(McArdle et al. 1994).  
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The widespread distribution of CNP gene expression in the central nervous system suggests that 
CNP has a multifunctional role in neuroendocrine regulation (Stepan et al. 1999). For example, 
the high expression in the rodent tegmentum (brainstem) indicates an involvement of CNP in 
autonomic control and its expression in the rat hippocampus suggests a role in learning and 
memory (Stepan et al. 1999). CNP affects bidirectional plasticity in the hippocampus (Decker et al. 
2010), by influencing hippocampal network oscillations in adult rats (Decker et al. 2009) — which 
raises the question as to whether CNP is involved with learning and memory. In support of this, 
central administration of CNP in rats has been shown to facilitate learning and consolidation of 
passive avoidance learning (Telegdy et al. 1999).   
 
Aside from memory and learning, CNP is involved with other neuroregulatory processes such as 
nervous system development (Kishimoto et al. 2008). CNP stimulates axonal branch formation of 
DRG neurons in the spinal cord, and provides a cue that is necessary for bifurcation of central 
sensory afferents (Zhao & Ma 2009). In cultures of embryonic DRG neurons, CNP stimulates 
branch formation, induces axonal growth, and attracts growth cones (Zhao & Ma 2009). In 
addition, NPR-B is the most highly expressed natriuretic peptide receptor in the developing rat 
brain, and its expression is highest around the first postnatal day of life, which coincides with an 
elevated expression of nestin — a marker protein for stem/progenitor cells — which indicates a 
role for NPR-B in perinatal neurogenesis (Müller et al. 2009). Other suggested roles include 
neuroprotection (Ma et al. 2010), regulation of blood-brain barrier permeability (Bohara et al. 
2014), involvement in pathways underlying pain hypersensitivity (Shepherd et al. 2014), and 
regulation of cocaine-induced changes in gene expression responsible for neuronal plasticity 
(Jouvert et al. 2004).  
 
Since its discovery in 1990, it has become clear that the effects of CNP in the central nervous 
system are extremely diverse. However, many of the studies have been conducted in vitro, so 
there is a need to establish how far the crucial roles for CNP determined from these studies 
extend to the in vivo situation. Measurement of CNP concentrations under various neurological 
conditions will be essential for adding to the ‘bigger picture’, as has been demonstrated by 
analysing CSF from patients with Parkinson’s disease (Espiner et al. 2014). 
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2.2.4 Regulation of CSF concentrations of CNP 
To date, there are no published data on CNP peptide concentrations in sheep CSF. However, pilot 
studies conducted with sheep (G Barrell, Lincoln University, 2009-2010, unpublished) revealed 
much higher concentrations of CNP and NTproCNP in CSF (1.5 – 6.1 and 58-332 pmol/L, 
respectively) than in peripheral plasma (0.6 – 1.7 and 16 – 33 pmol/L, respectively). In addition, 
there was some indication that CNP peptide concentrations were higher in CSF from lumbar than 
from cervical samples (3/5), and that concentrations tended to be lower in the first sample that 
was collected when sheep were still anaesthetised, suggesting that the anaesthetic drugs used for 
this work (diazepam and ketamine) suppressed CNP peptide secretion into the CSF. Following 
this, CNP peptide concentrations in CSF and plasma of adult sheep that were studied over a 24-
hour period revealed a complete absence of any diurnal pattern of secretion (Wilson et al. 2015).  
Further studies showed that both cortical activation via transcranial magnetic stimulation, and 
activation of the sympathetic nervous system via an intravenous bolus of caffeine, had no effect 
on CNP peptide concentrations in CSF or plasma (Wilson et al. 2011, unpublished). CNP and 
NTproCNP were present in CSF at high concentrations at all times in the sheep with no apparent 
effect of these two potentially stimulatory treatments on central or peripheral concentrations of 
the peptides.   
 
 The CSF of human subjects undergoing spinal anaesthesia for arranged orthopaedic procedures 
has been analysed for concentrations of CNP peptides (Schouten et al. 2011). Some of the 
patients had been on long-term medication for a variety of issues. Although the number of 
patients receiving any one class of drug limits conclusions from these studies, the only drug that 
had any effect on CNP levels in CSF was furosemide. Patients receiving long term furosemide 
treatment, which is known to potently reduce CSF formation (Johanson et al. 2008) and therefore 
CSF reabsorption, had a significantly increased NTproCNP:CNP ratio in CSF, compared with those 
not receiving the drug (Schouten et al. 2011). Furosemide did not affect the NTproCNP:CNP 
concentration ratio in plasma. The other drug classes used in these procedures which were 
without effect included a statin, angiotensin inhibitor, beta blocker, calcium channel blocker, anti-
depressant, proton pump inhibitor, and a glucocorticoid.  
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2.3 Rationale for thesis 
CNP has a high abundance in brain tissues relative to other natriuretic peptides, and is unique in 
that its concentration in CSF far exceeds circulating levels. In vitro studies show that CNP 
influences a diverse range of central processes, including stimulating neural growth and 
connectivity (Zhao & Ma 2009), neuroplasticity in hippocampal tissues (Decker et al. 2010), and 
effects on blood-brain barrier permeability (Bohara et al. 2014), however the functional role of 
CNP in vivo is unclear. At the time of commencing this thesis, there was only one report of CNP 
and NTproCNP concentrations in concurrent samples of CSF and blood (Schouten et al. 2011) 
which indicated that central and peripheral concentrations of CNP peptides are independently 
regulated, at least in healthy humans. 
 
It was hypothesised that these high concentrations of CNP peptides in CSF reflected secretion 
from nervous tissues, however there were no reports linking nervous tissue concentrations of 
CNP to levels in the CSF. Animal models are necessary for progress in this area — given the 
unlikelihood of obtaining healthy samples of human CSF — and large animal models are 
advantageous as repeated samples of CSF can be obtained to allow for studies of temporal 
changes in hormone concentrations. Given the potential clinical applications of elucidating the 
function(s) of a novel neuropeptide involved in the regulation of many important central 
processes, there is first a need to establish fundamental aspects of CNP physiology in the CSF, i.e. 
identify central sources and investigate factors capable of influencing central levels of CNP in vivo.  
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Chapter 3. General Methods 
 
This chapter describes methods which are common to several or all studies in this thesis. Other 
techniques or assays specific to individual studies are described in their respective chapters. 
3.1 Measurement of live weight and animal handling 
Live weight of sheep was measured by placing individual animals in a holding crush fitted with 
electronic scales (to the nearest 0.5 kg). Sheep were brought indoors and individually housed at 
Johnstone Memorial Laboratory (Lincoln University) throughout all trials, except for the study of 
CNP in pregnant sheep described in Chapter 4 where sheep were kept at Ashley Dene farm for 
the last 2 months of gestation. Jugular blood samples and CSF (from previously inserted cannulae) 
were collected by having an assistant lightly restrain the sheep in their individual pens. 
3.2 Measurement of natriuretic peptides 
3.2.1 Extraction of peptides from CSF and plasma 
NPs were extracted from plasma and CSF samples using solid-phase extraction columns (Sep-Pak 
C18, Walters, Milford, Massachusetts, USA). The columns were prepared by the addition of 5 mL 
of 100 % methanol followed by 5 mL of 0.1 % trifluoroacetic acid (TFA). Plasma (2 mL) and CSF (1 
mL) samples were then passed through the columns, followed by a further 5 mL of 0.1 % TFA. 
Peptides were eluted using 2 mL of 80 % isopropanol in 0.1 % TFA into polystyrene collection 
tubes containing 10 µL of 0.1 % Triton X-100 (addition of Triton to the collection tubes prevents 
binding of NPs to the tube). The eluant was collected, dried at 37 °C under an air stream and 
frozen at -20 °C. Dried down plasma extracts (from 2 mL plasma) were reconstituted in 500 µL of 
RIA assay buffer to ensure they were above the detection limit. Dried down CSF extracts (from 1 
mL CSF) were reconstituted in 1 mL of RIA assay buffer. 
3.2.2 Radioimmunoassay of natriuretic peptides 
Samples were assayed in duplicate, and all samples from individual sheep were included in the 
same assay to reduce the contribution of inter-assay variation. The detection limit, and between- 
and within-assay coefficients of variation reported in subsequent chapters reflect calculations 
based over a one year period of the respective study. These parameters were also calculated for 
the several years spanning the time period of this thesis and are reported below. 
 
CNP 
CNP was assayed as previously described (Yandle et al. 1993, Prickett et al. 2007), with minor 
changes: 50 µL standard (human proCNP (82-103) or sample extract was pre-incubated with 50 µL 
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of a commercial primary rabbit antiserum raised against proCNP (82-103) (Phoenix 
Pharmaceuticals Inc., Belbont, California, USA, catalogue number G-012-03) and diluted to 1:2000 
in RIA assay buffer, then incubated for 22-24 hours prior to the addition of 50 µL of tracer (125I 
labelled Tyr0-proCNP(82-103)) containing 3000 cpm. The antisera raised against proCNP (82-103) 
shows 100 % cross-reactivity with CNP-22 and hCNP-53 (Phoenix Pharmaceuticals data sheet). 
Within- and between-assay coefficients of variation were 5.1 % and 9.8 % respectively, at 9 
pmol/L, and the detection limit was 0.6 pmol/L. 
 
NTproCNP 
NTproCNP was measured as previously described (Prickett et al. 2001, Prickett et al. 2007) with 
minor changes (see appendix for a comparison of parallelism of ovine and human samples): 100 
µL standard or sample extract was pre-incubated with 50 µL primary rabbit antiserum raised 
against human NTproCNP (1-15) (J39, diluted 1:6000 in RIA assay buffer) then incubated for 22-24 
hours prior to addition of 50 µL of tracer(125I labelled proCNP(1-15)Tyr16) containing 3000 cpm. 
Following a further 22-24 h incubation period, bound and free labelled antigen were separated by 
addition of 500 µL of solid phase secondary antibody (5 % v/v donkey anti-rabbit Sac-cell (IDS Ltd, 
UK) diluted in potassium phosphate assay buffer). Peptide standards were made from synthetic 
ovine proCNP (1-19) (Mimotopes Pty Ltd, Clayton, Victoria, Australia). Within- and between-assay 
coefficients of variation were 7.8 % and 12.6 % respectively, at 64 pmol/L, and the detection limit 
was 2.7 pmol/L. 
 
3.3 Methods of cannulation for repeated CSF sampling 
The following section (3.3.1) describes the method that was employed on commencing this thesis 
and was used to collect CSF in pilot studies (5.1.2) and in 2 of 8 sheep in the dose-response study 
in Chapter 6. CSF was collected on most occasions, however the success rate of cannulation was 
poor, and each cannula would typically only last for approximately 6 days before CSF could no 
longer be drawn. Therefore, a new method with a longer patency period was sought and is 
described in 3.3.2. This new method was used for the remaining 6 sheep in the dose-response 
study, as well as the collection of CSF for size-exclusion high performance liquid chromatography 
described in Chapter 7. 
3.3.1 Cannulation of the cervical subarachnoid space 
Animals were fasted and had no access to water for 12 h before the cannulation procedure. Wool 
was clipped from one side of the neck and the skin was sprayed with 70 % v/v ethyl alcohol. 
Sheep were individually anaesthetised by a single intravenous injection (into the jugular vein) 
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with an equal volume mixture of diazepam (Ilium diazepam, 5 mg/mL, Troy Laboratories NZ Pty 
Ltd, Auckland, NZ, 0.5 mg/kg live weight) and ketamine hydrochloride (Phoenix Ketamine 
injection, 100 mg/mL, Phoenix Pharm Distributors Ltd, Auckland, NZ, 10 mg/kg live weight) which 
provided 20-30 minutes of sedation and analgesia. 
 
Once sedated, each animal was placed into sternal recumbency, with the forelimbs folded 
underneath with the hips flexed and the pelvic limbs under the body or extended alongside the 
abdomen. A handler gently straddled the sheep and held the sheep’s head steady while a 50 cm2 
area over the midline occipital region of the skull was clipped free of wool. The injection site was 
surgically prepared with a disinfectant scrub (1.6 % w/v available iodine (19.7 mg/mL crude 
iodine): Vetadine - Iodine Animal Wash, Bomac Laboratories Ltd, Wiri Station Road, Manakau 
City, Auckland, NZ) followed by 70 % v/v ethyl alcohol. 
 
Ventral-flexion of the head and neck of the sheep was maintained throughout the procedure in 
order to enlarge the opening of the atlanto-occipital space and allow for easy entry of the Tuohy 
needle. Care was taken not to obstruct the sheep breathing, which was regularly checked whilst 
held in this position. In most sheep, a palpable depression down the dorsal midline could be 
identified near the top of the triangle which joins the caudal aspect of the occipital protuberance 
and the wings of the first cervical vertebra of the spine. The insertion site of the cannula was 
targeted at this palpable depression (Plate 3.1).  
 
 
 
 
 
 
 
 
 
 
Plate 3.1 The site for CSF collection in anaethetised sheep. 
 
A Tuohy needle (16G x 3.23 inch, i.e. 1.7 x 80 mm, Braun Perican®, Melsungen, Hesse, Germany) 
was inserted in a caudal direction at an angle of approximately 15° from the vertical plane (Plate 
3.1). The tissues penetrated, in order, were: the skin and sub subcutaneous tissue, nuchal ligament, 
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dura mater and the arachnoid mater to reach the subarachnoid space of the cervical region. The 
nuchal ligament presents resistance to the passage of the needle. Correct placement of the cannula 
was identified by a distinct ‘pop’ and was confirmed when CSF could be slowly withdrawn from the 
needle hub by gentle aspiration. A polyamide catheter (0.6 x 1.05 x 1000 mm, Braun Perifix®ONE, 
Bethlehem, Pennsylvania, USA) was introduced through it, and fastened in place with cyanoacrylate 
adhesive (Superglue) plus adhesive tape. 
 
3.3.2 Cannulation of the cisterna magna 
The following describes the modification of a previously described method (Falconer et al. 1985) 
which allows for repeated collection of CSF from the cisterna magna, and was published in 
Laboratory Animals, 2015.  
 
Modification of a method for cannulation of the cisterna magna in 
sheep to enable chronic collection of cerebrospinal fluid 
 
Wilson, M.O., Barrell, G.K. (2015). Laboratory Animals 49: 85-87 
3.3.2.1 Abstract 
A method is described for chronic cannulation of the cisterna magna to enable repeated sampling 
of cerebrospinal fluid from conscious, ambulatory sheep by means of a flexible vinyl tube. Ease of 
sampling and duration of cannula patency are similar to those obtained with rigid, metal 
cannulae, but this modified method minimizes the degree of surgical intervention, and possible 
trauma, occurring during placement of the cannula. 
 
Keywords 
cannulation, cerebrospinal fluid, sheep, cisterna magna 
3.3.2.2 Introduction 
A variety of methods for cannulation of the cisterna magna and other cerebroventricular sites in 
sheep and goats have been described. However we consider the use of rigid, metal cannulae, with 
the attendant need to excavate a large section of the parietal bone and place securing 
attachments into the skull, to be unnecessarily invasive. To enable investigations of central roles 
of C-type natriuretic peptide,1 we have sought to establish a method that enables repeated 
collection of cerebrospinal fluid (CSF) from the cisterna magna of sheep. CSF can be collected 
from sheep at cervical and lumbar sites,2 although use of sedation is needed for this procedure 
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and it is not amenable to repeated and/or chronic sampling. We describe a simple modification of 
a reported method,3 which allows for repeated CSF collection with minimal surgical intervention. 
3.3.2.3 Materials and Methods 
Six yearling Coopworth ewes (live weight between 30 and 51 kg) were fasted for 24 h prior to 
surgery and water was withheld overnight. Each animal was given an intramuscular injection of 
analgesic (1 ml of 324 µg/ml buprenorphine hydrochloride, Temgesic injection – Reckitt Benckiser 
Healthcare (UK) Ltd., Slough, UK). Anaesthesia was induced with an intravenous injection of a 
combination of ketamine (10 mg/kg ketamine hydrochloride, Phoenix ketamine injection, Phoenix 
Pharm Distributors Ltd, Auckland, NZ) and diazepam (0.5 mg/kg, Pamlin injection, Parnell 
Laboratories New Zealand Ltd, Auckland, NZ). After endotracheal intubation, anaesthesia was 
maintained with 2 % v/v isoflurane in oxygen. Post surgery, each sheep received analgesic (as 
above) every 8 h for 2 days and rectal temperature was monitored daily. These procedures were 
approved by the Lincoln University Animal Ethics Committee.  
 
To maintain the sheep’s head in a stable position during surgery, its mandible was placed on a 
horizontal bar attached to an external steel frame on the operating table and a tapered bar, 
clamped one on each side of the same frame, was secured into each auditory meatus (Plate 3.2).  
 
 
 
Plate 3.2 Position of the sheep for cannulation of the cisterna magna. 
The anaesthetized animal is placed in a prone position with its mandible resting on a steel rod and 
the head secured by tapered steel bars which extend into each auditory meatus. 
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The surgical site was clipped free of wool, cleaned with povidone-iodine solution and disinfected 
with 70 % v/v isopropanol. Using aseptic procedures a 6 cm sagittal skin incision was centred over 
the depression on the parietal bone and underlying tissues were revealed with use of a retractor 
(e.g. Weitlaner) and further dissection. The periosteum was scraped from the underlying parietal 
bone to clear the entry site for drilling, the midline about 3 mm rostral to the nuchal ligament 
aponeurosis. A 2.5 mm hole was drilled by hand through the bone at 15° rostral to the vertical 
(90°), until the bit passed through the bone. The hole was enlarged to 5 mm diameter and bone 
chips were removed with cotton swabs and by flushing with saline solution. Each cannula was 
made from a 30 cm length of clear polyvinyl chloride tubing (Dural Plastics & Engineering, Auburn, 
New South Wales, Australia) with an outside diameter (o.d.) of 2.5 mm (internal diameter 1.5 
mm). At one end, the tip was sliced at an angle (45º) and 2 holes (2 mm diameter) were cut 
through the wall of the cannula on opposite sides, within 15 mm of the tip. Access to the distal 
end was provided by insertion of a sawn-off 1.65 mm o.d. (16 G) hypodermic needle with Luer 
hub. The dura mater and arachnoid membranes were carefully pierced in a caudal direction with 
a 10 G (3.4 mm outside diameter x 76.2 mm length) steel needle (Industrial Strength Llc., 
Wallingford, Connecticut, USA), through which the tip of the cannula was introduced and 
advanced caudally towards the cisterna magna (about 45 mm) until CSF flowed freely in the 
tubing – see Plate 3.3. Alternatively, the cannula could sometimes be introduced directly into the 
cisterna magna after the meningeal membranes were pierced. Appearance of CSF around the 
needle during its insertion indicated successful penetration of the meninges. The cannula was 
secured by placing an absorbable suture on to subcutaneous tissue near the bone entry site and 
tying it to the cannula with Chinese finger trap knotting. The needle was placed subcutaneously 
within the incision site and directed outwards so that it exited through the skin 5 cm lateral to the 
incision and was used to exteriorise the distal end of the cannula. After removal of the needle and 
attachment of the Luer hub to the cannula, a sampling port (BD Q-SyteTM 0.10 ml, Becton 
Dickinson Infusion Therapy Systems Inc., Sandy, Utah, USA) was fitted to the hub. Subcutaneous 
tissues were repaired above the bone entry site with continuous suturing (absorbable) and the 
skin was closed with interrupted sutures (non-absorbable). Plastic surgical adhesive tape (5 cm 
length) was placed on the cannula 10 cm from the skin entry site and secured to the skin with 
cyanoacrylate adhesive (‘instant glue’), and the skin entry site was sealed with a generous bleb of 
antiseptic ointment (Betadine povidine-iodine antiseptic-germicide ointment, The Purdue 
Frederick Company, Norwalk, Connecticut, USA). The exterior section of the cannula and the 
surgical area were covered with sterile cotton swabs that were held in place with flexible 
synthetic netting. The cannula port was disinfected with 70 % v/v isopropanol prior to sample 
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collection, after which 0.5 ml of sterile saline solution (0.9 % w/v) was injected into the cannula to 
occupy the dead space, antiseptic ointment was reapplied and cotton swabs were replaced. 
 
 
Plate 3.3 Mid-sagittal view of the head of a sheep showing the cerebrospinal fluid (CSF) cannula in 
situ. 
The cannula is introduced through a hole drilled in the parietal bone about 3 mm rostral to the 
nuchal ligament aponeurosis and inserted in a caudal direction so that the tip is located in the 
cisterna magna. 
3.3.2.4 Results 
All six sheep were successfully cannulated, and recovered completely to provide CSF samples. The 
cannulae remained patent for 9 to 19 days (mean 13.5 days) and 25 to 46 samples of CSF (1.0 to 
1.2 ml), were collected from each sheep. In most cases at 1 to 2 days before cannula patency 
failed, CSF flow into the collection syringe became noticeably reduced, which could be alleviated 
sometimes by prior administration of a small volume (< 0.5 ml) of saline solution through the 
cannula. After CSF ceased to flow, cannulae were removed and all sheep were returned to the 
farm in good health. 
3.3.2.5 Discussion 
This method enables repeated sampling of CSF from sheep with minimal restraint, without need 
for sedation post surgery and without ill effects. Sampling could be repeated on numerous 
occasions in a day for more than 2 weeks, which is a similar sampling performance to that 
described previously.3 However, we consider that the present technique is a refinement because 
it is less invasive due to the use of flexible tubing, rather than the rigid metal needle used 
previously,3 and requires less removal of the parietal bone. This contrasts with the relatively 
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major excavation of bone that is required for placement of a rigid metal needle and thus our 
method reduces the possibility of trauma to the dorso-caudal surfaces of the cerebellum. The 
utility of this technique for repeated collection of CSF from sheep will likely reduce the number of 
animals required to be subjected to the procedure. 
 
In situ cannulae in the cerebral ventricles and cisternae of goats and sheep invariably become 
coated with a fibrous membrane, so that the functionality of such cannulae has a limited time-
span.4 Because the ability to collect CSF repeatedly from sheep does not extend beyond two to 
three weeks, it is desirable to have a cannulation technique that has minimal impact on welfare of 
the animals but provides ready access for sampling. The method described meets these criteria 
and makes some progress on two of the three Rs of humane animal experimentation. 
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Chapter 4. Sustained increases in plasma C-type natriuretic peptides fail 
to increase concentrations in cerebrospinal fluid: evidence from 
pregnant sheep 
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which were executed by Sengodi Madhavan. The published manuscript which forms this chapter 
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anonymous reviewers. 
 
Sustained increases in plasma C-type natriuretic peptides fail to 
increase concentrations in cerebrospinal fluid: evidence from 
pregnant sheep 
 
Wilson, M.O.1, Barrell, G.K. 1, Prickett, T.C.R.2, Espiner, E.A.2 (2015). Peptides 69: 103-108 
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4.1 Abstract 
C-type natriuretic peptide (CNP) is a paracrine growth factor with high abundance in CNS tissues 
and cerebrospinal fluid (CSF). Consistent with findings of CNP transcripts in the cerebral 
microvasculature and hypothalamus, CNP increases the permeability of the blood-brain barrier 
and reduces food intake when administered intracerebroventricularly in rodents. Whether high 
concentrations of CNP in plasma can affect CSF levels is unknown. Accordingly we have studied 
changes (days 4, 87 and 116) in concurrent plasma and CSF concentrations of CNP peptides in 
pregnant sheep – a physiologically unique setting in which plasma CNP is elevated for prolonged 
periods. Preliminary studies in non pregnant sheep showed stable CNP levels in CSF during 
repetitive sampling. Compared with values in non pregnant controls, plasma concentrations of 
CNP peptides were markedly raised (30-fold) at days 87 and 116 in pregnant sheep, yet CSF levels 
in the two groups did not differ. CNP peptides in CSF decreased from day 4 to day 87 in pregnant 
sheep, possibly reflecting an adaptive response of the cerebral vasculature to increased 
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hemodynamic load. We conclude that sustained high concentrations of CNP – far exceeding levels 
encountered in human pathophysiology – fail to affect CNP peptide levels in CSF. 
 
Keywords: blood-brain barrier; C-type natriuretic peptide; cerebrospinal fluid, NTproCNP, 
pregnancy 
4.2 Introduction 
C-type natriuretic peptide (CNP), a paracrine growth factor regulating cell proliferation and 
maturation in many tissues,1 has a high abundance in tissues of the central nervous system 
(CNS)2,3 including cerebrospinal fluid (CSF).4,5 CNP transcripts are prominent in the cerebral 
microvasculature6 and specific CNP receptors (NPR-B) are expressed in the choroid plexus and in 
the hypothalamic neuroendocrine circuits.7 CNP promotes neurogenesis8 and connectivity within 
CNS structures9 and intracerebroventricular administration of CNP has been shown to reduce 
food intake in rodents10 and lower arterial blood pressure in sheep.11 Recently, studies in 
rodents12 show that CNP also increases the permeability of the blood-brain barrier (BBB). Taken 
together these findings raise the possibility that, as found for other systemic peptides affecting 
vegetative functions13 and/or neural development,14 CNP may also access the brain parenchyma 
and CSF. 
  
In health, CSF concentrations of CNP (i.e. proCNP 82-103; 2.2 kDa) and the amino-terminal (bio-
inactive) fragment of its propeptide (amino-terminal proCNP 1-50, i.e. NTproCNP; 5 kDa) far 
exceed concentrations in plasma in humans.5 These findings suggest that CNP is independently 
regulated in central and systemic circulations, and that transfer from plasma to CSF is minimal. 
Plasma CNP concentrations in adult humans are close to detection limits (approximately 1 
pmol/L) in normal health but may achieve levels as high as 10-20 pmol/L in subjects with septic 
shock.15 Whether such high concentrations of CNP can affect CSF concentrations has not been 
studied but is important to assess for the above reasons, especially now that treatment using 
systemic administration of CNP is undergoing trials in children with disorders of skeletal growth 
(ClinicalTrials.gov.NCT02055157). 
 
Hypothesising that CSF concentrations of CNP will not be changed by sustained elevations in the 
systemic circulation, we have now measured CNP forms in time-matched samples of CSF and 
venous plasma obtained from pregnant sheep – a physiologically unique setting in which the 
circulating concentrations of CNP forms in blood are markedly increased for prolonged periods.16 
Concomitant samples of cervical atlanto-occipital CSF and venous plasma were collected from 15 
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twin-bearing ewes throughout gestation and peptide concentrations were compared with values 
in 15 non pregnant control ewes similarly sampled over the same time period. To assess possible 
changes in BBB permeability in late gestation, plasma-CSF gradients in small molecules were also 
measured.  
4.3 Materials and methods 
Animal procedures 
All procedures involving animals were carried out in accordance with the Animal Welfare Act 
1999 (NZ) and were approved by the Lincoln University Animal Ethics Committee. Animals were 
adult crossbred Coopworth-based female sheep (15 non pregnant ewes and 15 pregnant ewes 
with twins), live weight 63.2 ± 1.6 kg (mean ± s.e.) that grazed pasture during the study. 
Pregnancy and day of conception were ascertained by collecting ewes that had been naturally 
mated in a single 48 h period. Ultrasound scanning 9 weeks later was used to select those with 
twin fetuses. Unmated ewes from the same flock were randomly selected for the non pregnant 
(control) group. All sheep were brought indoors briefly on 3 occasions throughout the gestation 
period; at 4, 87 and 116 days post conception (gestation length 145 ± 6 days, mean ± s.e.) for 
collection of samples of blood and CSF. On these occasions the ewes were weighed one day prior 
to sampling and had no access to feed for 24 h after which 10 mL of blood was collected via 
jugular venepuncture into an evacuated tube containing 18 mg of potassium ethylenediamine 
tetra acetate (BD Vacutainer®, Becton Dickinson, Franklin Lakes, NJ, USA), placed on ice then 
centrifuged at 2500 rpm for 10 minutes at 4 ºC. The time from blood collection until 
centrifugation did not exceed 2 h. Plasma was stored in polycarbonate tubes at -20 °C until 
assayed. 
Ewes were individually anaesthetised with 25 mg diazepam and 500 mg ketamine hydrochloride 
delivered in combination by i.v. injection into an external jugular vein. Wool was clipped from the 
CSF sampling site and the skin cleaned with povidone iodine solution and sprayed with 70 % (v/v) 
ethanol. While an assistant held the head of the animal in a nose-down flexed position, a 30 mm x 
0.70 mm (22 G) hypodermic needle was inserted into the atlanto-occipital space as described by 
Scott17 to obtain CSF. The landmark for needle incision into the atlanto-occipital space was the 
centre of an imaginary line connecting the caudal ear margins and the occipital protuberance.  A 
palpable depression down the cisternal dorsal midline could be identified at the sampling site. 1.5 
mL of CSF was drawn through the needle into a 3 mL syringe then transferred to a polycarbonate 
tube and placed on ice, before being transferred to a freezer (-20 °C) within 2 h. On occasions CSF 
could not be obtained but at least 13 animals per group (pregnant, non pregnant) were 
successfully sampled on each occasion. 
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To determine stability of CSF levels of CNP peptides and the effects of anaesthetics used in 
sample collection, preliminary studies were performed. Seven non pregnant Coopworth ewes 
aged 3-5 years (average live weight 50 kg) were housed indoors, exposed to natural lighting, and 
fed 0.9 kg lucerne chaff once daily at 0900 with free access to water for 7 days prior to study. 
These conditions were maintained during the intervention, except ewes were fed immediately 
after 0900 h samples were collected. Using an intravenous catheter (BD AngiocathTM IV Catheter, 
Franklin Lakes, NJ, USA) temporarily emplaced in the cervical subarachnoid space17 as described 
above, samples of CSF (1.0 – 1.2 ml) were withdrawn at two-hourly intervals for 24h. Jugular 
blood samples (10ml) were collected at the same times, and processed as described above. After 
the study period had finished, cannulae were removed and all sheep were returned to the farm in 
good health. The effects of anaesthetic agents were separately studied in 6 non pregnant female 
Coopworth ewes aged 3-7 years, mean live weight 70.2 ± 2.7 kg. Animals were housed as above, 
except they were fed lucerne pellets (SealesWinslow performance nutrition, Ashburton, NZ). 
Animals were similarly sampled before and 10 minutes after receiving diazepam (0.5 mg/kg Ilium 
diazepam, Troy Laboratories NZ Pty Ltd, Auckland, NZ) and ketamine hydrochloride (10 mg/kg, 
Phoenix Ketamine injection, Phoenix Pharm Distributors Ltd, Auckland, NZ) in combination. 
 
Hormone assays 
Plasma was stored in polycarbonate tubes at -20 °C until assayed. Hormones in CSF and plasma 
were measured by radioimmunoassay after extraction using Sep-Pak cartridges (Walters Corp., 
Milford, MA, USA). All samples from an individual animal were processed in duplicate in a single 
assay. CNP was assayed as previously described18 using commercial CNP-22 antiserum (catalogue 
number G-012-03, Phoenix Pharmaceuticals, Belmont, CA, USA). Within- and between-assay 
coefficients of variation were 5.9 and 10.4 % respectively. NTproCNP was measured in plasma and 
CSF by radioimmunoassay as described previously5,19 except that synthetic ovine proCNP (1-19) 
(Mimotopes Pty Ltd, Clayton, Victoria, Australia) was used as standard. Rabbit antiserum J39, 
raised against human proCNP (1-15), was used as the primary antibody. Since the sequence of 
ovine and human proCNP (1-15) differ at amino acid residue 14, concentrations obtained using 
the new ovine standard also differ from those previously reported.16 The following formula 
describes the numeric relationship for sheep plasma concentration read from human vs sheep 
NTproCNP standard curves: [ log sheep NTproCNP ] = 1.4 [ log human NTproCNP ] - 0.30. Within- 
and between-assay coefficients of variation were 6.7 and 7.3 %, respectively. The ratio of 
NTproCNP to CNP (NTproCNP:CNP) was calculated from molar concentrations of the respective 
peptides in each sample analysed.  
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Plasma and CSF gradients of small metabolites 
Glucose and β-hydroxybutyrate were measured in CSF and plasma samples collected from 8 non 
pregnant and 8 pregnant sheep on day 116. Analytes were measured enzymatically on an 
automated analyser (Hitachi Modular P, Hitachi High-Technologies, Corporation, Tokyo, Japan) at 
a commercial analytical laboratory (Gribbles Veterinary Pathology, Christchurch, NZ) using 
proprietary kits (glucose – hexose kinase, Roche Diagnostic Corporation, Indianapolis, IN, USA and 
β-hydroxybutyrate, Randox Laboratories Limited, Crumlin, County Antrim, UK). 
 
Statistical analysis 
Statistical analyses were performed using Genstat (16th edition, VSN International Ltd., Hemel 
Hempstead, UK). Repeated-measures ANOVA was used for each hormone in each fluid to assess 
whether a diurnal rhythm was present, to determine a difference in concentration over time for 
pregnant sheep, and to compare hormone concentrations and NTproCNP:CNP ratios between 
pregnant and non pregnant sheep at different time points. A Bonferroni post hoc analysis was 
carried out to determine changes within the pregnant group. A two-tailed t-test was used to 
compare values before and after the anaesthetic regimen, and to compare glucose and β-
hydroxybutyrate concentrations and ratios in CSF and plasma from pregnant and non pregnant 
sheep. Data are presented as mean ± s.e. 
4.4 Results 
Stability studies and effect of anaesthesia 
As shown in non pregnant sheep (Figure 4.1), repetitive sampling of plasma and CSF show 
relatively stable concentrations of both CNP peptides throughout the 24 h period of study (P > 
0.05). There was no evidence of any diurnal rhythm. 
Compared with concentrations in CSF before anaesthesia (CNP 1.85 ± 0.08, NTproCNP 730 ± 48 
pmol/L), values did not differ significantly 10 minutes after drug administration (1.69 ± 0.08 and 
682 ± 39 pmol/L, respectively). Likewise, plasma concentrations of CNP (0.84 ± 0.04 before, 0.78 ± 
0.04 pmol/L after) and NTproCNP (35.0 ± 2.6 before; 36.1 ± 1.8 pmol/L after) did not differ.  
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Figure 4.1 Diurnal variation of CSF and plasma concentrations of CNP peptides. 
CNP (A) and NTproCNP (B) concentrations in CSF (closed circles) and plasma (open circles) in 7 
non pregnant ewes sampled at two-hourly intervals for 24 h. Data are mean ± s.e., pmol/L. 
 
Effect of pregnancy on plasma and CSF peptides and metabolites 
Thirteen of the 15 pregnant sheep remained well during gestation and delivered healthy twin 
lambs without incident. However, one sheep died from causes unrelated to the study after the 
last sampling occasion prior to parturition, and one delivered a malformed lamb that died several 
days after birth. Mean gain in live weight from day 4 to day 116 was 7.6 ± 1.0 kg in pregnant 
sheep. Non pregnant ewes (controls) also remained in good health with minimal change in live 
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weight (mean loss 0.6 ± 1.1 kg) over the same time period. None of the animals exhibited signs of 
meningeal infection in any of the studies being reported. 
 
Changes in CNP peptides in plasma and CSF are shown in Figure 4.2. Plasma CNP concentrations 
in non pregnant ewes (Figure 4.2 A) were 0.81 ± 0.03, 0.81 ± 0.05 and 0.97 ± 0.05 pmol/L on day 
4, 87 and 116 respectively. In strong contrast, while similar on day 4 (0.91 ± 0.04 pmol/L), plasma 
CNP in pregnant ewes had risen markedly by day 87 (24 ± 1.5 pmol/L), increasing further by day 
116 (31.9 ± 2.0 pmol/L) as shown in Figure 4.2 A. Compared with day 4 values, these increases 
were highly significant (P < 0.001 by ANOVA). Concentrations of CNP in CSF in non pregnant ewes 
(Figure 4.2 C) were higher than concurrent plasma concentrations; 3.22 ± 0.3, 3.04 ± 0.25 and 
3.60 ± 0.28 pmol/L on day 4, 87 and 116 respectively. Despite the > 25-fold increase in plasma 
CNP concentration during gestation (Figure 4.2 A), concurrent levels of CNP in CSF in these 
pregnant sheep (3.15 ± 0.21, 2.43 ± 0.17, and 4.08 ± 0.33 on day 4, 87 and 116 respectively) did 
not change (P = 0.068), and did not differ from those in non pregnant ewes (P = 0.15, by 
repeated-measures ANOVA, Figure 4.2 C). 
 
As described above for plasma CNP, a similar pattern of change was observed in NTproCNP 
concentrations in plasma of pregnant sheep (Figure 4.2 B). Plasma NTproCNP concentrations in 
non pregnant ewes were 47 ± 3.0, 49 ± 2.0 and 55 ± 2.7 pmol/L at day 4, 87 and 116 respectively 
whereas values were much higher during gestation after day 4 (54 ± 2.0, 1423 ± 106 and 1904 ± 
276 pmol/L respectively; P < 0.001 by ANOVA). As noted with CNP, CSF concentrations of 
NTproCNP in non pregnant ewes (Figure 4.2 D) were much higher than concurrent levels in 
plasma. Again, in the face of greatly increased time-matched NTproCNP concentrations in plasma 
during gestation, concentrations of NTproCNP in CSF in these pregnant sheep did not differ from 
non pregnant values.  
 
Comparing values in pregnant and non pregnant sheep at individual time points, with the 
exception of the highly significant differences observed for both CNP and NTproCNP in plasma at 
87 and 116 days, values of CSF CNP and NTproCNP concentration did not differ between the 
groups at any time point. CSF CNP (Figure 4.2 C) and NTproCNP (Figure 4.2 D) concentrations both 
decreased significantly from day 4 to day 87 in pregnant sheep (P < 0.05, post hoc Bonferroni) 
despite the elevation in plasma concentrations of both peptides. Values did not differ significantly 
between 4 and 116 days in pregnant sheep.  
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The overall NTproCNP:CNP concentration ratio in plasma was 62 ± 2.6 and did not differ between 
pregnant and non pregnant sheep (P = 0.997, ANOVA), nor over time (P = 0.999, ANOVA). 
Similarly, values for the NTproCNP:CNP ratio in CSF (overall mean 299 ± 19) did not differ 
between pregnant and non pregnant sheep (P = 0.228, ANOVA).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Effect of pregnancy on CNP peptides in plasma and CSF. 
Concentration of CNP and NTproCNP in plasma (A, B) and CSF (C, D) of non pregnant (open bars) 
and twin-bearing (solid bars) ewes throughout the gestation period. Data are mean ± s.e., pmol/L, 
n = 15 per group; * P < 0.05, *** P < 0.001.  
 
As shown in Table 4.1, both glucose and β-hydroxybutyrate concentrations were higher in plasma 
than in CSF irrespective of status on day 116. Whereas plasma β-hydroxybutyrate concentration 
increased significantly in pregnancy, plasma glucose concentration fell. However, the plasma:CSF 
concentration ratio of β-hydroxybutyrate did not differ between pregnant (8.5 ± 0.51) and non 
pregnant sheep (8.2 ± 0.77, P = 0.68) despite significant differences in concentration in CSF (Table 
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4.1). Similarly, there was no difference in the plasma:CSF concentration ratio of glucose between 
pregnant (1.72 ± 0.25) and non pregnant sheep (1.74 ± 0.16, P = 0.96) despite significant changes 
in glucose concentration during pregnancy. 
 
Table 4.1 Concentration of small metabolites in CSF and plasma. 
Concentration of β-hydryoxybutyrate and glucose in CSF and plasma in pregnant and non 
pregnant sheep on day 116. Data are mean ± s.e. (mmol/L), n = 8 per group. 
 
 CSF 
pregnant 
CSF 
non pregnant 
P Plasma 
pregnant 
 
Plasma 
non pregnant 
P 
β-hydroxybutyrate 0.11 ± 0.01 0.05 ± 0.003 <0.001 0.93 ± 0.12 0.38 ± 0.02 0.002 
       
Glucose 1.59 ± 0.21 2.23 ± 0.15 0.027 2.55 ± 0.31 3.73 ± 0.16 0.005 
 
4.5 Discussion 
 
Findings that CNP increases the permeability of the cerebrovascular endothelium12 raise the 
possibility that systemic concentrations of the peptide may access the central circulation and 
contribute to concentrations of CNP in CSF. This has not been studied previously but is an 
important issue as intraventricular administration of CNP affects food intake and energy 
regulation in rodents10 and lowers systemic blood pressure in sheep.11 In healthy adults, plasma 
CNP concentrations are low (< 1-2 pmol/L),20 less than 30 % of CSF levels,5 making it unlikely that 
systemic CNP contributes significantly to CSF levels of CNP. However at much higher 
concentrations – as may be achieved during septic shock15 or by exogenous treatments in 
children in order to promote skeletal growth – conditions of access may be more favourable. The 
present study – capitalising on a unique finding of sustained increases in plasma CNP during ovine 
pregnancy16 – shows that CSF levels are unaffected by these high levels in the peripheral 
circulation which also fail to affect the permeability of the BBB to small molecules. In addition we 
report significant reduction in CSF concentrations of both CNP forms at mid gestation – possibly 
mediated by hemodynamic changes in the systemic circulation associated with pregnancy. 
Although concentrations of both CNP and NTproCNP in CSF are much higher than plasma levels in 
humans,5 contributions from specific brain nuclei, spinal cord or CNS vascular tissues to levels in 
CSF are not known. In preliminary studies in non pregnant sheep, here we show that, as in 
humans, concentrations of both peptides were much higher in CSF compared with concurrent 
plasma levels. CSF concentrations of both CNP peptides were relatively stable during a prolonged 
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period of repetitive sampling and showed no diurnal changes. Further, levels in CSF and plasma 
were unaffected by anaesthesia induced by the drugs used in the study. Consistent with this 
evidence of stability is the close agreement in peptide levels within the two study groups 
(pregnant and non pregnant) on day 4. Changes in plasma CNP in ovine pregnancy (approximately 
25-fold increase), induced by greatly increased placental secretion16 and achieving levels of 30-40 
pmol/L, clearly fail to increase concurrent levels in CSF. It is possible, that failure to detect 
evidence of access to CSF is a consequence of some adaptive or compensatory change associated 
with the pregnant state. For example, changes in protein binding or other protein-protein 
interactions, or alterations in clearance or degradation of CNP could be responsible. For several 
reasons this is unlikely. Our previous studies of CNP in ovine pregnancy21 show no evidence of 
protein binding of CNP. More importantly, the ratio of NTproCNP to CNP in CSF does not differ 
between pregnant and non- pregnant groups. Conceivably, pregnancy associated changes in CNP 
clearance (by NPR-C) or altered degradative pathway activity could affect CNP but such changes 
would not be expected to affect NTproCNP.1,5 For both peptides to be changed similarly (in both 
direction and degree) such that the ratio was unchanged we consider implausible but cannot be 
completely excluded. 
 
Whether our findings extend outside pregnancy also requires consideration. Pregnancy 
represents a major hemodynamic challenge22 and results in significant changes in cardiac output, 
redistribution of regional blood flow and remodelling in cerebral blood vessels, where 
parenchymal arterial lumen diameter is increased and the vascular wall becomes thinner23 – all of 
which could affect BBB integrity. Although the threshold affecting transfer of solutes and small 
molecules at different levels of arterial pressure may change, several lines of evidence indicate 
that the BBB remains intact and unaltered in normal gestation.23 Our observation that small 
molecule plasma:CSF gradients, as measured on day 116, do not change in pregnancy are 
consistent with this view. It is therefore reasonable to conclude that our findings will have general 
application – including non pregnant states. However it is relevant to note that while plasma CNP 
values in the current study greatly exceed those likely to be observed in pathophysiological states 
in humans,20,24,25 they are several orders of magnitude lower than those (1-100 nmol/L) shown to 
increase BBB permeability in tissue preparations – or achieved after intravenous doses (10 
nmol/kg) that increase permeability in mice.12 Whether equivalent (e.g. 20 µg/kg) or higher doses 
of CNP administered to humans alter BBB permeability therefore remains unknown. 
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Significant reduction in both CSF CNP and NTproCNP concentrations at mid gestation in pregnant 
sheep was an unexpected finding. As already discussed, hemodynamic changes associated with 
pregnancy also impact on the cerebral vasculature. Of note, natriuretic peptides of brain origin 
are reported to participate in the regulation of CSF formation and volume.26, 27 In a previous study 
of concurrent CSF and plasma CNP forms in humans, a significant inverse correlation was found 
between plasma and CSF concentrations of CNP.5 Since there was also a significant association of 
plasma CNP with arterial blood pressure it was suggested that these systemic factors may reduce 
‘vascular CNP’ sourced within the BBB28,6 – and constitute a servo mechanism contributing to the 
autoregulation of cerebral blood flow and the maintenance of intracranial fluid volume.26 In 
pregnancy, although no change occurs in cerebral blood flow or pressure, there is extensive 
remodelling within brain parenchymal arterioles, with consequential increase in wall tension and 
wall stress.23 This, along with increased capillary density and vascular volume in pregnancy could 
reflect the afferent limb in the servo mechanism previously postulated. In diminishing CNP 
production within the brain’s vasculature, such changes could be important in the homeostatic 
regulation of intracranial fluid volume.26,27 Hemodynamic stress is likely to be near maximum by 
mid gestation - at least in humans22 and could account for the temporal changes we observe in 
CSF CNP. In future studies it will be instructive to examine temporal changes in cerebral blood 
flow, BBB integrity and changes in CNP during pregnancy, and the effects of specific CNP 
antagonists once they become available. 
In summary, sustained high concentrations of CNP forms in the systemic circulation – greatly 
exceeding concentrations encountered in human pathophysiology – do not increase CNP levels in 
CSF. Reduced CSF CNP forms at mid gestation may reflect an adaptive response of the cerebral 
vasculature to increased circulating blood volume. 
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4.7 Additional information, excluded from the manuscript 
Pregnant and non pregnant sheep were obtained using the following procedure: after 
progesterone controlled internal drug release devices (CIDRs) were inserted and withdrawn, a 
crayon-harnessed vasectomised ram was introduced in order to identify ewes that were cycling. 
Ewes that were marked with the crayon by the vasectomised ram were deemed non pregnant — 
15 of which were randomly selected to comprise the non pregnant group of sheep for the current 
study — and the rest were subject to artificial insemination (as part of a separate study). 12 days 
following AI, an entire crayon-harnessed ram was introduced to the mob for mating with the 
ewes that did not conceive to the AI. Only 15 pregnant sheep were required for this study, 
however as it was too early in the gestation period to confirm pregnancy status via ultrasound 
scanning, samples of CSF and plasma were collected from 20 of these sheep. Once pregnancy 
status was confirmed after the first sampling period, 15 sheep were randomly selected to remain 
in the trial. 
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Chapter 5. Investigation of candidate stimuli to evoke changes in CSF 
concentration of CNP peptides 
 
Statement 
I was involved with the study design and animal procedures, and all assays were carried out by 
me except for the testosterone assay, which was done by Canterbury Health Laboratories 
(Christchurch, NZ). I received significant technical assistance with animal procedures, and the 
writing of this chapter benefitted from comments from my PhD supervisors. 
5.1 Investigation of candidate stimuli to evoke changes in CSF concentration of CNP 
peptides in sheep 
5.1.1 Introduction 
As discussed in Chapter 2, there are many regions of the CNS that express CNP and its receptors, 
any of which could be candidates for sources of CNP. At the onset of these studies, no 
physiological event or drug treatment had been reported to be capable of altering CNP peptide 
concentration in CSF. Preliminary studies on sheep, carried out as an Honours degree project, 
revealed the absence of a diurnal rhythm (Wilson et al. 2015), and a lack of response to cerebral 
cortex activation (in the form of transcranial magnetic stimulation) and general sympathetic 
activation (peripheral administration of caffeine; unpublished, Wilson et al. 2011). To overcome 
this lack of a known stimulus/suppressant that will acutely elevate or reduce the CSF 
concentrations of CNP peptides, a series of pilot studies was undertaken in search of a candidate 
for this purpose. Certainly, identification of a treatment stimulus or suppressant that is able to 
alter CNP peptide concentrations in CSF would be invaluable in future studies to determine the 
source of CNP peptides in CSF. Compounds were selected that targeted a range of major brain 
pathways, and/or showed potential in the literature to play a role in the regulation of CNP 
secretion in the brain (5.1.2). The studies described in this section were pilot studies which served 
the sole purpose of identifying a central stimulus or suppressant of central CNP. Therefore, they 
involved small group sizes, no statistical analysis and sometimes no measure of drug efficacy (e.g. 
l-deprenyl and progesterone). As part of the same general objective aimed at identifying central 
regulators of CNP peptides, studies were undertaken in a second animal model — the red deer 
stag — to investigate whether the profound seasonal changes in appetite and reproductive 
activity exhibited by this species affected CSF levels of the CNP peptides (5.2). 
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5.1.2 Rationale for selection of candidate stimuli to effect changes in CSF 
concentration of CNP peptides 
 
Anaesthetics/sedatives 
In earlier pilot studies designed to develop a method for repeated collection of CSF samples in 
sheep, it was observed that CNP peptide concentration was lower in the initial samples which 
were obtained — whilst the animals were under the influence of ketamine/diazepam — than in 
subsequent samples (n = 5, Lincoln University 2009–2010, unpublished). This suggested that brain 
regions sensitive to the depressive effects of anaesthetics and sedatives were the possible 
sources of CNP peptides appearing in CSF. Consequently, samples of CSF were collected before, 
during and after anaesthesia to map any changes in CSF concentrations of CNP peptides which 
could be linked to the decrease and subsequent increase in arousal level that accompanies 
anaesthesia and recovery. The compounds investigated were ketamine (on its own or in 
conjunction with the sedative, diazepam) and isoflurane.  The sedative, diazepam, was also tested 
on its own.  
 
Lipopolysaccharide 
There are many studies linking CNP to inflammation described in the literature, however the 
nature of CNP’s involvement is unclear. Whereas higher plasma concentrations of CNP are 
associated with severe inflammation in adults (Koch et al. 2011), acutely ill children were shown 
to have lower plasma concentrations of the CNP peptides (Prickett et al. 2013). Evidence for an 
anti-inflammatory effect of CNP was published by Qian et al. (2002) where it was shown that 
overexpression of CNP reduced macrophage infiltration in injured arteries, and suppressed the 
expression of adhesion molecules that were stimulated by the injury in vitro. Elevated plasma 
concentrations of CNP have been observed in patients diagnosed with Crimean-Congo fever 
(Turkdogan et al. 2012) although it is unlikely that this is related to CNP having an active role in 
this setting — instead CNP may be released from endothelial cells which are damaged by the virus 
(Ergonul et al. 2004). 
 
Suga et al. (1993) reported that lipopolysaccharide (LPS), a pyrogenic endotoxin, induces CNP 
secretion from bovine endothelial cells in vitro. Furthermore, Osterbur et al. (2013) found that 
LPS, tumour necrosis factor-α and interleukin-1β stimulated NTproCNP secretion from canine 
aortic vascular endothelium in vitro. Interleukin 1-β, which can act as an endogenous pyrogen in 
the rat brain (Dascombe et al. 1989), was the strongest stimulant of NTproCNP secretion of all the 
stimulants tested (Osterbur et al. 2013). CNP may also be involved in the central control of 
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thermoregulation, because it was shown that intracerebroventricular administration of CNP 
acutely elevated colon temperature in rats (Pataki et al. 1999). 
 
LPS, when administered to sheep at a dose of 700 ng/kg live weight, reliably produces a fever in 
our laboratory.  It was used here to provide a model inflammatory response to determine the 
possible role of this stimulus on the concentration of CNP peptides in CSF. 
 
Progesterone  
There are several studies linking sex steroids to the regulation of CNP synthesis. Exogenous 
oestrogen has been shown to increase plasma concentrations of CNP peptides in pre-pubertal 
ewes (Prickett et al. 2008). Testosterone treatment in children with growth hormone deficiency 
and idiopathic short stature is accompanied by markedly increased plasma concentrations of 
NTproCNP (Olney et al. 2007). However, evidence against a direct effect of testosterone on CNP 
synthesis was provided in later studies by Prickett et al. (2008), where it was shown that 
exogenous testosterone had no effect on plasma concentrations of CNP peptides in pre-pubertal 
lambs. In contrast to testosterone and oestrogens, the effects of progesterone on CNP peptides 
have not been studied. Controlled internal drug release devices (CIDRs) are silicon coated devices 
containing progesterone which are inserted intra-vaginally to large animals such as sheep and 
cattle (Wheaton et al. 1993). After a period of time whereby the progesterone is slowly released, 
the CIDRs are removed, allowing oestrus to be synchronised throughout a herd of animals. CIDRs 
were used here as a convenient progesterone delivery source to investigate its possible role in 
physiology of the CNP peptides in the CNS.  
 
Morphine  
Opioid receptors are widely distributed in the brain and are bound by endogenous ligands 
including β-endorphin and various forms of encephalin; their actions possibly providing analgesic 
effects under normal physiological conditions (Wolozin & Pasternak 1981). Morphine is a 
selective µ opioid receptor agonist which is commonly prescribed to relieve acute and chronic 
pain (reviewed by Mellon & Bayer 1998) and targets a specific set of brain pathways. 
Furthermore, Babarczy et al. (1995) reported that central administration of CNP prior to a 
morphine injection depressed the antinociceptive properties of the opiate in mice. The effect of 
morphine on the affective state, locomotor activity and other behavioural aspects have been well 
characterised in sheep (Verbeek et al. 2012). A dose was selected that has been shown to be safe 
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but sufficient to induce behavioural changes and affect arousal status, as measured by an 
increase in locomotor activity and number of vocalisations (Verbeek et al. 2012). 
 
 L-deprenyl 
Espiner et al. (2014) showed that CSF concentrations of NTproCNP were reduced in Parkinson’s 
disease patients — compared with CSF from individuals without a neurological disorder — and 
that the decline seen with disease progression was prevented in patients who received L-
deprenyl. L-deprenyl (Selegiline) was developed in the 1960s for possible use as an anti-
depressant, but was approved by the FDA (Food and Drug Administration, USA) in 1989 for 
treatment of Parkinson’s disease because it is a potent and selective inhibitor of monoamine 
oxidase B enzyme (Knoll 1983). Monoamine oxidase B enzyme degrades dopamine, and loss of 
dopamine (due to neurodegeneration in the substantia nigra) is one of the hallmarks of 
Parkinson’s disease (Grosch et al. 2016). Whether changes in dopamine levels would affect CSF 
concentrations of CNP peptides is unknown, however several studies have reported the ability of 
CNP to influence dopamine pathways. Thiriet et al. (2001) reported that microinjections of CNP 
into the rat brain prevented cocaine-induced dopamine release and altered transcription factors 
that coordinated changes in gene expression underlying neuronal plasticity. Jouvert et al. (2004) 
later confirmed the site of action of CNP and showed that these changes were mediated via 
cGMP-dependent protein kinase I. The most common therapeutic dose that is prescribed for 
Parkinson’s disease patients is 10 mg l-deprenyl, taken daily through the form of two 5 mg 
tablets. Hypothesising that changes in dopamine levels may alter CSF concentrations of CNP 
peptides, the effect of a single dose of 10 mg l-deprenyl was investigated here.   
 
Dexamethasone 
Several studies have shown that glucocorticoids have the potential to regulate CNP peptide 
pathways, however whether they act at the level of the CNS is not known.  Prickett et al. (2009) 
reported that plasma concentrations of CNP and NTproCNP in growing lambs were lower 24 and 
48 h after repeated (125 µg/kg live weight for 2 days) administration of dexamethasone, a 
synthetic glucocorticoid. In contrast, it has been shown that dexamethasone increases expression 
of NPPC in chondrocytes in vivo (Agoston et al. 2002). On this background of contradictory 
results, the present study investigated the effect of a single peripherally-administered bolus of 
dexamethasone on central concentrations of CNP peptides. 
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5.1.3 Methods 
Sheep were brought indoors one week prior to each trial and fed a maintenance level diet of 
lucerne chaff and pellets (SealesWinslow performance nutrition, Ashburton, NZ) with water 
available ad libitum. Food and water was withheld for the night prior to the cannulation 
procedure, whereby individual animals were cannulated at the cervical epidural space for 
repeated collection of CSF samples as described in 3.3.1. Prior to the cannulation procedure, 
sheep were given a single s.c. injection of an antibiotic (2.5 mL Depocillin, 300 mg/mL procaine 
penicillin, MSD Animal Health, Upper Hutt, NZ). CSF sampling commenced 2 days after the 
cannulation procedure. When catheter patency allowed, different studies were conducted with 
individual sheep, with a minimum of 2 days between treatments. As the objective of this series of 
studies was to identify a compound capable of acutely altering CSF concentrations of CNP 
peptides, multiple samples were collected within several hours of treatment in most cases and  
concurrent blood samples (for plasma) were collected on the same occasions. CSF and plasma 
samples were assayed for CNP and NTproCNP as previously described in 3.2.2. Assay detection 
limits were 0.61 and 5.4 pmol/L, respectively. 
 
Ketamine and diazepam in combination 
CSF and plasma samples were collected immediately prior to a single i.v. bolus of a combination 
of diazepam and ketamine (0.5 mg/kg live weight, Ilium diazepam, Troy Laboratories NZ Pty Ltd, 
Auckland, NZ and 10 mg/kg live weight, Phoenix Ketamine injection, Phoenix Pharm Distributors 
Ltd, Auckland, NZ, respectively, n = 4) and at 10, 30 and 120 minutes post injection. 
 
Diazepam 
CSF and plasma samples were collected immediately prior to a single i.v. bolus of diazepam (1.0 
mg/kg live weight, Ilium diazepam, Troy Laboratories NZ Pty Ltd, Auckland, NZ, n = 4) and at 10, 
30 and 120 minutes post injection. 
 
Ketamine 
CSF and plasma samples were collected immediately prior to a single i.v. bolus of ketamine (20 
mg/kg live weight, Phoenix Ketamine injection, Phoenix Pharm Distributors Ltd, Auckland, NZ, n = 
4) and at 10, 30 and 120 minutes post injection. 
 
Isoflurane 
CSF and plasma samples were collected immediately before anaesthesia was induced with 
isoflurane by mask (in oxygen, 5 % v/v) and maintained with an endotracheal tube at 2-3 % for 30 
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minutes (Isoflurane, registered to Piramal Healthcare Limited, India. Marketed and distributed by: 
Merial New Zealand Ltd, Manukau City, NZ, n = 4). CSF and plasma samples were collected 10, 30 
and 120 minutes after induction of anaesthesia. 
 
Lipopolysaccharide 
An estimate of core temperature was obtained by using a digital rectal thermometer (Geratherm 
Medical AG, Geschwenda, Germany) prior to and after a single i.v. bolus of LPS (Sigma-Aldrich, St 
Louis, Missiouri, USA, Lot 30 K4114, Serotype 055:B5, 700 ng/kg, n = 4) dissolved in 0.9 % w/v 
saline solution at a rate of 20 µg/mL. Rectal temperature was regularly recorded and CSF and 
plasma samples were collected immediately prior to treatment and at various time points after as 
core temperature increased between 150 and 210 minutes post injection. 
 
Progesterone 
CSF and plasma samples were collected immediately prior to the intra-vaginal insertion of a 
progesterone CIDR (Eazi-breed CIDR, Interag, Hamilton, 0.3 g progesterone/insert. Distributed by 
Pfizer, Auckland, n = 4), which was administered using a plastic applicator and removed after 3 h. 
Samples were collected at 3 and 6 h after CIDR insertion. 
 
Morphine 
 CSF and plasma samples were collected immediately prior to the i.v. administration of a single 
bolus of morphine (0.84 mg/kg live weight, morphine hydrochloride BP oral solution 2 mg/mL, 
Pharmacia Cooporation, New Jersey, USA, n = 4) and at 40 minutes and 2, 3, and 24 h after 
treatment. 
 
L-deprenyl 
CSF and plasma samples were collected immediately prior to a single i.v. bolus of l-deprenyl (10 
mg/sheep, Selegiline hydrochloride, Sigma-Aldrich, St Louis, Missouri, USA, dissolved in 0.9 % w/v 
saline solution at a rate of 2 mg/mL, n = 3) and at 30, 100 and 150 minutes after treatment. In a 
subsequent trial, the same protocol was followed with a different group of sheep (n = 3). 
 
Dexamethasone 
CSF and plasma samples were collected immediately prior to a single i.m. bolus of 
dexamethasone (Dexa 0.2, PhoenixPharm Distributors Ltd, Auckland, NZ, 0.25 mg/kg live weight), 
and 24 h following treatment (n = 4). In a subsequent trial, the same protocol was followed 
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except the route of administration was i.v. and samples were collected at 2, 4, 8, 24 and 48 h post 
treatment (n = 3). 
5.1.4 Results 
Most samples were collected as intended, however occasionally a CSF sample could not be 
obtained due to a loss of patency of the catheter. Mean catheter patency was 6 days. In cases of 
premature failure of a cannula, a replacement animal was introduced to the trial. 
 
CSF concentrations of NTproCNP were elevated 24 h after dexamethasone administration in all 4 
sheep (Figure 5.9), and CSF concentrations of both peptides were elevated in 1 of 3 sheep 
administered with l-deprenyl (Figure 5.8). Therefore, the effect of the respective compounds on 
CSF concentrations of CNP peptides was investigated further with 3 different sheep. This ‘follow–
up’ study revealed a marked increase in CSF concentrations of NTproCNP 8 h after 
dexamethasone in all 3 sheep. CSF concentrations of CNP were elevated 8 h after dexamethasone 
in 2 sheep. In plasma, CNP and NTproCNP concentration was markedly elevated 2, 4 and 8 h after 
dexamethasone, but had returned to baseline concentrations 24 h post treatment. In contrast, 
NTproCNP concentrations in CSF remained elevated in all 3 sheep (Figure 5.11). 
 
Whereas a marked increase in CNP peptide concentration was observed after dexamethasone, 
there was no consistent change in CNP or NTproCNP concentration in CSF or plasma after l-deprenyl 
(Figure 5.10). There were no consistent changes in CSF concentrations of CNP and/or NTproCNP at 
any time point following adminstration of ketamine, diazepam, diazepam and ketamine in 
combination, isoflurane, LPS, progesterone and morphine (Figure 5.1 to Figure 5.7). Behavioural 
changes were observed in all sheep that received anaesthetics; and there was a noticable reduction 
in locomotor activity after 10 minutes, i.e. all sheep were lying down, following administration with 
diazepam. Most sheep were standing again 30 minutes after injection and activity levels were close 
to normal 2 h post treatment. After ketamine, several behaviours were displayed that were 
indicative of its dissociative effect, including an increase in vocalisations, increase in eye and head 
movement shown 10 and 30 minutes post injection, with most sheep returning to their normal 
(calmer) state by 2 h. Following diazepam and ketamine (in combination), sheep were anaethetised 
within several minutes and remained in this state for 20-30 minutes. Similarly, isoflurane induced 
then maintained anaesthesia for 30 minutes. 
 
Behavioural changes were observed for the first 30 minutes after morphine; three sheep began 
grinding their teeth whilst maintaining a fixed gaze within minutes of treatment, and the fourth 
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sheep showed an increase in alertness and interest in its surroundings. A mild elevation of 
temperature was induced by LPS. Mean rectal temperature was 39.1°C prior to LPS 
administration and 39.3 and 39.7 °C at 2.5 h and 3 h 20 minutes later, respectively.  
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Figure 5.1 Effect of diazepam. 
CNP (left) and NTproCNP (right) concentration in CSF (top) and plasma (bottom) of individual 
sheep (n = 4) following administration with a single bolus of diazepam (1.0 mg/kg live weight, i.v.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Effect of ketamine. 
CNP (left) and NTproCNP (right) concentration in CSF (top) and plasma (bottom) of individual 
sheep (n = 4) following administration with a single bolus of ketamine (20 mg/kg live weight, i.v.). 
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Figure 5.3 Effect of diazepam and ketamine in combination. 
CNP (left) and NTproCNP (right) concentration in CSF (top) and plasma (bottom) of individual 
sheep (n = 4) following administration with a single bolus of diazepam and ketamine in 
combination (0.5 and 10 mg/kg live weight, respectively, i.v.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Effect of isoflurane. 
CNP (left) and NTproCNP (right) concentration in CSF (top) and plasma (bottom) of individual 
sheep (n = 4) anaethetised with isoflurane (induced at 5 % and held at 2-3 % for 30 minutes).  
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Figure 5.5 Effect of LPS. 
CNP (left) and NTproCNP (right) concentration in CSF (top) and plasma (bottom) of individual 
sheep (n = 4) following administration of a single bolus of LPS (0.7 µg/kg live weight, i.v.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Effect of progesterone. 
CNP (left) and NTproCNP (right) concentration in CSF (top) and plasma (bottom) of individual 
sheep (n = 4) following exposure to progesterone for 3 h (intra-vaginal progesterone CIDR 
inserted at 0 h and removed after 3 h).  
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Figure 5.7 Effect of morphine. 
CNP (left) and NTproCNP (right) concentration in CSF (top) and plasma (bottom) of individual 
sheep (n = 4) following administration of a single bolus of morphine (0.84 mg/kg live weight)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 Effect of l-deprenyl. 
CNP (left) and NTproCNP (right) concentration in CSF (top) and plasma (bottom) of individual 
sheep (n = 4) following administration of a single bolus of l-deprenyl (10 mg/sheep, i.v.).  
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Figure 5.9 Effect of dexamethasone. 
CNP (left) and NTproCNP (right) concentration in CSF (top) and plasma (bottom) of individual 
sheep (n = 4) following administration of a single bolus of dexamethasone (0.25 mg/kg, i.m.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 Effect of l-deprenyl (follow-up study). 
CNP (left) and NTproCNP (right) concentration in CSF (top) and plasma (bottom) of individual 
sheep (n = 3) following a single bolus of l-deprenyl (10 mg/sheep, i.v.). 
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Figure 5.11 Effect of dexamethasone (follow-up study). 
CNP (left) and NTproCNP (right) concentration in CSF (top) and plasma (bottom) of individual 
sheep (n = 3) following a single bolus of dexamethasone (0.25 mg/kg live weight, i.v.). 
 
5.1.5 Discussion 
This series of pilot studies confirms previous observations showing that CSF concentrations of the 
CNP peptides exceed those in plasma and are remarkably stable within individuals over a time 
period of several hours (Wilson et al. 2015). These results suggest that levels of CNP peptides in 
CSF remain unchanged even during significant alterations in brain activity that occur with 
anaesthesia. This finding, along with the fact that the structure of CNP is highly conserved across 
species (2.1.2), and that CNP concentrations are consistently higher in CSF (relative to circulating 
levels), supports the idea that the latter is necessary for some basic aspect of homeostasis in the 
brain that may be common to all mammalian species. Furthermore, it can be speculated that the 
integration of neuronal activity of cortical regions is not essential for the maintenance of the 
higher concentrations of CNP in CSF — as a reduction of the ability of the brain to integrate 
information from different cortical regions (via thalamic relay) is the common denominator of 
most anaethetics — despite their varying modes of action (Alkire et al. 2008). 
 
The finding that high CNP levels in the CSF are maintained despite the depression of higher brain 
neuronal activity is supportive of existing literature which proposes CNP as an important signal in 
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the CNS and, suggests that CNP signalling may be necessary even during the unconscious state 
(reviewed by Prado et al. 2010). The finding that CSF concentrations of CNP peptides remain 
unchanged following administration of diazepam and ketamine is important for studies where 
CSF samples are collected from sedated or anaesthetised animals (Chapter 4 and Chapter 6), 
because it rules out anaesthesia as a potential confounding factor when determining 
concentrations of CNP and NTproCNP. 
 
These studies achieved the objective of identifying a stimulus capable of acutely changing CSF 
concentrations of CNP peptides and identified dexamethasone as the reliable candidate for this 
task. Although plasma levels of CNP and NTproCNP were also increased, the elevation of 
NTproCNP concentration 24 h after dexamethasone — but not in plasma — suggests that the 
peptides in the two fluids are regulated independently and diminishes the possibility of a 
‘spillover effect’ of peptides passing from the peripheral circulation to the CSF. Although this 
possibility deserves further consideration, data from a recent study in humans also indicate that 
CNP peptides in CSF and plasma are independently regulated (Schouten et al. 2011). 
 
Although the objective was to screen candidates for their ability to provide an acute stimulus or 
to suppress levels of CNP peptides in the CNS (that could be used in future studies), controls, such 
as saline-treated animals, were not included in these studies. This means that some of the 
compounds used here can not be fully ruled out as potential modifiers of CNP levels in the CNS.  
Also, it was not always possible to ascertain whether an effective dose had been used in the pilot 
study.  For instance, the elevation of rectal temperature following administration of LPS was 
minor (mean maximum of 39.7 °C) compared with expected values above 40 °C (Breen and 
Barrell, 2002). Likewise, other compounds, e.g. l-deprenyl, progesterone, etc. may have been 
effective at higher doses than were used here. In simplistic terms, these pilot studies were of the 
nature of a ‘fishing expedition’ and were conducted in this way using ‘best guess’ dosages to, 
rather hopefully, identify potential candidates for further study whilst minimising the effort and 
animal usage that would have been required for an exhaustive study in each case.  Finding 
dexamethasone to be a suitable candidate, following this minimalistic approach, can be 
considered as serendipitous. Not only has it proven to be a reliable stimulator of CNP peptide 
levels in CSF, but it also points to involvement of an endogenous corticosteroid pathway in the 
regulatory physiology of the CNP peptides.  Importantly, for the subsequent studies in this thesis, 
the pilot studies have achieved their objective in revealing a suitable candidate stimulus for 
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raising CNP peptide levels in the CSF and for alteration of gene expression in pituitary and central 
nervous tissues. 
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5.2 Investigation of the effect of seasonal changes in appetite and food intake on CNP 
peptide concentrations in red deer (Cervus elaphus) stag plasma and CSF 
5.2.1 Introduction 
Several studies suggest that CNP is involved in the regulation of energy balance and appetite. 
Following observations that NPPC and NPRB — the genes encoding the precursor and receptor of 
CNP, respectively — are detected throughout nuclei of the hypothalamus which are strongly 
linked with appetite regulation (Langub et al. 1995a, Langub et al. 1995b, Herman et al. 1996b), it 
was speculated that CNP might be involved in the regulation of energy balance and appetite.  
 
The use of knockout mice in studies of CNP are complicated by the skeletal deformities that occur 
when the NPPC or NPRB gene is disrupted (Tamura et al. 2004), which compromises the animal’s 
ability to eat. Consequently, Inuzuka et al. (2010) generated CNP-knockout mice with targeted 
chondrocyte-specific NPPC expression (CNP-Tg/NPPC-/-), so that changes related to the absence of 
CNP could be observed, while minimising skeletal problems. These mice — with a rescued body 
length and lack of NPPC mRNA in the hypothalamus — were leaner and had a significantly 
reduced body weight at 20 weeks of age, when compared with CNP-Tg/NPPC-/- mice. 
Furthermore, they lost more body weight during 48 h of starvation, ate less after a refeed, had 
improved insulin sensitivity, and had significantly higher uncoupling protein-1 mRNA levels in 
brown adipose tissue, which is activated during thermogenesis (reviewed by Ricquier & Bouillaud 
2000). Altogether, data from Inuzuka et al. (2010) support the hypothesis that CNP might increase 
body fat accumulation and reduce energy expenditure via a reduction in thermogenesis. 
 
In contrast, Yamada-Goto et al. (2013) demonstrated that CNP suppresses food intake when 
administered centrally to mice prior to refeeding after a 48-h fasting period. This effect was 
blocked by an antagonist for melanocortin-3 and melanocortin-4 receptors, suggesting that CNP 
has a central anorexigenic action which acts partly through activation of the melanocortin system. 
This anorexigenic effect was observed only when CNP was administered centrally — and not 
peripherally. In the same study, CNP significantly suppressed neuropeptide Y- and ghrelin-induced 
food intake when CNP (both CNP-22 and CNP-53) was centrally co-administered with 
neuropeptide Y. CNP may exert its actions via direct or indirect stimulation of hypothalamic 
neurons, as indicated by the increase in the number of c-Fos-positive cells in multiple 
hypothalamic nuclei following central administration of CNP (Yamada-Goto et al. 2013). 
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Although there is evidence to suggest that CNP is implicated in the regulation of appetite, the 
nature of its involvement is unclear. As part of the same objective described in 5.1, studies were 
undertaken in a second animal model, the red deer stag. The appetite and live weight of red deer 
(Cervus elaphus), especially stags, vary markedly over different seasons of the year in response to 
changes in photoperiod. After summer, when the daily photoperiod begins to decrease, dramatic 
physiological changes occur in the stag in preparation for an active reproductive season (the ‘rut’) 
including marked testes growth, increase in circulating levels of testosterone and increased sperm 
production. During the rut (which occurs from late-March to late-April in NZ) stags become hyper-
active and invest a large amount of energy into competition for access to hinds for mating and 
their appetite is greatly reduced — and consequently up to 30 % of their body weight is lost 
(Stevenson et al. 1992). When photoperiod begins to increase in late-winter/early-spring, the 
appetite and food intake of stags is greatly increased, and their body weight recovers until the 
beginning of the next rut season. In this study, it is hypothesised that red deer stags may have 
seasonal changes in CNP levels in their CSF that could be associated with their very pronounced 
appetite cycle. Using this physiologically unique setting, changes in central levels of CNP peptides 
were assessed in vivo, in relation to the dramatic changes in appetite and body weight. 
5.2.2 Methods 
Animal procedures 
Six adult red deer stags were grazed on ryegrass/white clover pasture at the Lincoln University 
Research Farm for the duration of the trial, and were brought into yards on sampling days which 
occurred every 2 months from September 2013 to September 2014. Stags were transferred 
individually from a yard and secured in a standing position using a padded side loading 
mechanical deer crush (Keane Deer Yards, Rangiora, NZ) which was positioned over weighing 
scales during the sampling procedures. Once secured, live weight was recorded, and a 10 cm by 3 
cm patch of hair was clipped from the neck. Body condition score was recorded at all sampling 
occasions except in November, and was assessed by the same person at all times. Two stags 
departed from the trial prior to the last 2 sampling occasions (one stag died of causes unrelated 
to the trial and one died unexpectedly following administration of the anaesthetic) and were 
replaced by 2 stags of similar live weight and age which were recruited into the group to maintain 
the sample size of 6. 
 
Blood was collected via jugular venepuncture into 2 evacuated tubes containing 18 mg of 
potassium ethylenediamine tetra acetate (BD Vacutainer®, Becton Dickinson, Franklin Lakes, New 
Jersey, USA). Blood in EDTA tubes was placed on ice then centrifuged at 2500 rpm for 10 min at 
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4°C. The time from blood collection until centrifugation did not exceed 2 h. Plasma was stored in 
polycarbonate tubes at −20°C until assayed. Stags were individually anaesthetised with a single 
xylazine/ketamine combination bolus (Phoenix Xylaket 15/5, 150 mg/ml xylazine hydrochloride 
and 50 mg/ml ketamine hydrochloride, Phoenix Pharm Distributors Ltd, NZ) using 0.05 mL/kg live 
weight administered via the jugular vein. Hair was clipped from around the CSF sampling site 
(Plate 5.1) and the site was cleaned with povidone-iodine solution (Vetadine - Iodine Animal 
Wash, 1.6 % w/v available iodine, 19.7 mg/mL crude iodine, Bomac Laboratories Ltd, Auckland, 
NZ) and disinfected with 70 % isopropanol. Once the animal was anaesthetised, an assistant 
flexed the head fully downwards and a sterile hypodermic needle (22 G x 1½” (0.71 x 38 mm)) 
was inserted into the atlanto-occipital space (Plate 5.1) and 2 mL CSF was withdrawn. CSF 
samples were stored in polythene Eppendorf containers and placed directly on ice, prior to 
storage at -20 °C. Anaesthetic reversal agent was administered (2 mL yohimbine hydrochloride 10 
mg/mL, Phoenix Pharm Distributors Ltd, NZ) by i.v. delivery whereupon the stag was released 
from the crush and monitored until fully conscious. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plate 5.1 Collection of CSF from the atlanto-occipital space of a red deer stag. 
Collection of CSF from the atlanto-occipital space of a red deer stag. The tissues penetrated, in 
order, are: the skin and subcutaneous tissue, nuchal ligament, dura mater and the arachnoid 
mater to reach the subarachnoid space.  
 
Hormone assays 
CSF and plasma samples were processed as described in 3.2 for measurement of CNP and 
NTproCNP concentration. Plasma testosterone concentration was measured using an in-house 
enzyme-linked immunosorbent assay (ELISA) at Canterbury Health Laboratories (Christchurch, NZ) 
as previously described (Elder & Lewis 1985). Briefly, 50 µL of each sample was manually 
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dispensed (in duplicate or quadruplet) into wells of a 96-well microtitre plate blocked with a 
conjugate to reduce non-specific antibody binding using an automated ELISA analyser (Behring 
ELISA Processor M, CSL Behring, King of Prussia, USA) and incubated overnight at 4°C with 
antiserum to testosterone (raised in rabbits). Plates were washed with phosphate-buffered saline 
solution containing a detergent and aspirated prior to the addition of a peroxidase-labelled goat-
antirabbit IgG and incubated for a further 2 h. Plates were washed again and 100 µL of enzyme 
substrate was added. Colour development was allowed to occur in the dark for 15 minutes and 
the enzymatic reaction was terminated using 100 µL of 1.25 M H2SO4. The absorbance was read 
at 492 nm on the automatic analyser and results were interpolated from a standard curve. Assay 
precision was determined by analysing 6 sets of duplicates from 3 pools of plasma; intra-assay 
variation was 7.6, 9.8 and 12 % for samples with mean concentrations of 4.3, 13.8 and 22.7 
nmol/L, respectively. Inter-assay variation did not exceed 12.5 % for the 3 pools (Elder & Lewis 
1985).  
 
Statistical analysis 
Concentrations of CNP and NTproCNP in CSF and plasma, as well as live weight and plasma 
testosterone concentration were compared across time points using logged data (log10) and a 
repeated-measures ANOVA in Genstat Version 16 (VSN International Ltd., Hemel Hempstead, UK) 
and least significant differences were used to determine differences between specific time points. 
The relationship between peptide levels in plasma, plasma testosterone concentration, live 
weight and body condition score was determined using GraphPad Prism version 6.01 for 
Windows (GraphPad Software Inc, La Jolla, California, USA, www.graphpad.com). Two ANOVA 
analyses were run using both possible data sets that resulted according to how the newly 
recruited stag data were arranged, and results did not differ between data sets.  
5.2.3 Results 
All data are presented in Figure 5.12 as mean ± s.e. As shown in Figure 5.12 A, mean live weight 
changed significantly through the year (p < 0.001) and increased from the first sampling occasion 
in December (beginning of summer) to January (p < 0.05) by approximately 50 kg. Mean live 
weight was significantly higher in January and March (192 ± 7 and 188 ± 6 kg, respectively) than 
during the following months, i.e. in May, July, and September (p < 0.05) when mean live weight 
decreased by approximately 30 kg (158 ± 3 kg in September). Body condition score followed the 
same pattern of change as live weight (Figure 5.12 A). Plasma testosterone concentration (Figure 
5.12 B, closed circles) peaked in March (the beginning of autumn and the mating season), 
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whereby concentrations exceeded those in samples from all other time points by 5- to 30-fold (p 
< 0.05).  
 
CSF concentrations of both peptides markedly exceeded those in the plasma (3- to 4- fold for 
CNP, 11- to 17-fold for NTproCNP) at all time points, except in March when the difference was 
smaller (2- and 7-fold for both peptides, respectively). Following a similar pattern to testosterone, 
plasma concentrations of CNP and NTproCNP varied throughout the year (p < 0.001), with a peak 
concentration occurring in March. This increase in concentration was more progressive (p < 0.05), 
i.e. appeared to commence earlier, than the rise in plasma testosterone concentration.   In 
March, plasma CNP and NTproCNP concentration was approximately 2-fold higher than at other 
time points (Figure 5.12 D). Both CNP and NTproCNP concentrations were lower in plasma 
samples collected in May and July, than in samples from the previous sampling time points 
(November, January and March, p < 0.05). 
 
Whereas plasma concentrations of CNP and NTproCNP changed significantly throughout the year, 
very little variation occurred in CSF (Figure 5.12 C). Mean concentrations of CNP in CSF ranged 
between 2.1 ± 0.4 and 3.7 ± 0.6 pmol/L and means were not significantly different between any 
time points considered here. Mean concentrations of NTproCNP in CSF were similar across 
different months in most cases — except there was a slight rise (p < 0.05) between September 
(437 ± 40 pmol/L) and the following March (557 ± 32 pmol/L).  
 
Concentrations of CNP and NTproCNP were positively correlated in plasma (r = 0.88, p < 0.0001) 
but not in CSF (Figure 5.13). Plasma testosterone concentration was positively correlated with both 
plasma CNP (r = 0.58, p < 0.001) and plasma NTproCNP concentration (r = 0.61, p < 0.0001, Figure 
5.14). Live weight was positively correlated with both CNP and NTproCNP concentration in plasma 
(r = 0.70, p < 0.001 and r = 0.54, p < 0.05, respectively, Figure 5.15) and with plasma testosterone 
concentration (r = 0.4518, p < 0.05, Figure 5.15). The lack of major change in CSF concentrations of 
CNP and NTproCNP throughout the year precluded any attempt to correlate these peptide levels 
with the other measurements. 
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Figure 5.12. CNP and NTproCNP concentration in CSF and plasma of red deer stags, in relation to 
annual changes in live weight and plasma testosterone concentration. 
Time trend of CNP (left axis) and NTproCNP (right axis) concentrations in CSF and plasma over a 
one year period in six red deer stags (pmol/L), in relation to seasonal indicators (testosterone 
level and live weight). All data is presented as mean ± s.e. A) Live weight (kg, closed circles) and 
body condition score (open circles). B) Plasma testosterone concentration (nmol/L). C) CSF 
concentrations of CNP (closed circles) and NTproCNP (open circles). D) Plasma concentrations of 
CNP (closed circles) and NTproCNP (open circles).  
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Figure 5.13 Relationship between CNP and NTproCNP in CSF and plasma in stags. 
Relationship between CNP (log10) and NTproCNP (log10) concentration in plasma (left) and CSF 
(right) in samples collected from red deer stags (n = 6) every two months for a one year period. 
 
Figure 5.14. Relationship between testosterone and CNP peptides in stag plasma. 
Relationship between testosterone (log10) and CNP (log10) concentration (left) and NTproCNP 
(log10) concentration (right) in plasma of red deer stags (n = 6) collected every two months over a 
one year period.  
 
 
 
 
 
 
 
 
Figure 5.15. Relationship between live weight and (log10) plasma concentrations of CNP, NTproCNP 
and plasma in red deer stags. 
Relationship between live weight (kg) and plasma concentrations of A) CNP, B) NTproCNP (both 
pmol/L) and C) testosterone (nmol/L) in red deer stags over a one year period (n = 6). 
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5.2.4 Discussion 
 
Despite the marked seasonal pattern of change in live weight that occurs in relation to the 
breeding season in red deer stags there were no related temporal changes in CSF concentrations 
of the CNP peptides. However, there was a marked increase in plasma concentrations of CNP and 
NTproCNP coinciding with the beginning of the rut which had a similar temporal pattern of 
change to that of the circulating levels of testosterone. To date, this is the second report of a 
relationship between the plasma concentrations of testosterone and the CNP peptides.  Olney et 
al. (2007) reported an increase in plasma concentrations of NTproCNP that occurred in children 
receiving testosterone treatment for growth deficiency. As previously mentioned (5.1.2), a direct 
effect of testosterone on peripheral levels of CNP peptides was ruled out in another study in pre-
pubertal lambs (Prickett et al. 2008).  
 
Whether the temporal pattern in circulating concentrations of CNP peptides in stags (with peak 
concentrations occurring in autumn) reported here differs from those in red deer hinds is difficult 
to ascertain. A previous report of CNP peptides in non pregnant red deer hinds indicated a 
different temporal pattern, whereby highest CNP and NTproCNP values occurred in spring 
(McNeill et al. 2010). However, the variation reported by (McNeill et al. 2010) was not significant, 
and data from January to March were not available for these red deer hinds. Whereas there was 
a significant relationship between live weight and circulating concentrations of CNP peptides in 
red deer stags, McNeill et al. (2010) found no association between plasma CNP forms and live 
weight in red deer hinds or ewes. 
 
The physiological significance (if any) of the coinciding peak concentrations of CNP, NTproCNP 
and testosterone in plasma at the start of the breeding season (autumn) reported here is 
unknown. However, there is a general trend for CNP peptide levels in plasma and CNP 
concentration in CSF to increase from winter to summer. This spring-related rise coincides with 
the increase in live weight and body condition score (recorded in the current study and the report 
by Gaspar-López et al. 2009), and increase in plasma leptin concentration (Gaspar-López et al. 
2009). Also, S Voice (unpublished adult stag data from our laboratory, n = 8) showed a marked 
increase in plasma concentrations of CNP (0.55 to 0.9 pmol/L) and NTproCNP (12 to 22 pmol/L) 
for the same time period. Together, this fits a picture of a possible regulatory relationship with 
appetite — deserving of further study, but not substantiated by results from the current study.   
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CSF concentrations remained unchanged despite the increased levels in plasma, which is consistent 
with human studies reporting independent regulation between fluids (Schouten et al. 2011). As the 
stags were not cannulated for CSF collection, it was not possible to examine the effect of xylazine 
and ketamine on central concentrations of CNP and NTproCNP, however findings from sheep 
indicate that the effect of anaesthetics is not a confounding factor in these measurements (Chapter 
4, and Figure 5.1 to Figure 5.4). Although CNP signalling in the brain may be altered during the rut, 
these findings indicate that appetite and live weight changes are not associated with changes in 
central concentrations of these peptides — and therefore for the purpose of these studies, were 
not considered to be worth pursuing as influencers of CNP secretion in central tissues.  
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Chapter 6. Dexamethasone increases production of C-type natriuretic 
peptide in the sheep brain 
Statement 
I was involved in all aspects of this chapter including study design, animal procedures, statistical 
analysis and writing of the manuscript, and all natriuretic peptide assays were carried out by me. 
Measurement of gene expression was carried out by me for 3 of the 7 tissue regions examined, 
and the rest by Bryony McNeill (Deakin University, Geelong, Australia). The writing of the 
manuscript which forms this thesis benefitted from contributions from all authors. This 
manuscript has been formatted for submission to the Journal of Endocrinology (currently under 
review), therefore the nomenclature has been selected accordingly and differs from other 
chapters. Here, NPR-B and NPR-C are referred to as NPR-2 and NPR-3, respectively. In the interest 
of formatting consistency in this thesis, short titles have been added to the existing figure 
legends. 
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6.1 Abstract 
Although C-type natriuretic peptide (CNP) has high abundance in brain tissues and cerebrospinal 
fluid (CSF), the source and possible factors regulating its secretion within the central nervous 
system (CNS) are unknown. Here we report the dynamic effects of a single IV bolus of 
dexamethasone or saline solution on plasma, CSF, CNS and pituitary tissue content of CNP 
products in adult sheep, along with changes in CNP gene expression in selected tissues. Both CNP 
and NTproCNP (the amino-terminal product of proCNP) in plasma and CSF showed dose 
responsive increases lasting 12-16 h after dexamethasone whereas other natriuretic peptides 
were unaffected. CNS tissue concentrations of CNP and NTproCNP were increased by 
dexamethasone in all of the 12 regions examined. Abundance was highest in limbic tissues, pons 
and medulla oblongata. Relative to controls, CNP gene expression (NPPC) was upregulated by 
dexamethasone in 5 of 7 brain tissues examined. Patterns of responses differed in pituitary tissue. 
Whereas the abundance of CNP in both lobes of the pituitary gland greatly exceeded that of brain 
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tissues, neither CNP nor NTproCNP concentration was affected by dexamethasone — despite an 
increase in NPPC expression. This is the first report of enhanced production and secretion of CNP 
in brain tissues in response to a corticosteroid. Activation of CNP secretion within CNS tissues by 
dexamethasone, not exhibited by other natriuretic peptides, suggests an important role for CNP 
in settings of acute stress. Differential findings in pituitary tissues likely relate to altered 
processing of proCNP storage and secretion.  
6.2 Introduction 
C-type natriuretic peptide (CNP), a paracrine growth factor which regulates cell proliferation and 
maturation, is widely expressed along with its receptor (NPR2) throughout the brain and spinal 
cord in mammals (Komatsu et al. 1991, Langub et al. 1995, Herman et al. 1996) including primates 
(Abdelalim & Tooyama 2011). In contrast to other natriuretic peptides, concentrations of 
products of CNP gene expression (CNP and amino-terminal proCNP, NTproCNP) in cerebrospinal 
fluid (CSF) greatly exceed those in the systemic circulation (Schouten et al. 2011, Wilson et al. 
2015) and presumably reflect the high CNP abundance relative to other natriuretic peptides 
identified in brain tissues (Pemberton et al. 2002). Although the functional role of CNP in nervous 
tissues is unclear, in vitro evidence shows that CNP stimulates neural growth and connectivity 
(Zhao & Ma 2009) and neuroplasticity in hippocampal tissues (Decker et al. 2010). Changes in CNP 
gene expression in the perinatal and later periods of brain maturation (Müller et al. 2009) further 
suggest that CNP in brain tissues is subject to regulation but putative secretagogues have yet to 
be identified.  
In the course of study of the regulation of CNP products in CSF in conscious sheep, we 
determined that dexamethasone — which suppresses plasma levels of CNP and NTproCNP when 
chronically administered to growing lambs (Prickett et al. 2009) or children (Prickett et al. 2012a) 
— conversely, abruptly increases concentrations of these peptides in CSF and plasma after an IV 
bolus injection. This novel observation has initiated a series of studies aimed to determine the 
temporal sequence and dose responsivity of CNP peptides in plasma and CSF to stimulation by 
dexamethasone and to identify the sites in the central nervous system (CNS) targeted by this 
glucocorticoid. Mindful of the well-recognised and profound effects of glucocorticoids on brain 
function (Wolkowitz et al. 2009), the focus of these studies has been the brain and nearby organs. 
Based on the initial observations of CNP responses in CSF, we hypothesised that i) the increases in 
CSF concentrations of CNP would be dose dependent and differ from the dynamic changes 
exhibited in plasma and ii) the increases in CSF concentration would be associated with 
corresponding increases in brain tissue abundance of CNP as well as increased CNP gene 
69 
 
expression. We further postulated that among the family of natriuretic peptides, the response 
would be specific to CNP products.    
6.3 Methods 
 
Animal procedures 
All procedures involving animals were conducted at Lincoln University and carried out in 
accordance with the Animal Welfare Act 1999 (New Zealand) and were approved by the Lincoln 
University Animal Ethics Committee. 
 
Responses of CNP peptides in plasma and CSF to graded doses of dexamethasone. (Study 1). We 
first determined the dose response of peripheral venous plasma and cisternal CSF concentrations 
of CNP peptides to dexamethasone in chronically cannulated conscious sheep (Study 1). Eight 
healthy yearling Coopworth ewes (average live weight 42 kg, 9–14 months old) were  housed 
indoors for 1 week prior to study and fed concentrated lucerne pellets (SealesWinslow, 
Ashburton, New Zealand) and lucerne chaff at 0900 h every day at maintenance nutritional level, 
with water provided ad libitum. This feeding regime was continued for the duration of the study. 
One day before cannulation, sheep were fasted for 24 h and water withheld overnight. Initially 
CSF samples were collected from 2 of the sheep using cannulae that were placed into the cervical 
epidural space whilst the sheep were anaesthetised.  Thereafter, with the need for improved 
cannula patency, all CSF samples from other sheep were collected from the cisterna magna via an 
indwelling cannula (Wilson & Barrell 2015). For samples collected from the cisterna magna, 0.5 
mL of CSF — which occupied the dead space in the cannula — was withdrawn under aseptic 
conditions using a 3 mL disposable syringe and discarded. At each sampling time point, 1.0–1.2 
mL of CSF was withdrawn and transferred immediately to a polycarbonate tube on ice, then 
stored at -20°C until assayed. Blood samples were obtained as described previously (Wilson et al. 
2015) and were collected on the same occasions as the CSF samples. Dose response studies 
commenced at least 2 days after cannulation, and continued over a study period of 6 days. Dosing 
comprised a single IV bolus injection of dexamethasone sodium phosphate in aqueous solution 
(Dexa 0.2, PhoenixPharm Distributors Ltd, Auckland, New Zealand) at 0.025, 0.063, 0.125, and 
0.25 mg dexamethasone/kg live weight, or saline solution (0.9 % w/v) that was delivered 
according to a balanced incomplete block design. This ensured that 4 different individuals were 
allocated to each dose of dexamethasone.  The sampling was conducted immediately prior to 
administration of dexamethasone or saline solution, and at 4, 8, 12, and 16 h post administration 
for measurement of CNP and NTproCNP. 
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Responses of brain, pituitary and spinal cord levels of CNP peptides to dexamethasone. (Study 2). 
In this study, 14 healthy Texel-Romney wethers (average live weight 77 kg, 2 years old) were 
sampled as described above except that CSF samples were obtained under light anaesthesia — as 
previously described (Wilson et al. 2015) — and blood samples were collected (Wilson et al. 2015) 
immediately prior to a single IV bolus of dexamethasone containing 0.25 mg/kg live weight (n = 
7), or saline (control, n = 7), and again at 8 h post injection. At that point, sheep were individually 
euthanised by captive bolt and exsanguinated. The brain and pituitary gland were rapidly 
removed and approximately 0.5 g of selected tissues from 14 sites were excised and instantly 
placed in liquid nitrogen. Specific zones sampled were the anterior pituitary gland, posterior 
pituitary gland, olfactory bulb, septum, thalamus, hypothalamus, mammillary body, 
hippocampus, occipital cortex, pineal gland, cerebellum, pons, medulla oblongata, and cervical 
spinal cord. The frozen samples were stored on dry ice until they were transferred to a -80°C 
freezer within 2–3 h. 
 
Measurement of peptide concentration and gene expression 
Samples of frozen brain and pituitary tissue (mean 70 ± 10 mg) were finely diced on a chilled (dry 
ice) melamine chopping board, weighed and gently boiled for 5 minutes in 10 mL distilled water 
containing 10 µL 1 % Triton X-100. After boiling, the tissue suspension was cooled on ice and 610 
µL of glacial acetic acid was added. The tissue suspension was homogenised (3 x 20 second bursts 
at 400 Hz) using an Ultra-Turrax homogeniser (IKA-Labortechnik, Staufen, Germany). The tissue 
homogenates were then centrifuged (3000 g, 4°C, 30 minutes), and processed thereafter in an 
identical manner to the CSF and plasma samples. 
 
Hormone assays. Hormones levels in CSF, plasma, brain and pituitary tissue were measured by 
radioimmunoassay after extraction using solid phase cartridges (Sep Pak, Waters Corp., Milford, 
MA). All samples from an individual animal were processed in duplicate in a single assay. CNP and 
NTproCNP were assayed as previously described (Wilson et al. 2015) and tissue concentrations 
were calculated from wet weight of tissue homogenised, assay buffer reconstitution volume and 
radioimmunoassay result. The ratio of NTproCNP to CNP (NTproCNP:CNP) was calculated from 
molar concentrations of the respective peptides in each sample. Atrial natriuretic peptide (ANP) 
concentration was measured as previously reported (Yandle et al. 1986) except: 50 µL 
standard/sample was pre-incubated with 50 µL of primary rabbit antiserum diluted to 1:12500 for 
24 h at 4 ⁰C, to which 50 µL of iodinated ANP was added (2500 cpm/50 µL). Following a second 
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incubation period, bound and free-labelled antigen were separated by addition of 500 µL of solid 
phase secondary antibody (5 % v/v Donkey anti-Rabbit Sac-cell (IDS Ltd, UK) diluted in assay 
buffer containing 2 % polyethylene glycol. After 30 minutes incubation at room temperature, 
tubes were centrifuged for 10 minutes, and radioactivity of the pellet was counted following 
aspiration of the supernatant. B-type natriuretic peptide (BNP) concentration was measured as 
previously described (Pemberton et al. 1997) except: 50 µL standard/sample was pre-incubated 
for 24 h at 4 ⁰C with 50 µL of primary rabbit antiserum, to which 50 µL of iodinated BNP was 
added (5000 cpm/50 µL). After a second incubation period, bound and free-labelled antigen were 
separated in a similar manner as the ANP protocol, except the assay was incubated for 30 
minutes in an ice bath.  The detection limit (pmol/L) for each assay was: 7.3 for ANP, 4.9 for BNP, 
0.6 for CNP and 1.9 for NTproCNP. Intra- and inter-assay coefficients of variation respectively 
were 7.8 % (21-100 pmol/L) and 10.4 % (at 86 pmol/L) for ANP, 9.9 % (4-20 pmol/L) and 15 % (at 
23.6 pmol/L) for BNP, 6.3 and 7.9 % at 9 pmol/L for CNP and 7.4 and 11.4 % at 64 pmol/L for 
NTproCNP. 
 
Quantitative real-time PCR. Total RNA was extracted from approximately 40 mg of tissue using 
the ReliaPrepTM RNA Tissue Miniprep System (Promega, Madison, WI), according to the 
manufacturer’s instructions. RNA purity was determined using a NanoDrop ND-1000 
spectrophotometer (Thermo Fisher Scientific, Wilmington, DE). cDNA was synthesised from 1 µg 
of RNA template using an iScript™ cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA). 
Quantitative real-time PCR was performed using iQ SYBR green supermix (Bio-Rad Laboratories, 
Hercules, CA) and specific primers for ovine NPPC (Forward: GGT CAG AAG GGC GAC AAG A; 
Reverse: TGT ATT TGC GCG CGT TGG G), NPR2 (Forward: TGC CCT CTA TGC CAA GAA GC; Reverse: 
GTA GAA AGG CCC ACT GCG AA) and NPR3 (Forward: CAC CCA GGA GGT TAT TGG TGA; Reverse: 
AAG GAG AGC TGT TCG TGT GCT) on a Stratagene MX3000p thermal cycler (Agilent Technologies, 
Santa Clara, CA). Gene expression was normalised to cDNA concentration, quantified using a 
Quant-iT™ OliGreen® ssDNA assay kit (Thermo Fisher Scientific, Waltham, MA). To determine 
relative gene expression, mean Ct values were power transformed from their logarithmic format, 
and divided by sample cDNA concentration. 
 
Statistical analyses 
Changes in CNP and NTproCNP concentration in CSF, plasma and CNS tissue in response to saline 
or dexamethasone administration were analysed separately. In Study 1, a repeated measures 
ANOVA was used to compare area under the curve for the logged (log10 here and in all cases 
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thereafter) data using Genstat Version 16 (VSN International Ltd., Hemel Hempstead, UK). Data 
from one sheep were excluded when pregnancy became apparent at the time of sample 
collection. In Study 2, a repeated measures ANOVA was used to compare logged concentrations 
of the various peptides in CSF, plasma, and CNS tissues in response to dexamethasone or saline 
solution, as well as the ratio of CNP:NTproCNP concentration in CNS tissues which was calculated 
for each sheep.  Least significant differences were used to identify differences in CNP and 
NTproCNP concentration between treatment groups in specific CNS tissues. The relation between 
peptide concentration in tissue (logged) and the percentage difference in peptide concentration 
after dexamethasone was determined using linear regression analysis in GraphPad Prism version 
6.01 for Windows (GraphPad Software Inc, La Jolla, CA, www.graphpad.com). Gene expression 
levels of NPPC, NPR2 and NPR3 were compared separately using a repeated measures ANOVA in 
Genstat Version 16 (VSN International Ltd., Hemel Hempstead, UK) using logged data, and least 
significant differences were used to identify differences between saline- and dexamethasone-
treated sheep for each tissue. 
6.4 Results 
 
All studies were accomplished as planned, and data collection was complete for Study 1. In Study 
2, CSF samples were collected from 13 of 14 sheep at baseline, and from 10 of 14 sheep following 
treatment. No adverse events were noted in any animal during either study, nor were any signs of 
infection evident in cannulated animals. 
 
Dose responses to dexamethasone (Study 1). 
On the control day (saline injection), plasma and CSF concentration of both CNP and NTproCNP 
were stable during the 16 h period of sampling. As expected, mean concentrations of CNP and 
NTproCNP in CSF were higher than in plasma (3.32 ± 0.14 vs 0.94 ± 0.02 pmol/L; 817 ± 24 vs 47.7 
± 1.3 pmol/L respectively, P < 0.001 for both). There was no significant association between time 
matched plasma and CSF concentrations for either peptide. Serial changes in CSF and plasma 
levels evoked by a range of doses of dexamethasone are shown in Figure 6.1. Dose dependent 
increases in both CNP peptides were observed within 4 h in plasma and somewhat later in CSF, 
although the magnitude and duration of responses differed in the two circulations. Overall, 
relative responses of plasma CNP and NTproCNP concentration to the highest dose of 
dexamethasone (8-fold and 6-fold increase respectively) exceeded those in CSF (3.3-fold and 1.5-
fold respectively). In CSF both the onset and the offset of responses were delayed relative to 
those observed in plasma. Further, time to peak CSF concentrations of NTproCNP (Cmax, 16 h) 
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was delayed compared with that of CNP (Cmax 8-12 h) and the NTproCNP concentration in CSF 
remained above pre injection levels 16 h after dexamethasone administration in 3 of the 4 
studies. Whereas a significant increase above control levels of plasma CNP and NTproCNP 
concentration was generated by the two lowest doses of dexamethasone (0.025 and 0.063 
mg/kg, P < 0.05), these doses failed to raise levels of these peptides in CSF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Effect of different doses of dexamethasone on CSF and plasma concentrations of CNP 
and NTproCNP. 
Mean CNP (left) and NTproCNP (right) concentration in CSF (A and B) and plasma (C and D) of 
sheep following different doses of dexamethasone: 0 (saline), 0.025, 0.063, 0.125, 0.25 mg/kg live 
weight. Data are presented as geometric means. n = 8 (saline) and 4 per dexamethasone dose 
level. 
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CNS and pituitary tissue responses to dexamethasone (Study 2). 
To ensure that responses in CSF and systemic concentrations of CNP products on the day of tissue 
collection were comparable to those observed in the dose response study, both peptides were 
measured in plasma (at 2 hourly intervals over 8 h) and CSF (pre injection and at 8 h after 
treatment). Concentrations of both peptides prior to injection were similar in saline- and 
dexamethasone-treated sheep and did not change significantly after saline injection in the 8 h 
period prior to tissue collection (Figure 6.2).  Again, as in Study 1, significant increases of CNP and 
NTproCNP concentration in both plasma and CSF were recorded following IV dexamethasone 
(0.25 mg/kg).  
 
Figure 6.2 Confirmation of the effect of dexamethasone. 
Mean CNP (left) and NTproCNP (right) concentration in CSF (A and B) and plasma (C and D) of 
sheep treated with saline solution (open bars/circles) or dexamethasone (closed bars/circles). 
Data are presented as geometric means. In CSF, n = 6 (saline) and 7 (dexamethasone) per group 
at 0 h, n = 5 per group at 8 h. In plasma, n = 7 per group. *significant difference between groups, 
P < 0.05. 
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Figure 6.3 Tissue concentrations of CNP and NTproCNP. 
Mean concentrations (wet weight basis) of CNP (left panels) and NTCNP (right panels) in brain (A 
and B) and pituitary gland (C and D) tissues in saline- (open bars) and dexamethasone-treated 
sheep (filled bars) 8 h following treatment. Data are presented as geometric means, n = 7 per 
group. *significant difference between groups, P < 0.05. Tissue regions were abbreviated to the 
following: AntP (anterior pituitary gland), PosP (posterior pituitary gland), Thal (thalamus), Hyp 
(hypothalamus), Med (medulla oblongata), Pons (Pons), MamB (mammillary body), OccC 
(occipital cortex), SpiC (spinal cord), Hip (hippocampus), Sep (septum), Cer (cerebellum), OlfB 
(olfactory bulb), PinG (pineal gland). 
 
Across the wide range of neural tissues examined, both CNP and NTproCNP were detected in all 
tissue extracts. As shown in Figure 6.3 A, in control sheep, concentrations of CNP in the brain 
were highest in limbic tissues (thalamus, hypothalamus, mammillary body), medulla oblongata 
and pons. Low abundance was observed in the pineal gland, olfactory bulb and occipital cortex. In 
contrast, CNP concentrations were much higher in the anterior pituitary (28.2 ± 3.5 pmol/g) and 
posterior pituitary (15.7 ± 4.5 pmol/g) lobes (Figure 6.3 C). Excepting pituitary tissue, 
concentrations of NTproCNP (Figure 6.3 B and D) in tissues from saline injected (control) sheep 
were almost 10-fold higher (8.3 ± 0.7) than those of CNP. Dexamethasone increased 
concentrations of both peptides in most tissues examined (Figure 6.3 A and B).  Compared with 
76 
 
controls, there were significant increments in CNP concentration following dexamethasone in 6 of 
the 14 selected tissues and those for NTproCNP were significant in 11 of these tissues. The 
relative abundance of both peptides across brain tissues from controls was largely preserved in 
tissues extracted from dexamethasone-treated animals. Again, responses in pituitary tissues 
differed. Neither CNP nor NTproCNP abundance in the posterior lobe was affected by 
dexamethasone (Figure 6.3 C and D). NTproCNP levels in the anterior pituitary lobe were 
increased after dexamethasone (Figure 6.3 D), however this was not significant — and in contrast 
to brain tissues — CNP concentration was unaffected. Considering all 14 tissues, the percentage 
difference (dexamethasone versus control) in CNP concentration was significantly greater in 
tissues with relatively low abundance (r = 0.64, P < 0.05, Supplemental Figure 6.1). A similar 
inverse relation was observed for NTproCNP (r = 0.54, P < 0.05).  
 
Concentrations of the 2 peptides in control sheep were highly correlated in brain (r = 0.68, P < 
0.0001) and pituitary gland (r = 0.81, P < 0.05), and even more so after dexamethasone: (r = 0.80 
and 0.88 respectively, P < 0.0001 for both). However, as shown in Supplemental Figure 6.2, across 
all studies the concentration ratio of NTproCNP to CNP in both pituitary lobes was close to unity 
(1:1) — much lower than found in brain tissues (5:1 to 10:1). 
 
Gene expression 
NPPC, NPR2, and NPR3 gene expression in selected tissues from saline- and dexamethasone-
treated sheep is shown in Figure 6.4. NPPC expression levels were upregulated by 
dexamethasone (P < 0.001) in 5 of the 7 tissues examined: anterior pituitary, posterior pituitary, 
hypothalamus, hippocampus and pons. No significant change in NPPC expression was found in 
occipital cortex or olfactory bulb tissue. Except for the downregulation of NPR2 in hypothalamic 
tissue following treatment with dexamethasone (P < 0.05), changes in NPR2 and NPR3 gene 
expression in the other tissues after dexamethasone were not significant (Figure 6.4). Despite 
markedly lower NTCNP:CNP ratios in the anterior and posterior pituitary gland, NPR3 expression 
in these tissues did not differ from that in the other regions examined here. 
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Figure 6.4 Effect of dexamethasone on gene expression of NPPC, NPR2 and NPR3. 
Relative gene expression of A) NPPC B) NPR2 and C) NPR3 in tissues from brain and pituitary gland 
of sheep obtained at 8 h following treatment with IV saline solution (open bars) or a single IV 
dose of dexamethasone (closed bars). Data are presented as geometric means, n = 7 per group. 
*significant difference between groups, P < 0.05. 
 
Specificity of CNP responses. 
Whether natriuretic peptide responses to dexamethasone are specific to CNP was addressed by 
measuring the concentration of ANP and BNP in samples obtained in Study 2. As shown in Figure 
6.5, whereas small fluctuations in plasma ANP and BNP concentration were observed after saline 
or dexamethasone, the mean values for either hormone after dexamethasone (0.25 mg/kg live 
weight) did not differ from those following the saline treatment. Both ANP and BNP were 
undetectable in CSF, including samples obtained after dexamethasone. In brain tissue extracts, 
ANP was undetectable in 29 of 42 samples examined. In 3 tissues where ANP was detectable 
(olfactory bulb, thalamus and pons) concentrations after dexamethasone (mean 0.84 ± 0.43 
pmol/L, n = 6) were low and did not differ from control sheep (mean 0.72 ± 0.30, n = 7). BNP was 
undetectable in 37 of 39 samples analysed. 
 
Figure 6.5 Specificity of CNP responses. 
Geometric mean plasma ANP (left) and BNP (right) concentration in sheep treated with saline 
solution (open circles) or dexamethasone (filled circles). Data are presented as geometric means, 
n = 7 per group. 
 
78 
 
6.5 Discussion 
CNP is the most abundant of the natriuretic peptides present in CNS tissues (Ueda et al. 1991, 
Kaneko et al. 1993). Whereas its role in the early development and maturation of cerebral 
neurons (Müller et al. 2009), and in axonal branching of sensory neurons entering the CNS (Zhao 
& Ma 2009) is well-defined, factors regulating CNP production within the brain and related tissues 
of adults in vivo have not been studied. Here we show that a single IV bolus injection of 
dexamethasone abruptly increases plasma and CSF concentrations of CNP peptides selectively 
and dose dependently. These changes are associated with marked increases in peptide 
concentrations in a wide range of CNS tissues, and upregulation of NPPC mRNA expression in 5 of 
the 7 cranial tissues examined here. Collectively these novel findings suggest that CNP may 
mediate some of the acute effects of stress on brain function, which now warrants further study. 
As part of physiological studies examining fluctuations of CNP peptides in CSF drawn from 
conscious adult sheep, we found that doses of dexamethasone — at levels that can reduce 
plasma concentrations of CNP peptides in lambs when administered for several days (Prickett et 
al. 2009) — actually raise concentrations of CNP in CSF during the first 12 h. 
 
In more focussed studies we now show that in contrast to relatively unchanged levels that persist 
after administration of saline, a single IV bolus injection of dexamethasone induces a prompt 
increase in CNP and NTproCNP concentrations in both plasma and CSF. ANP and BNP levels were 
unaffected. As noted in humans (Schouten et al. 2011), in the absence of interventions (i.e. 
saline-treated animals here), concentrations of CNP and NTproCNP were much higher in CSF than 
in time matched samples of plasma. Lack of any significant correlation between levels in the two 
circulations suggests independent regulation and little, if any, exchange across the blood-brain 
barrier (BBB). After dexamethasone, onset of the response in CNP peptide levels occurred earlier 
in plasma (within 4 h), was dose dependent and of shorter duration than was observed in CSF. 
Presumably delayed entry of dexamethasone to the CNS (Balis et al. 1987), diffusion and bulk 
flow of CNP peptides from extra-cellular fluid to CSF (Leng & Ludwig 2008) and slower clearance 
of CNP peptides in CSF (particularly NTproCNP), are the basis of these temporal differences. 
Sustained elevations of NTproCNP in CSF 16 h after dexamethasone, when plasma levels had 
returned to baseline, suggests that any increase in permeability of the BBB by CNP (Bohara et al. 
2014) is minimal in this experimental setting. 
  
In order to examine likely sources of the response of CNP peptides in CSF, we measured their 
relative abundance in 12 selected tissues within the CNS 8 h after saline or dexamethasone (0.25 
mg/kg live weight) – a dose which strongly stimulated plasma and CSF CNP peptides in these 
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same sheep when compared with the control study. In controls, the relative abundance of CNP 
peptides in CNS tissues was similar to that previously reported in adult sheep (Pemberton et al. 
2002), rodents (Jankowski et al. 2004) and humans (Komatsu et al. 1991, Totsune et al. 1994). 
Highest concentrations were found in tissue sampled from thalamus, hypothalamus, mammillary 
body and medulla oblongata. Overall, concentrations of the two peptides were highly correlated 
in brain and pituitary gland of control sheep — with levels of NTproCNP approximately 5–10 fold 
those of CNP in brain tissue. Of the 12 CNS tissues examined, the concentration of both peptides 
was higher after dexamethasone when compared with controls — significantly so in 11 and 6 
tissues for NTproCNP and CNP respectively. Tissues with lower abundance after saline exhibited 
proportionately higher levels after dexamethasone (Supplemental Figure 6.1). This trend was 
more obvious in the CNP response — possibly reflecting higher rates of secretion (loss to 
extracellular fluid and CSF) for this peptide, particularly in tissue zones adjacent to cerebral 
ventricles. Again, after dexamethasone significant associations were observed between CNP and 
NTproCNP but in 4 tissues (hypothalamus, pineal gland, occipital cortex and medulla oblongata) 
the ratio of NTproCNP to CNP was significantly increased compared with control values. 
 
Presumably higher rates of CNP degradation and/or egress from the neuropil account for these 
glucocorticoid-induced differences. Viewed in relation to proportionate increases in CSF at 8 h 
after dexamethasone (0.25 mg/kg live weight) the increase in brain tissue CNP content (2-4 fold) 
is commensurate with that observed in CSF (3-4 fold) and lends credibility to the possibility that 
the changed levels in CSF are a consequence of enhanced secretion from tissues within the CNS. 
Proof that these changes involve increased synthesis of the peptides is provided by the evidence 
presented here for upregulation of NPPC in the hypothalamus, hippocampus, and pons. In 
contrast, NPPC expression in the occipital cortex and olfactory bulb was not increased by 
dexamethasone — despite significant increases in both CNP and NTproCNP concentration in 
these tissues. Presumably this discrepancy relates to differences in mRNA stability (rapid 
degradation compared with peptide loss) and/or co-production of inhibitory microRNAs.  
 
Whether longer term treatment with dexamethasone could sustain the responses we observed 
here in CNS tissues is unknown but important to resolve – particularly since plasma levels of CNP 
peptides are suppressed by prolonged dosing with dexamethasone in growing lambs and children 
(Prickett et al. 2009, Prickett et al. 2012a). In the latter studies, contributions of NTproCNP to its 
plasma concentrations are likely to be sourced from growth plate proliferating chondrocytes 
(Prickett et al. 2005, Prickett et al. 2012b) — which are depleted by glucocorticoids (Siebler et al. 
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2002) — so it is not surprising that the temporal responses of CNS tissues to glucocorticoids are 
likely to vary from those in other body regions.  
 
Although it is not part of the CNS, and is unprotected by the BBB, the pituitary gland in sheep and 
humans has an unusually high CNP content (Yandle et al. 1993, Pemberton et al. 2002, Thompson 
et al. 2009), so its potential to contribute to the amount of CNP in plasma or CSF was an 
important factor in selecting this organ for closer study. Findings in pituitary tissue differ from 
those in CNS tissues in several respects. First, in control sheep the concentration of CNP is much 
higher in both anterior and posterior lobes than in any of the regions of the CNS reported here. 
Second, in both lobes there are equimolar concentrations of CNP and NTproCNP, reducing the 
ratio of NTproCNP:CNP to unity (1:1) – much lower than that found in CNS tissues (5:1 to 10:1, 
Supplemental Figure 6.2). Previous work (Yandle et al. 1993) has also shown that the pituitary 
processing of proCNP is unique in that pituitary tissue contains predominantly CNP-53, 
contrasting with the presence of equal amounts of CNP-53 and the smaller peptide CNP-22 in 
hypothalamic extracts. These findings suggest that under physiological conditions different 
functions are subserved in the pituitary gland — with less degradation and reduced processing 
being consistent with accumulation and storage. Thirdly, although NPPC expression in both lobes 
is significantly upregulated after dexamethasone, abundance of peptides was not changed.  
 
Together these unexpected findings raise the possibility that both peptides are actively secreted 
from the pituitary gland into the systemic circulation in response to dexamethasone, and thus 
could make significant contributions to the responses recorded in plasma after IV administered 
dexamethasone. If so, a disproportionate amount of CNP-53 would be expected to appear in the 
systemic circulation.  More recent studies in our laboratory confirm this and show that the profile 
of high molecular weight immunoreactive CNP forms in plasma closely reflect the profile found in 
anterior pituitary tissue extracts (manuscript in preparation, Chapter 7). Others have shown that 
CNP in anterior pituitary tissue appears to be exclusively associated with gonadotroph cells 
(Thompson et al. 2009, McArdle et al. 1994). Reports that acute stress or glucocorticoid 
administration stimulate gonadotrophin secretion in some settings (Maeda & Tsukamura 2006) 
may be relevant in this context. Although we have not found evidence of a CNP arterio-venous 
concentration gradient across the pituitary gland in samples of plasma drawn from the inferior 
petrosal vein in human subjects with Cushing’s disease (unpublished), further study of the acute 
effect of glucocorticoids on pituitary secretion of CNP peptides is warranted. 
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Our study was not designed to address either the origins or actions of CNP at the cellular level but 
these questions become highly relevant in light of the present findings — and of the manifold 
effects of glucocorticoids on brain function (Wolkowitz et al. 2009). Notably, CNP responses in 
CSF were observed after a dexamethasone dose of 0.125 mg/kg live weight — which corresponds 
to the therapeutic range for adult humans. The wide array of glucocorticoid-responsive CNS 
tissues identified here suggests that commonalities — such as capillary networks (Vigne & Frelin 
1992) or glial tissues (Parpura & Zorec 2010) — all of which are recognised sites of CNP 
production — are likely to be involved.  One possible action of dexamethasone, increasing the 
CNP mRNA response to shear stress in brain capillaries (Zhang et al. 1999), might account for the 
present results. In cultured murine cerebral cortex neurons, activation of voltage-sensitive 
calcium channels during potassium-induced depolarisation strongly upregulates NPPC expression 
over a 6 h period (Kim et al. 2010). Since glucocorticoids specifically enhance L-type calcium 
channel amplitude in a variety of neurons sourced from brain tissues (Joëls & Karst 2012), the 
glucocorticoid-induced increases in CNP we observed may have resulted from such membrane-
level events (Wolkowitz et al. 2009). 
 
Responses from astrocytes or microglia — ubiquitous in CNS tissues and an important source of 
natriuretic peptides, including CNP (Deschepper 1998) — may also have contributed to these 
findings. Of note, dexamethasone elicits a dose dependent CNP response from cells of 
monocyte/macrophage lineage (Kubo et al. 2001) which, within the BBB, constitute the microglia.  
To our knowledge no glucocorticoid response element has been identified in the CNP gene in any 
species. Interestingly, glucocorticoids act directly and specifically to increase ANP gene 
transcription in rodent cardiomyocytes (Gardner et al. 1988) and other tissues (Gardner et al. 
1986) yet we found no evidence that ANP or BNP is affected by dexamethasone in either the 
systemic circulation or CNS tissues. Concerning possible actions of CNP in glial tissues, there is a 
strong body of evidence that cGMP, a downstream mediator of CNP activity and more responsive 
to CNP than either ANP or BNP (Deschepper & Picard 1994), regulates several crucial intercellular 
actions including Na+/H+ exchangers, neurotransmitter re-uptake, gap junctions, cell pH and brain 
cell water content (Kim et al. 2010). In this context, it is important to note that dexamethasone 
mitigates cerebral glioma tumour oedema – a cell type highly responsive to CNP (Eguchi et al. 
1992). Conceivably, this well-described pharmacological action of dexamethasone is mediated at 
least in part by CNP which could have therapeutic implications now that CNP agonists are 
available for use in humans. 
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Supplemental Figure 6.1 Relationship of the percentage increase in CNP peptide concentration 
following dexamethasone and levels in control sheep. 
Relationship of the percentage increase in mean log10 CNP (left) and NTproCNP (right) 
concentration following dexamethasone (n = 7) above that of saline-treated sheep (n = 7) for 14 
cranial tissues. 
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Supplemental Figure 6.2 Ratio of CNP:NTproCNP concentration in tissues. 
Mean ratio of NTproCNP:CNP in 14 cranial tissues from saline- (open bars) and dexamethasone-
treated (filled bars) sheep obtained at 8 h following treatment. Data are presented as geometric 
means, n = 7 per group. *significant difference between groups, P < 0.05. Tissue regions were 
abbreviated to the following: AntP (anterior pituitary gland), PosP (posterior pituitary gland), Thal 
(thalamus), Hyp (hypothalamus), Med (medulla oblongata), Pons (Pons), MamB (mammillary 
body), OccC (occipital cortex), SpiC (spinal cord), Hip (hippocampus), Sep (septum), Cer 
(cerebellum), OlfB (olfactory bulb), PinG (pineal gland). 
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Additional data 
 
The following data were collected for studies in this chapter, however were excluded from the 
submitted manuscript.   
 
Confirmation of correct pituitary gland dissection 
Prior to commencing tissue collection for measurement of CNP peptide concentration and gene 
expression analysis, dissections were practiced using brains from sheep killed at a local abattoir 
(Canterbury Fresh Lamb, Christchurch). In order to confirm that the pituitary gland was accurately 
dissected, tissues were sent to a pathology laboratory (Gribbles Veterinary Pathology, 
Christchurch) for a routine haematoxylin and eosin staining, and viewed under a bright field 
microscope (Nikon Eclipse 50i microscope, Tokyo, Japan). Images were captured using 
microscope imaging software (NIS Elements Imaging Software, Basic Research, Tokyo, Japan, 
Plate 6.1). Correct dissection was confirmed by the higher density of nuclei (stained blue) in the 
anterior pituitary gland (left), compared with the posterior pituitary gland (right). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plate 6.1 Ovine anterior (left) and posterior (right) pituitary gland stained with haematoxylin and 
eosin. 
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Comparison of gene expression levels of NPPC, NPR2 and NPR3 across tissues 
 
To compare gene expression levels of NPPC, NPR2 and NPR3 within groups, gene expression was 
calculated relative to the lowest Ct (threshold cycle) value of all samples analysed, and compared 
using a repeated-measures ANOVA. Significant differences between tissues were identified using 
least significant differences. The main finding was that despite markedly different concentration 
ratios of NTproCNP:CNP in the brain (5:1 to 10:1) compared with the anterior and posterior 
pituitary glands (1:1), the expression level of NPR3 (NPRC) was similar between tissues within the 
control group (Figure 6.6 C). This suggests that differences in clearance rates of CNP may be a 
result of higher enzymatic degradation occurring in the brain — such as insulin-degrading enzyme 
or neprilysin — compared with in the pituitary gland. It is relevant to note that neprilysin 
expression was not detected in the posterior pituitary gland of the rat, and was found in low 
levels in the anterior pituitary gland (Facchinetti et al. 2003). In contrast, neprilysin expression 
levels were highly variable throughout the brain (Facchinetti et al. 2003) — which may account 
for some of the variation in NTproCNP:CNP concentration ratios measured in the current study. 
Additionally, there may be some differences in clearance receptor activity that are not reflected 
by mRNA levels; Ardaillou et al. (1996) reported that NPR3 protein (NPR-C) is increased by 
dexamethasone without affecting mRNA levels. 
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Figure 6.6 Comparison of gene expression levels in brain and pituitary gland tissue within groups 
of saline- and dexamethasone-treated sheep. 
Relative gene expression of A) NPPC, B) NPR2, and C) NPR3 are presented as geometric means (n 
= 7 per group). Gene expression levels do not differ between tissues given the same letter. 
Tissues with different letters have significantly different levels of gene expression for that 
respective gene (p < 0.05).  
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Effect of dexamethasone on glucose concentration 
In order to confirm that dexamethasone was being administered at an effective dose 
concentration capable of producing effects that were typical of glucocorticoids, glucose 
concentration was measured in plasma from sheep given saline solution or dexamethasone 
(0.025, 0.063, 0.125, 0.25 mg/kg live weight, Figure 6.7), as described in 6.3. Glucose 
concentration was also measured in CSF of sheep given dexamethasone (0.25 mg/kg live weight, 
n = 3) and saline solution (n = 1, Figure 6.8). Plasma and CSF glucose concentration were 
measured using the hexokinase method in an automated analyser (Enzymatic Assay Glucose 
Hexokinase, Abbott c8000 analyser, Abbott reagents) by Canterbury Health Laboratories, 
Christchurch, NZ. Two-tailed unpaired Student’s t-tests were used to compare glucose 
concentrations in plasma using GraphPad Prism version 6.01 for Windows (GraphPad Software 
Inc, La Jolla, California, USA, www.graphpad.com). 
 
Mean plasma glucose concentration did not differ between groups in Study 1 prior to treatment, 
ranging from 3.5 to 4.9 mmol/L in individual sheep at baseline, and did not differ between 0 and 8 
h in control sheep (mean change 0.00 ± 0.11 mmol/L). All doses of dexamethasone used here 
elevated glucose levels in plasma sampled at 8 h after administration (p < 0.001) where mean 
concentrations had increased to between 5.98 ± 0.11 mmol/L (lowest dose) and 7.28 ± 0.77 
mmol/L (highest dose). This response was sustained for a period of 24 h following the highest 
dose of dexamethasone (0.25 mg/ live weight, n = 2) in contrast to control levels which remained 
consistently lower (mean change -0.23 ± 0.17, n = 3). 
 
In control sheep, glucose concentration in CSF was approximately 65 % of concomitant plasma 
levels (n = 1) and levels were similar on each of the 3 days they were measured. Following the 
highest dose of dexamethasone (0.25 mg/kg live weight), CSF glucose concentration was 
increased by 1.5-fold to 2-fold in 2 sheep, and was unchanged in 1 sheep (Figure 6.8). 
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Figure 6.7 Plasma glucose concentration in sheep administered with dexamethasone or saline. 
Left: Glucose concentration in plasma of sheep administered with saline solution (open circles, n 
= 3) or dexamethasone (closed circles, n = 2) 24 h after treatment. Right: Mean glucose 
concentration (± s.e.) in plasma from sheep immediately before (open bars) and 8 h after (closed 
bars) i.v. injection with saline solution or dexamethasone (n = 4 per group). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8 CSF glucose concentration in sheep administered with dexamethasone or saline  
Left: 24 h profile of glucose concentration in CSF of sheep (n = 3) given a single i.v. injection of 
dexamethasone (0.25 mg/kg). Right: CSF glucose concentration in one sheep following 
administration with saline solution. 
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Effect of dexamethasone on the transfer of small metabolites from plasma to CSF 
Concentrations of glucose and β-hydroxybutyrate were analysed in 6 matched pairs of CSF and 
plasma, collected immediately before and 8 h after a single i.v. bolus of saline or dexamethasone 
(0.25 mg/kg live weight). Samples were analysed by a commercial laboratory (Gribbles Veterinary 
Pathology, Christchurch, NZ) as previously described (Chapter 6) and were a mixture of samples 
from across the several studies described in this chapter. The purpose of this was to assess the 
effect of dexamethasone on the movement of small molecules from plasma to CSF. However, CSF 
concentrations of β-hydroxybutyrate were below the assay detection limit (possibly due to 
sample degradation as some samples were several years old) so it was not possible to assess this 
for β-hydroxybutyrate. Two-tailed unpaired Student’s t-tests were used to compare glucose 
concentrations in CSF and plasma, and β-hydroxybutyrate concentration in plasma of saline- and 
dexamethasone-treated sheep using GraphPad Prism version 6.01 for Windows (GraphPad 
Software Inc, La Jolla, California, USA, www.graphpad.com). 
 
Β-hydroxybutyrate concentration in plasma did not differ between groups prior to treatment 
(saline: 0.26 ± 0.05 mmol/L, dexamethasone: 0.26 ± 0.03 mmol/L). 8 h after treatment, 
concentrations of β-hydroxybutyrate increased in both groups, however this was not significant 
(saline: 0.34 ± 0.01 mmol/L, dexamethasone: 0.43 ± 0.07 mmol/L). 
 
In time-matched samples, baseline concentrations of glucose did not differ between groups in 
plasma (4.4 ± 0.1, 4.4 ± 0.2 mmol/L) or CSF (3.0 ± 0.2, 3.0 ± 0.2 mmol/L) in saline- or 
dexamethasone-treated sheep, respectively. Plasma and CSF concentrations of glucose in control 
sheep were unchanged after 8 h (4.4 ± 0.03 and 3.1 ± 0.2 mmol/L, respectively). In contrast, 
dexamethasone increased glucose concentrations in both plasma (8.1 ± 0.9 mmol/L) and CSF 
(5.35 ± 0.7 mmol/L) at 8 h (p < 0.05 for both). Despite increases in glucose concentration in both 
fluids, the concentration ratio of glucose in plasma:CSF was unchanged following dexamethasone 
treatment (0.7 ± 0.06, 0.7 ± 0.03, 0 and 8 h, respectively), and was 0.7 ± 0.05 at both time points 
in control sheep. 
 
Without any indication from CSF measures of β-hydroxybutyrate, it is difficult to ascertain 
whether dexamethasone or increased concentrations of CNP has any effect on the blood-brain 
barrier in this setting. However, the finding that there was no change in the concentration ratio of 
glucose in CSF:plasma suggests that the rate of transfer of glucose from the blood to CSF was 
unaltered by dexamethasone or raised levels of CNP, and was consistent with findings reported in 
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Chapter 4 — whereby the CSF:plasma ratio of both glucose and β-hydroxybutyrate was unaltered 
by the high concentrations of CNP that occur in plasma in pregnant sheep. Whereas Bohara et al. 
(2014) reported that supra-physiological doses of CNP reduced the presence and gene expression 
of blood-brain barrier proteins (zonula occludins-1), and increased the permeability of the BBB to 
sodium fluorescein in mice, an opposite effect on the BBB has been reported for dexamethasone 
(Hedley-Whyte & Hsu 1985). Therefore, in this case, is possible that any effect on the BBB by 
either dexamethasone or CNP could be countered by the other.  
 
 
 
  
96 
 
Chapter 7. Molecular forms of C-type natriuretic peptide in cerebrospinal 
fluid and plasma reflect differential processing in brain and pituitary 
tissues 
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This chapter contains a manuscript which has been formatted for submission to Peptides. 
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out all aspects of the laboratory work. The manuscript which forms this chapter benefitted 
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Molecular forms of C-type natriuretic peptide in cerebrospinal fluid 
and plasma reflect differential processing in brain and pituitary 
tissues 
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2Department of Medicine, University of Otago, Christchurch 8140, New Zealand.  
 
7.1 Abstract 
C-type natriuretic peptide (CNP) is a paracrine growth factor present in CSF at concentrations that 
far exceed its circulating levels in blood. It is widely distributed in the brain and both major lobes 
of the pituitary gland. Following our recent finding that an intravenous bolus of dexamethasone 
(0.25 mg/kg) in sheep acutely raises concentrations of CNP peptides throughout the brain as well 
as in CSF and peripheral plasma, we have characterised the molecular forms of CNP in cranial 
tissues following administration of dexamethasone or saline solution using size-exclusion high 
performance chromatography (SE-HPLC) and radioimmunoassay for CNP and NTproCNP. Three 
immunoreactive-CNP components were identified as proCNP (1-103), CNP-22 and CNP-53, and 
the presence and ratio of these different fragments differed between tissues. Similar profiles 
were obtained in CSF extracts from saline- and dexamethasone-treated sheep, whereby the 
predominant fragment was CNP-53, with CNP-22 present as a minor peak in 6 of 6 extracts. 
Profiles were similar for hypothalamic and posterior pituitary gland extracts, except an earlier 
eluting product (proCNP 1-103) was consistently present, and more abundant in profiles from 
dexamethasone-treated sheep — consistent with increased synthesis in these tissues. In contrast, 
SE-HPLC profiles of anterior pituitary gland and plasma extracts were devoid of CNP-22 and 
97 
 
contained mainly the CNP-53 and proCNP (1-103) fragments. This is the first report of the 
presence of proCNP (1-103) in plasma. The similarity in SE-HPLC profiles of plasma extracts and 
those from the anterior pituitary gland supports existing evidence for release of CNP from the 
anterior pituitary gland into the circulation. 
 
7.2 Introduction 
C-type natriuretic peptide (CNP) is a paracrine growth factor widely expressed in tissues of the 
central nervous system (CNS) where the peptide exhibits actions promoting neurogenesis1, 
learning2 and axonal connectivity3. Consonant with the prominence of CNP in CNS tissues, 
concentrations of CNP peptides in cerebrospinal fluid (CSF) greatly exceed those in plasma of 
humans4 and sheep5. Concentrations are especially enriched in pituitary tissues6,7, yet CNP 
concentrations in the systemic circulation are low and close to detection limits in adult 
mammals8. Although CNP in pituitary tissue appears to be co-located with gonadotrophic cells9, 
its regulation, function and metabolism in this tissue are unknown. 
 
CNP is synthesized as a 103 amino residue peptide (proCNP 1-103, proCNP) which is highly 
conserved in mammals10. The penultimate 22 amino acids form a ring structure at the carboxy 
terminal.  ProCNP is cleaved intracellularly by furin11 yielding a 53-amino acid residue peptide 
(proCNP 51-103, CNP-53) and an inactive amino-terminal fragment (proCNP 1-50, NTproCNP) 
which are likely to be secreted in equimolar proportions. CNP-53 is further cleaved – presumably 
extracellularly and at unknown sites – to CNP-22 (proCNP 82-103) which retains the ring structure 
and full biological activity. Both bioactive forms (CNP-53 and CNP-22) are subject to rapid 
degradation at source12 whereas the inactive fragment NTproCNP remains intact for longer 
periods and is readily detectable in plasma prior to clearance by renal filtration and excretion13. 
 
Study of CNP in pathophysiology has employed immunoassays using antisera directed to proCNP 
51-103 (therefore detecting both CNP-53 and CNP-22), or alternatively assays detecting the 
amino-terminal inactive fragment (NTproCNP) using antisera directed to proCNP 1-50. Depending 
on the objective, results from these assays add to our knowledge of CNP’s regulation and 
metabolism but cannot specify the precise molecular form(s) – necessary for delineating 
pathways connecting production, secretion and metabolism. When analyses enabling identity of 
specific forms have been undertaken – for example using size-exclusion high performance liquid 
chromatography (SE-HPLC) to separate products by molecular size – the predominant form in 
most tissues expressing CNP has been CNP-538,14,15. Notably, processing of proCNP appears to 
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differ in hypothalamic tissues (where both CNP-53 and CNP-22 residue forms are detected) and 
pituitary – in which CNP-22 is low or undetectable15. In plasma, when CNP immunoreactivity has 
been detected it has been attributed to CNP-22 based on gel permeation chromatography8 
although the low concentrations limit reliability and accuracy of analyses using SE-HPLC. To our 
knowledge, higher molecular weight forms such as proCNP have not been identified in plasma in 
any species, and no study has examined tissue and circulating molecular forms concurrently in 
the course of changes in CNP production. 
 
An opportunity to characterize CNP molecular forms in tissues and associated fluids was recently 
provided by the availability of samples collected during the course of a study of the CNP response 
in brain and related tissue to dexamethasone (paper in submission). Compared with a saline 
injection, concentrations of CNP in brain tissues increased 2-4 fold and were commensurate with 
increases (3-4 fold) in CSF 8 h after a single injection of intravenous dexamethasone (0.25 mg/kg). 
In light of evidence of differential processing in hypothalamic and pituitary tissues15, we 
hypothesized that molecular forms would differ in hypothalamic tissue and CSF when compared 
with forms in the pituitary gland and plasma. Accordingly we have used SE-HPLC and 
radioimmunoassay (RIA) to examine relative abundance of proCNP, CNP-53 and CNP-22, together 
with amino-terminal proCNP forms, in samples of tissue and associated fluids collected from 
controls and dexamethasone-treated sheep. 
 
7.3 Methods 
All procedures involving animals were carried out in accordance with the Animal Welfare Act 
1999 (New Zealand) and were approved by the Lincoln University Animal Ethics Committee.  
 
Animal procedures 
Appropriate brain and pituitary gland samples suitable for HPLC-RIA analysis were obtained from 
13 of the 14 healthy Texel-Romney wethers sampled in our recent study (Chapter 6). Details of 
animal housing and sample collection have been described previously (paper in submission). 
Briefly, CSF and plasma samples were collected prior to and 8 h after administration with 
intravenous (i.v.) saline (controls) or dexamethasone (0.25 mg/kg live weight), and sheep were 
sacrificed 8 h after the injection.  
 
In the current study, after grazing on pasture at Lincoln University Research Farm, sheep were 
brought indoors for one week prior to the study and fed concentrated lucerne pellets 
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(SealesWinslow, Ashburton, New Zealand) and lucerne chaff at 0900 h every day at the 
maintenance nutritional level, with water provided ad libitum. At least 2 days before the study, 
the cisterna magna was catheterised under anaesthesia as previously described16. Sample 
collection began at least 2 days after the cannulation procedures. Groups of sheep 
(Supplementary Table 7.1) received a single dose of intravenous dexamethasone (Dexa 0.2, 
PhoenixPharm Distributors Ltd, Auckland, New Zealand, 2mg/mL, 0.25 mg/kg live weight) or 
saline solution (0.9 % w/v). 
 
CSF and plasma sample collection 
For study of the molecular forms of CNP using SE-HPLC-RIA, at least 10 mL of CSF and 40 mL of 
plasma were required for each analysis. This requirement was met on the control day (saline 
injection) by withdrawal of 7 (2 mL) CSF samples and jugular blood (5-6 mL) at intervals of not less 
than 20 minutes. For the sheep receiving dexamethasone, CSF and blood samples for SE-HPLC 
were collected at known peak response times of CNP and NTproCNP concentration, which were 
approximately 7-9 h and 4-6 h post treatment for CSF and plasma, respectively. Additional CSF 
samples were collected for measurement of CNP and NTproCNP immunoreactivity. 
Concentrations are listed in Supplementary Table 7.1. These samples were drawn immediately 
prior to injection of saline solution or dexamethasone and again at 8 h post injection. All plasma 
and CSF samples were rapidly placed on ice, centrifuged within 10 min and stored at -20 °C until 
assayed. 
 
Tissue collection and extraction 
After euthanasia by captive bolt stunning and exsanguination, brain and pituitary gland were 
rapidly removed. Approximately 0.5 g of tissue was excised from anterior pituitary gland, 
posterior pituitary gland and hypothalamus and rapidly frozen in liquid nitrogen. Later, tissues 
were treated as previously described (paper in submission), homogenised, centrifuged and then 
processed identically to CSF and plasma samples (Wilson et al. 2015). Tissue concentrations of 
CNP and NTproCNP immunoreactivity are listed in Supplementary Table 7.1.  
 
Size-exclusion HPLC-RIA 
CSF, plasma, and tissue homogenates from each sheep were extracted using three Sep-Pak C18 
cartridges (Waters Corp., Milford, Massachusetts, USA) as previously described17. Tissue 
homogenate was extracted over a single cartridge, while CSF and plasma samples were extracted 
across several (3-5) cartridges. 100 µl of 20 % CH3CN in 0.1 % trifluoroacetic acid (TFA) was added 
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to each extract, and extracts were vortex mixed then centrifuged at 780 g for one minute and 
combined, after which the total volume was spun at 3600 g for five minutes. 10 µl of detergent 
(0.1 % TritonTM X-100, Sigma-Aldrich, St Louis, Missouri, USA) was added to each collecting well on 
the HPLC block, which was then placed ready for collection.  
 
Prior to loading, 20 % CH3CN in 0.1 % TFA was run through the column. 50 µl of sample was 
injected onto the column with a Hamilton syringe, and fractions were collected at a rate of 0.5 
mL/minute. Fractions from CSF and plasma were assayed for measurement of CNP and NTproCNP 
concentrations, and fractions from hypothalamic and pituitary extracts were assayed for CNP 
concentration only. Collected fractions were dried under an air stream and assayed as previously 
described for measurement of CNP and/or NTproCNP5 using commercial CNP-22 antiserum 
(catalogue number G-012-03, Phoenix Pharmaceuticals, Belmont, California, USA) and rabbit 
antiserum J39 (raised locally against human proCNP (1-15), respectively. CNP-22 and CNP-53 
exhibit equal cross reactivity with the antiserum provided by Phoenix Pharmaceuticals.  The 
detection limit for each assay was 0.6 and 1.9 pmol/L for CNP and NTproCNP, respectively. 
 
Chemicals and reagents 
Purified standards of CNP-53 for SE-HPLC were obtained from Peninsula Labs (San Carlos, 
California, USA) and CNP-22 was obtained from BaChem (Bubendorf, Switzerland). NTproCNP 
standard was synthesised by Mimotopes Pty Ltd, Clayton, Victoria, Australia (proCNP 1-19, Lot 
#93001) and was reported to be > 95 % purity according to the manufacturers. The column was 
calibrated with four molecular weight markers: bovine serum albumin (BSA, 66.5 kDa), 
cytochrome C (12 kDa), aprotinin (6.5 kDa) and tyrosine (181 Da) (Sigma Aldrich, St Louis, 
Missouri, USA).  
 
Statistical analysis 
To calculate relative abundance, peptide concentrations in fractions corresponding to respective 
peaks were summed (i.e. area under the curve — AUC) and expressed as a percentage of the total 
CNP immunoreactants in the sample. Two-tailed unpaired Student’s t-tests were used to detect 
significant differences in the respective proportions between groups in various tissues, using 
GraphPad Prism version 6.01 for Windows (GraphPad Software Inc, La Jolla, California, USA, 
www.graphpad.com). 
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7.4 Results 
Elution profiles of CNP peptides and molecular weight standards following SE-HPLC are shown in 
Supplemental Figure 7.1. CNP-53 and CNP-22 eluted in fractions 27-29 and 34-36, respectively. 
Higher molecular weight forms consistent with proCNP eluted in fractions 24-25. 
 
Hypothalamic and posterior pituitary tissue 
In hypothalamic tissue, remarkably similar HPLC profiles were observed in 6 individual sheep 
(Figure 7.1). The major molecular form (i.e. largest peak) was CNP-53. Preceding this peak was a 
smaller peak, consistent with proCNP, and this peak appeared to be higher (although not 
statistically significant) in the 3 dexamethasone-treated sheep (Figure 7.1). Also, in all 6 cases, 
there was a clearly defined, late eluting, smaller peak consistent with CNP-22 (Figure 7.1). In 
posterior pituitary lobe tissues (Supplemental Figure 7.2) remarkably similar proportions of 
molecular forms consistent with proCNP and CNP-53 were observed in saline- and 
dexamethasone-treated sheep. Late eluting material (CNP-22) was more variable than observed 
in the hypothalamic extracts but was clearly identifiable in 6 of the 8 cases. 
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Figure 7.1 Size-exclusion HPLC profiles of CNP-immunoreactive fractions from hypothalamic tissue 
in saline-treated (left) and dexamethasone-treated (right) sheep. 
 
  
103 
 
Anterior pituitary tissue 
In all 6 HPLC profiles for anterior pituitary gland tissue, the major molecular form was CNP-53 
(Figure 7.2). Smaller peaks consistent with proCNP were also identified. In contrast, any products 
eluting in fractions 34-36 (CNP-22) were either very low in presence or undetectable. As noted in 
hypothalamic and posterior pituitary tissue (above), proCNP was consistently present and was 
increased following dexamethasone (p < 0.05). 
 
 
Figure 7.2 Size-exclusion HPLC profiles of CNP-immunoreactive fractions from anterior pituitary 
tissue extracts in saline-treated (left) and dexamethasone-treated (right) sheep. 
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CSF   
CNP-53 was the dominant molecular form observed in HPLC profiles for CSF (Figure 7.3) and 
constituted a broad based peak, suggesting the presence of slightly smaller immunoreactive 
fragments of the molecule. A small peak, presumably CNP-22, eluted in fractions 34-36 all 6 cases. 
In contrast to hypothalamic and posterior pituitary tissues, peaks consistent with proCNP in the 
CSF profiles were variable, very small and not affected by dexamethasone. Immunoreactive 
NTproCNP profiles (Supplemental Figure 7.3) contained a major and clearly defined peak 
consistent with the 5 kDa peptide NTproCNP in all 8 cases, together with a smaller, later eluting 
product of lower molecular weight. There was no evidence of proCNP in any of the NTproCNP 
profiles for CSF. 
 
Figure 7.3 Size-exclusion HPLC profiles of CNP-immunoreactive fractions from CSF extracts in saline-
treated (left) and dexamethasone-treated (right) sheep.   
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Plasma 
As in the case of CSF, a broad immunoreactive peak consistent with CNP-53 was evident in HPLC 
profiles from plasma – preceded by a large amount of higher molecular weight peptide in 
fractions 24-25 in all 6 sheep, consistent with the presence of proCNP in this fluid (Figure 7.4). In 3 
of the 6 cases (including both dexamethasone-treated sheep), the magnitude of the proCNP peak 
was similar to that of CNP-53. With the possible exception of profiles obtained after treatment 
with dexamethasone, CNP-22 was not identified in plasma. Immunoreactive NTproCNP HPLC 
profiles obtained from plasma are shown in Figure 7.5. The predominant peak eluting in fractions 
26-31 was consistent with the 5kDa peptide NTproCNP 1-50. Two other smaller peaks were 
present in all 6 cases — one eluting early (fractions 23-25 consistent with proCNP) and the other 
being an unidentified late eluting form (fractions 33-35).  
106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4 Size-exclusion HPLC profiles of CNP-immunoreactive fractions from plasma extracts in 
saline-treated (left) and dexamethasone-treated (right) sheep.  
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Figure 7.5 Size-exclusion HPLC profiles of NTproCNP-immunoreactive fractions from plasma 
extracts in saline-treated (left) and dexamethasone-treated (right) sheep. 
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Relative percentage abundance of CNP forms  
Table 7.1 lists the relative contributions of each of the 3 molecular forms to CNP 
immunoreactivity in tissue and fluids analysed in saline- and dexamethasone-treated animals. 
CNP-53 is the most abundant molecular form identified in all extracts. Notably CNP-22 is 
markedly lower in anterior pituitary gland and plasma, but higher in hypothalamus, posterior 
pituitary gland and CSF. ProCNP is proportionately increased after dexamethasone in 
hypothalamus, anterior and posterior pituitary tissues and possibly in plasma, whereas in CSF the 
proportion of proCNP is low and falls even lower after dexamethasone. 
 
Table 7.1 Percentage of CNP immunoreactivity attributed to different fragments in plasma, CSF, 
and tissue samples from sheep subject to size-exclusion HPLC, following dexamethasone 
or saline. 
Astericks (*) indicate a significant difference (p < 0.05) in the proportion of the fragment in the 
respective tissue, between saline- and dexamethasone-treated sheep. Data are presented as 
mean ± s.e. 
 
 
  ProCNP (1-103) CNP-53 CNP-22 n 
CSF Control 6 ± 2.1 72 ± 9.3 22 ± 11.4 3 
Dex 2 ± 0.8 92 ± 0.8 6 ± 0.8 3 
Plasma Control 20 ± 6.6 80 ± 6.6 0 ± 0.0 4 
Dex 37 ± 4.5 57 ± 3.0 6 ± 1.4 2 
Hypothalamus Control 17 ± 3.7 68 ± 2.3 15 ± 1.5 3 
Dex 31 ± 4.6 61 ± 4.9 8 ± 1.9* 3 
  Anterior 
pituitary 
Control 11 ± 2.0 84 ± 2.3 5 ± 0.3 3 
Dex 19 ± 1.7* 79 ± 1.9 2 ± 1.7 3 
Posterior 
pituitary 
Control 12 ± 0.7 71 ± 7.9 17 ± 8.5 4 
Dex 16 ± 3.5 69 ± 3.8 15 ± 6.8 4 
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7.5 Discussion 
Despite the increasing recognition of CNP’s role in CNS pathophysiology18, there are only limited 
reports of the precise molecular forms of CNP – either in selected tissues or in circulating fluids 
such as plasma and CSF. When molecular forms are reported, commonly only a single analysis is 
shown and to our knowledge no study has characterised the CNP forms in multiple tissues in the 
course of interventions that stimulate CNP production. Mindful of the differential processing of 
proCNP in brain and pituitary tissue15, we have taken advantage of a physiological setting where 
CNP secretion has been markedly stimulated over a short time frame (8 h), and show that the 3 
molecular forms in tissues reproducibly carry their signature profiles into their respective 
circulations within and outside the blood-brain barrier. As postulated, proportions of these 3 
molecular forms were similar in hypothalamus, posterior pituitary gland and CSF. Quite 
unexpectedly, profiles in anterior pituitary tissue closely simulated the profile in plasma and were 
distinguished by the virtual absence of CNP-22 and the presence of clearly defined peaks of the 
high molecular weight peptide, proCNP. 
 
Using SE-HPLC immunoassay techniques, most reports identify CNP-53 as the major component 
in tissue extracts6,8,14 with smaller but variable amounts of CNP-22. ProCNP has also been 
identified as a small component in some studies where a large amount of tissue has been 
extracted19,20. In sheep, we have previously identified small peaks of proCNP using SE-HPLC-RIA of 
CNP in whole pituitary extracts (unpublished) and in placenta21 both of which tissues have high 
CNP abundance. In contrast, neither rat nor fetal lamb tissue extracts contain detectable levels of 
proCNP when measured by SE-HPLC-RIA of NTproCNP22,23. These discrepancies are likely to be 
due to weight of tissue extracted, CNP enrichment and the relative sensitivity of the 
immunoassay employed. 
In the current study, although CNP-53 was the major molecular form, clearly defined peaks of 
proCNP were found in all studies — excepting in extracts of CSF. Notably proCNP — but not other 
forms — was proportionately increased by dexamethasone, compared with control (saline). 
These observations are consistent with a direct and prompt effect of dexamethasone 
upregulating NPPC expression in both hypothalamic and posterior pituitary gland tissues (paper in 
submission), and with delayed processing to smaller forms — although rapid degradation of lower 
molecular weight forms cannot be excluded. As previously reported in sheep hypothalamus15, 
CNP-22 was clearly defined as the late eluting peak in the present study. However the 
concentration ratio of CNP-22 to CNP-53 (1:5) differed from that reported previously15 (1:1). CNP-
22 was also identified in posterior pituitary tissue. It constituted a prominent peak in several of 
the profiles but was undetectable in 2 out of the 8 studies. Such variation could be related to 
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uneven distribution of CNP-22 along the length of the hypothalamo-hypophyseal stalk, which 
might also account for the lower relative abundance of CNP-22 in the hypothalamus if the plane 
of excision of this tissue was not uniform. In extracts of CSF, although CNP immunoreactivity was 
much lower than found in hypothalamic fractions, CSF SE-HPLC profiles were similar except for 
the very low content of proCNP which was also undetectable in assays using NTproCNP. 
Presumably proCNP, even when enriched by dexamethasone, is processed prior to exocytosis so 
little enters the extracellular space from either hypothalamic or posterior pituitary lobe tissue.  
 
This is the first report of CNP molecular forms in ovine CSF, profiles of which strongly resemble 
those reported in humans4. CNP-53 was the major component — contributing some 70-90 % of 
the total immunoreactivity although the broad and irregular late eluting material observed in 
some of the profiles is likely to represent smaller degraded immunoreactive products. CNP-22 
was identified in all 6 CSF profiles — and in one was a major peak — and was more conspicuous 
than seen in the single study of human CSF4. Profiles derived from assays of NTproCNP are almost 
identical in sheep and human in showing a predominant peak (fractions 26-32) consistent with 
the 5 kDa form (NTproCNP), and a much smaller but consistent, unidentified, peak eluting in 
fractions 33-35 which has been observed previously in sheep plasma24. 
 
Molecular forms of CNP in the anterior pituitary gland, and possible links with those in plasma 
were of special interest not least for the unusually high abundance of immunoreactive CNP in the 
anterior lobe6,7 but also the apparent lack of processing of CNP-53 to CNP-2215. We have recently 
confirmed the unusually high content of CNP in ovine anterior lobe tissue (paper in submission) 
which is some 15-fold greater than was found in hypothalamic tissue. Similar enrichment (10-fold) 
is reported in rat anterior pituitary tissues6. Here we confirm that CNP-53 is the predominant 
form. Smaller peaks of proCNP were also present in SE-HPLC profiles from the anterior pituitary 
gland, increasing after dexamethasone in all 3 cases – which aligns with the marked increase in 
NPPC expression in this tissue after dexamethasone (paper in submission). CNP-22 content of the 
anterior lobe profiles – in contrast to clearly defined peaks in profiles from hypothalamic tissue – 
was very low or absent but trended towards even lower relative abundance after 
dexamethasone. A similar trend was also noted for hypothalamic tissue. As previously reported 
(Supplemental Figure 6.2) the ratio of NTproCNP:CNP is much higher in the hypothalamus (5:1) 
compared with both the anterior and posterior pituitary glands (1:1) — consistent with higher 
degradation rates of CNP in the former tissue. Since we find no difference in NPRC expression in 
the two tissues (Figure 6.6), hydrolysis by neprilysin, prominently expressed in brain tissues25 may 
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account for these observations. However to our knowledge, neprilysin, which cleaves CNP-22 at 
multiple sites, does not affect generation of CNP-22 from CNP-53 or proCNP12. Clearly, further 
work is required to clarify the mechanism regulating CNP-22 production and its role in 
pathophysiology which would logically be pursued in hypothalamic tissues. 
 
Quite unexpectedly, profiles using SE-HPLC-RIA CNP assays of plasma show a virtual absence of 
CNP-22, yet major peaks of a high molecular weight form — consistent with the presence of 
proCNP — in all 6 samples. Smaller but clearly detectable peaks were visible in the same fractions 
using RIA NTproCNP assays. This co-location rules out the presence of proCNP 1-81 (a putative 
cleavage by-product of CNP-22 formation) since the antiserum in the CNP assay is solely directed 
to the C-terminal ring structure of proCNP. Differences in sensitivity of the two assays (lower for 
NTproCNP) presumably account for the differences in peak size of proCNP, and also may explain 
in part the absence of detectable proCNP in CSF using SE-HPLC-RIA for NTproCNP. Prominent 
peaks consistent with CNP-53 were evident in all 6 studies of plasma. Previous reports of CNP 
immunoreactive forms directed to the C-terminal ring in human plasma find only CNP-228,26. Low 
concentrations of bioactive CNP immunoreactivity in plasma in most species limits the ability to 
characterise molecular forms but when plasma concentrations are high, as in pregnant sheep27, 
both CNP-53 and CNP-22 were identified. On the other hand, as found in the present study, 
antisera directed to the N terminus of proCNP consistently detect a 5 kDa peptide which is likely 
to be proCNP 1-50 or closely related peptide. The smaller unidentified peak eluting in fractions 
33-35 — also found previously in sheep plasma27 and consistently found here in CSF — likely 
represents a degraded product of proCNP of molecular weight similar to CNP-22 but containing 
residues 1-15 of the prohormone. Taken together, our findings of proCNP and CNP-53 — but not 
CNP-22 — in ovine plasma strongly suggest that the very high abundance of both of these high 
molecular weight forms in the anterior pituitary gland is the likely source. Consistent with this is 
the relative increase in proCNP after dexamethasone in both anterior pituitary and plasma — 
linkages that are not observed in hypothalamic or CSF profiles.  
 
In further support of active secretion from anterior pituitary stores are our previous findings; 
where plasma concentrations of both CNP and NTproCNP increase markedly after 
dexamethasone, yet content of immunoreactive CNP in the anterior pituitary gland was 
unaffected — even when NPPC was clearly upregulated by dexamethasone (paper in submission). 
The absence of CNP-22 in plasma — a further signature of pituitary origin — suggests that 
processing from larger forms to CNP-22 does not occur in the systemic circulation at least in adult 
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sheep. Although rapid degradation of CNP-22 in blood cannot be excluded, this is unlikely to 
explain its absence as clearly detectable peaks of CNP-22 are observed in CSF, whereby CNP 
concentrations are typically only 3-fold higher than in plasma. It will be instructive to further 
define molecular forms in plasma and other tissues in other mammals in the light of these 
findings which have the potential to illuminate links between CNP production and sites of CNP-22 
generation in tissues and its concentration in the systemic circulation. 
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Supplementary material 
Supplementary Table 7.1 Mean (± s.e.) concentration of CNP and NTproCNP in tissues subject to 
size-exclusion HPLC from saline- and dexamethasone-treated sheep. 
 
 
  
Analyte Treatment 
Hypothalamus 
 
(pmol/g, 
n = 3/group) 
Posterior 
pituitary 
(pmol/g, 
n = 
4/group) 
Anterior 
pituitary 
(pmol/g, 
n = 4/group) 
CSF 
 
(pmol/L, n = 4/group, 
0 and 8 h , respectively) 
CNP 
Saline 3.24 ± 0.3 
21.49 ± 
6.3 
21.28 ± 0.7 2.23 ± 0.05, 2.93 ± 0.6 
Dexa 5.91 ± 1.0 
19.43 ± 
2.9 
30.97 ± 4.0 3.13 ± 0.6, 11.36 ± 3.6 
NTproCNP 
 
Saline 
 
2.55 ± 0.5 
27.13 ± 
7.8 
22.15 ± 1.5 849.23 ± 68, 976.08 ± 50  
Dexa 
 
50.11 ± 13.2 
26.62 ± 
5.1 
54.11 ± 8.8 888.7 ± 38, 1398 ± 33.8  
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Supplemental Figure 7.1 Size-exclusion HPLC profiles of ovine CNP-53 (fractions 27-29) and CNP-22 
(fractions 34-36) standards. 
Molecular weight markers are indicated by arrow heads; bovine serum albumin: V0, cytochrome 
C: 12 kDa, aprotinin: 6.5 kDa, tyrosine: 181 Da 
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Supplemental Figure 7.2 Size-exclusion HPLC profiles of CNP-immunoreactive fractions from 
posterior pituitary gland extracts in saline-treated (left) and dexamethasone-treated 
(right) sheep. 
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Supplemental Figure 7.3 Size-exclusion HPLC profiles of NTproCNP-immunoreactive fractions from 
CSF extracts in saline-treated (left) and dexamethasone-treated (right) sheep. 
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Chapter 8. Final discussion and future directions 
8.1 Major contributions of this thesis 
 
The findings of this thesis contribute significantly towards elucidating the abundance of CNP in 
the CNS, by relating changes in CSF concentrations of CNP peptides to their distribution, form and 
regulation in related tissues. In vivo studies such as those described in this thesis are necessary as 
they are an essential part of establishing fundamental aspects of physiology — particularly as CNP 
may be an invaluable therapeutic and/or diagnostic tool in certain settings of central 
pathophysiological disorders (Mahinrad et al. 2016). While numerous studies have mapped out 
sites of NPPC and NPRB expression in the CNS (Minamino et al. 1991, Yeung et al. 1996b, 
Moriyama et al. 2006), relatively little has been reported on sites and abundance of CNP peptides 
themselves. Advancing our knowledge about the regulation of CNP synthesis in vivo and 
identifying central sources of CNP in the brain is part of the crucial groundwork necessary to allow 
for the development of practical applications in future. 
 
The demonstration that markedly elevated concentrations of CNP and NTproCNP in the 
circulation — as occurs during ruminant pregnancy — do not result in increased levels in the CSF, 
is supportive of the hypothesis that central sources of CNP peptides exist (Chapter 4). This 
observation is in agreement with the single report by Schouten et al. (2011) describing concurrent 
levels of CNP peptides in human CSF and plasma, where concentrations were independent in the 
respective fluids. Prior to this study, there were no known physiological states or compounds 
capable of acutely altering concentrations of CNP peptides in CSF or nervous tissue. A method for 
cannulation of the cisterna magna was developed to facilitate repeated collection of CSF samples 
from conscious sheep (Chapter 3), following which a series of pilot studies were conducted in 
order to identify a compound or physiological state capable of altering CSF concentrations of CNP 
peptides (5.1.2). The consequences of the finding that CSF concentrations of CNP peptides 
concentration were not altered during or after anaesthesia were two-fold; firstly, it added to the 
growing body of evidence that CNP peptide concentrations in CSF are remarkably stable and 
presumably necessary for some aspect of brain homeostasis. Secondly, it established that 
anaesthesia was unlikely to be a confounding factor in studies where anaesthesia was necessary 
for obtaining single samples of CSF. 
 
Upon finding that a single intravenous dose of dexamethasone resulted in elevated 
concentrations of CNP peptides in CSF (and plasma), the change in concentration of CNP peptides 
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in response to different doses of dexamethasone was characterised in the respective fluids 
(Chapter 6) which indicated a dose-response relationship with dexamethasone and a differential 
response between CSF and plasma. Hypothesising that the increase in CSF concentration of CNP 
peptides was a result of increased peptide synthesis and release into extracellular fluid/CSF from 
one or more regions of brain tissue, CNP and NTproCNP concentration was measured in a wide 
selection of tissues sampled from brains of dexamethasone- and saline-treated sheep (Chapter 6). 
This revealed a widespread response to dexamethasone in central tissues. The demonstration 
that gene expression levels of NPPC increased in response to stimulation with dexamethasone 
suggests that increased peptide concentration is a result of increased synthesis of CNP peptides. 
Of the natriuretic peptide family, this effect was shown to be specific to CNP, as no response was 
shown for ANP or BNP in plasma, CSF and brain tissue. The measurement of the gene expression 
levels of NPRB and NPRC, which encode for the CNP receptor and clearance receptor, 
respectively, provided an insight into CNP signalling and clearance pathways in response to 
dexamethasone. Characterisation of different molecular size forms of CNP through size-exclusion 
HPLC revealed different profiles and proportions of the respective forms in CSF, plasma, brain 
tissue and anterior and posterior pituitary glands (Chapter 6). 
 
These studies establish multiple sources for CNP in the CNS.  The identification of dexamethasone 
as a secretagogue for CNP in the CNS implicates CNP as a potentially important mediator of 
glucocorticoid-mediated pathways. Together, these findings highlight a difference in the 
processing of proCNP among brain and anterior and posterior pituitary glands and portray the 
pituitary gland as a major peripheral source. The novel contributions of this thesis are outlined in 
Table 8.1. 
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Table 8.1 Summary of novel findings presented in this thesis. 
The demonstration that both CSF and plasma concentrations of CNP and NTproCNP 
remained stable throughout anaesthesia 
The finding that markedly elevated plasma concentrations of CNP and NTproCNP 
throughout gestation in sheep do not lead to increased concentrations in CSF  
Demonstration of independent regulation of peripheral and central levels of CNP and 
NTproCNP in pregnant sheep and red deer stags 
First report of a stimulus (dexamethasone) capable of acutely increasing CSF 
concentrations of CNP and NTproCNP  
The finding that concentrations of CNP and NTproCNP are increased in multiple brain 
tissues following dexamethasone administration 
The demonstration that the stimulating effect of dexamethasone on peptide synthesis is 
specific to CNP, as ANP and BNP concentrations were unchanged in plasma, CSF and brain 
tissue 
Demonstration of increased NPPC expression in brain tissues following dexamethasone, 
suggesting that increased peptide concentrations reflect increased synthesis 
The finding that the ratio of NTproCNP: CNP in the anterior and posterior pituitary gland 
(1:1) is markedly different from the ratio in brain tissues (5:1 to 10:1) 
Evidence from differing HPLC profiles suggesting that CNP processing differs between the 
anterior and posterior pituitary gland  
Identification of large irCNP fragments in plasma, consistent with proCNP (1-103) 
The finding that NPRC gene expression levels are similar between brain and both lobes of 
the pituitary gland— despite large differences in the NTproCNP:CNP ratio between the 
brain and pituitary gland  
 
 
8.2 Elucidating the role of CNP in the central nervous system: future studies 
The identification of dexamethasone as a stimulant of CNP synthesis is a crucial step towards 
elucidating the abundance of CNP peptides in the CNS. Now that a secretagogue for CNP peptides 
in brain tissue has been identified, dexamethasone can be used to facilitate studies designed to 
answer existing questions, as well as ones that arose from this study. 
 
8.2.1 Identification of sources of CNP in brain at the cellular level 
In order to determine the central role/s of CNP in vivo, the next key step will be to identify 
specific cell types which synthesise CNP following dexamethasone stimulation. A comparison of 
brain tissue from both dexamethasone- and saline-treated sheep using double-labelling 
immunohistochemistry techniques will be necessary to identify cells which show an increased 
presence of CNP and/or NTproCNP, whilst simultaneously confirming the cell type through the 
use of specific markers for neurons (e.g. neurotrace), subtypes of glial cells (e.g. glial fibrillary 
acidic protein, GFAP) and cerebral capillary endothelial cells (e.g. vascular endothelial growth 
factor, VEGF). 
 
122 
 
There are many possible candidates for the central source of CNP peptides, because NPPC 
expression and the CNP peptide have been measured in both neuronal and glial cells — as 
previously discussed. Had there been only one region in the CNS identified as being responsive to 
one of the well-characterised secretagogue candidates with known specific actions — such as l-
deprenyl — it may have been easier to narrow down the precise (presumably neural) pathways 
and mechanisms by which CNP secretion was stimulated. Given that glucocorticoids have many 
diverse effects on brain function, there is a large array of possible mechanisms that lead to the 
increase of CNP peptide concentration in brain tissue and CSF following dexamethasone 
administration to sheep. It has been estimated that glucocorticoids regulate between 10 and 100 
genes per cell (Hayashi et al. 2004). However, the finding that stimulation with dexamethasone 
increased the concentration of CNP and NTproCNP in multiple tissues sampled throughout the 
brain suggests that responding cells may be those that are common across the respective 
stimulated regions, e.g. pericytes, astrocytes, microglia or brain capillary endothelial cells.  
 
Originally it was thought that the only function of glial cells was to provide structural support for 
neurons. However, it is becoming increasingly clear that glial cells are involved in the regulation of 
a multitude of functions including fluid, ion, pH and transmitter homeostasis plus development 
and the processing of synaptic information (reviewed by Sofroniew & Vinters 2010). Some of 
these actions, including the regulation of cerebral blood flow, water balance and 
neuroinflammation are common to both NPs (Prado et al. 2010) and dexamethasone (Leenders et 
al. 1985, Tajima et al. 1990, Sorrells et al. 2009). The substantial presence of CNP in astrocytic 
endfeet of rat Müller cells — which are essentially retinal astrocytes which wrap around ganglion 
cells and their fibres and blood vessels (Newman & Reichenbach 1996) — suggests a role for CNP 
in glia-ganglion cell communication, and/or the regulation of blood flow in vessels/intraocular 
pressure (Cao et al. 2004). Also, CNP (but not ANP) is capable of stimulating cGMP accumulation 
in cultures of rat astrocyte cells (Kobayashi et al. 1993). 
 
Dexamethasone is known to alter cerebral blood flow in some settings, although the mechanism 
is unclear (Leenders et al. 1985). It is possible that CNP is secreted by astrocytes following 
stimulation by dexamethasone and acts to alter blood flow in cerebral vessels. NPRB transcripts 
are expressed in the human retina, providing evidence for a local NP system (Rollín et al. 2004), 
which is supported by Fernández-Durango et al. (1999) who demonstrated that CNP potently 
stimulated guanylate cyclase activity in ciliary process membranes, and decreased intraocular 
pressure in rabbits. It is plausible that CNP has a similar effect on glial cells that exist outside of 
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the retina. Of note, cell water content of glial cells is reduced following exposure to ANP by 
approximately 30 % (Latzkovits et al. 1993). 
 
It is also relevant to note that monocytes and macrophages are capable of secreting natriuretic 
peptides (Naruko et al. 1996). Whether microglia — which originate from monocyte precursors 
and constitute the brain immune cells (Ginhoux et al. 2013) — are sources of CNP in this setting is 
worth investigating. Although glucocorticoids are known for their anti-inflammatory properties, 
recent studies have shown that glucocorticoids can mediate pro-inflammatory effects in certain 
settings — particularly in the CNS (reviewed by Sorrells et al. 2009). This mostly occurs during 
chronic stress (Sorrells et al. 2009), however in the absence of injury, acute stress can activate 
inflammatory mediators in the CNS, for example increases in prostaglandin E2 in the rat cerebral 
cortex occur following psychological stress induced by immobilisation (Madrigal et al. 2003). 
Microglia can be ‘primed’ by glucocorticoids, such that the cells can undergo changes and become 
‘sensitised’ where although they do not immediately produce an inflammatory response, they 
produce exaggerated levels of inflammatory mediators when they are further stimulated (Frank 
et al. 2010). Using a murine restraint model of psychological stress and corticosterone 
administration, it has been shown that both glucocorticoids and stress are capable of activating 
microglia via the glucocorticoid receptor (GR), and these are blocked by GR antagonists (Nair & 
Bonneau 2006). It is relevant to note here that dexamethasone is a specific agonist of the GR, and 
its affinity for the GR is 6- to 10-fold greater than that of cortisol (Arriza et al. 1988, Spencer et al. 
1990). In contrast, the mineralocorticoid receptor (MR) has a high affinity for cortisol (Funder 
1997), and none for dexamethasone (Rebuffat et al. 2004). Frank et al. (2010) suggested that the 
GR may be the predominant mediator of corticosterone-induced sensitisation of pro-
inflammatory processes. Whether CNP contributes to the priming of microglia is now a key 
question. 
 
Identifying which cell type(s) in the CNS are stimulated to produce CNP following stimulation with 
dexamethasone may provide an insight into the actions of CNP downstream. As this is a key line 
of future investigation, some preliminary efforts were directed towards double-staining 
fluorescent immunohistochemistry, whereby sheep brain tissues were labelled using antibodies 
for CNP and NTproCNP, neurons (neurotrace) and glial cells (GFAP). This staining was inconclusive 
due to strong background staining and could not be pursued further because of time and 
resource constraints. Strong immunohistochemistal staining of tissues with DAB (3,3’-
Diaminobenzidine) showed some promise as some individual cells could be identified, however 
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the staining of even thin sections of wax-embedded tissue (3-5 µm) was too strong to 
discriminate between most cells, so this was also inconclusive. 
 
Furthermore, pinpointing the mechanism by which dexamethasone administration leads to 
increased concentrations of CNP peptides in brain tissues and in the CSF will be revealing. 
Although some rapid effects of glucocorticoids have been attributed to non-classical signalling via 
receptors located on the cell membrane of neuronal cells in specific regions (reviewed by Tasker 
et al. 2005), the upregulation of NPPC in brain tissue following dexamethasone implicates 
classical glucocorticoid receptor signalling in the central regulation of CNP synthesis — at least 
partially. Currently, it is unknown whether CNP synthesis is increased by direct upregulation of 
NPPC by dexamethasone, or whether this occurs indirectly, i.e. as a response to altered changes 
in fluid dynamics such as CSF pressure, volume, or shear stress. To remove the latter influences, 
dexamethasone-induced CNP secretion should be measured in vitro in cultures of various cell 
types. This would also allow studies of steroid specificity, modulators and the effect of alterations 
in related receptor levels.  
 
8.2.2 The effect of changes in physical fluid dynamics 
Considering that dexamethasone can alter physical factors of fluids in certain settings — i.e. 
intracranial pressure and cerebral blood flow (Behrens et al. 1998, Rohde et al. 2015), and is 
routinely used to decrease intracranial pressure in patients with brain tumours (Rangel-Castillo et 
al. 2008 — it would be useful to determine the effect of changes in these properties on CSF 
concentrations of CNP peptides, and vice versa, via central administration of CNP. In vitro studies 
reveal opposing effects of CNP and dexamethasone on the expression of water channel 
aquaporin-4 (AQP4), which supports the possibility that CNP may act to counterbalance some 
actions of dexamethasone; AQP4 expression is upregulated by CNP in cultured astrocytes 
(Miyajima et al. 2004) and downregulated by dexamethasone in the perihematomal area of rats 
with intracerebral haemorrhage (Gu et al. 2007). 
 
Although such studies would be valuable, they would be expensive due to the large amount of 
peptide needed to substantially alter CSF concentrations in sheep, and the technology required — 
such as functional magnetic resonance imaging. For these studies, it would be advantageous to 
identify a compound capable of suppressing secretion of CNP in brain tissue, and/or inhibiting its 
action, so that the effect of a decrease in CNP peptide concentration or activity on these physical 
aspects could also be studied. 
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When investigating the influence of CNP on cerebral blood flow, it will be necessary to bear in 
mind previous ovine studies which support a role for CNP in fetal-maternal signalling and effects 
on blood vessel delivery of nutrients to the fetus. In parallel to the observation that central and 
peripheral concentrations of CNP peptides are independently regulated, it has been shown that 
fetal and maternal plasma concentrations of CNP peptides are also independently regulated in 
sheep (Prickett et al. 2007). Trophoblast binucleate cells, which are unique to ruminants and 
facilitate the transport of fetal products into the maternal circulation, have been identified as an 
important site of CNP production (McNeill et al. 2011). This and other evidence implicates CNP as 
an important fetal-maternal signal that serves to favour fetal growth. Maternal circulating 
concentrations of CNP peptides are increased following nutrient restriction in early (Madhavan et 
al. 2015) and late gestation (Prickett et al. 2007), and are positively correlated with fetal number, 
which can also be seen as a form of caloric restriction (McNeill et al. 2009). Whether there are 
parallel roles for CNP in meeting the metabolic demands of neural tissue and the fetus by 
affecting blood supply in the brain and placenta, respectively, remains to be seen. 
 
8.2.3 Sources and function of CNP in the pituitary gland 
The novel finding that the concentration ratio of NTproCNP:CNP differs markedly in both the 
anterior and posterior pituitary gland (both 1:1) compared with other brain regions (5:1 to 10:1) 
is of significance for several reasons. Firstly, it highlights the importance of measuring NTproCNP 
in studies involving CNP. Prior to this finding, it was widely accepted that the highest 
concentrations of CNP in any tissue existed in the pituitary gland, following reports that 
concentrations of CNP in the anterior and posterior pituitary gland of rats exceeded those in the 
brain by approximately 13- and 3-fold, respectively (Komatsu et al. 1991). However, the data 
provided in Chapter 6 indicate that although CNP concentration is higher in the anterior and 
posterior pituitary gland than in most brain tissues sampled, this difference is minimal when 
NTproCNP concentration — which is a better indicator of CNP secretion due the short half-life of 
CNP (Hunt et al. 1994, Prickett et al. 2001) — is compared. The difference in concentration ratio 
of NTproCNP:CNP between the brain tissues sampled and pituitary gland tissue indicates that 
relatively very little clearance of CNP occurs in the pituitary gland of healthy normal individuals. 
This results in an apparent abundance of the peptide in the pituitary — relative to brain tissue — 
which may lead to the incorrect assumption that this is a result of pituitary gland having a 
markedly higher level of secretion than the brain.  
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Given that CNP concentrations in the peripheral circulation are reported to be close to assay 
detection limits (Hama et al. 1994) in most species, it was assumed that the relatively high 
abundance of CNP in the pituitary gland solely reflected a paracrine/autocrine role for the 
peptide. Other studies have since provided evidence to support this including; a) CNP potently 
stimulates cGMP accumulation in pituitary cell lines, including somatotrophs, gonadotrophs 
(reviewed by Fowkes & McArdle 2000), b) NPRB is expressed in normal human adult and fetal 
pituitary cells, and the identification of NPR-B protein and related mRNA expression in human 
pituitary adenomas regardless of the cellular origin of the tumour (Thompson et al. 2012), c) the 
visualisation of NPR-B receptors in the anterior and posterior pituitary gland as well as in the pars 
intermedia (Konrad et al. 1992), d) CNP inhibits LH secretion in rats when centrally administered 
(Huang et al. 1993). However, there are several findings described in Chapter 6 and Chapter 7 
which support the possibility of an endocrine role for CNP — in addition to these paracrine 
actions.  Firstly, the finding that expression of NPPC is increased in both the anterior and posterior 
pituitary glands following stimulation with dexamethasone — despite no significant change in 
peptide content — suggests that CNP is synthesised in the pituitary gland and released into the 
circulation. Furthermore, the high degree of similarity between HPLC profiles of CNP 
immunoreactive forms in the anterior pituitary gland and in plasma — both containing a high 
proportion of proCNP (1-103), CNP-53, and minimal CNP-22 — provide further support for the 
anterior pituitary gland as a major source of “CNP” in the circulation; including after stimulation 
with dexamethasone. It is apparent that little degradation of CNP occurs in the pituitary gland, as 
indicated by the 1:1 NTproCNP:CNP concentration ratio, which is indicative of accumulation and 
storage for future release into the circulation — possibly stimulated at times of high stress. Taken 
together, these points indicate that it is likely that targets of CNP are both local and distant. 
 
Addressing the question of whether the release of CNP from other peripheral sources (for 
example muscle, liver or adipose tissues) is increased in response to dexamethasone — and to 
what degree — may provide insight into the significance of the contribution of the pituitary gland 
to the peripheral circulation. More specifically, obtaining samples of blood from the inferior 
petrosal sinus for measurement of CNP peptide concentration would also be valuable in 
determining the pituitary gland contributions to circulating levels of CNP under normal and 
dexamethasone-stimulated conditions. It is unknown why both the anterior and posterior 
pituitary glands — two tissues of very different origin, histology and function — possess high 
concentrations of CNP peptides. However given the ubiquitous nature of CNP, roles may differ 
between the endocrine aspect of the pituitary gland, and the glial-cell containing posterior 
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pituitary gland (Hatton 1988). Characterising the type of CNP-positive cells in both the anterior 
and posterior pituitary glands of sheep is a key step necessary for identifying the physiological 
relevance of CNP in the pituitary gland. McArdle et al. (1994) identified the majority of CNP-
positive cells in the rat pituitary to be gonadotropes and found no CNP-positive cells in the 
posterior pituitary gland — or in heart tissue. Although McArdle et al. (1994) and other earlier 
reports (Komatsu et al. 1991, Minamino et al. 1993) failed to detect CNP in heart tissue, or 
attributed its cross reactivity with ANP (Minamino et al. 1991), later studies have in fact identified 
CNP transcripts in rat atria and ventricles (reviewed by Nishikimi et al. 2006). In light of the recent 
findings of this thesis, closer examination of CNP peptides using immunohistochemical staining 
and in situ hybridisation in both anterior and posterior pituitary glands is warranted. NTproCNP 
antibodies should also be considered in these studies. 
 
8.3 Limitations 
Although the studies that comprise the research chapters of this thesis contributed significant 
novel findings regarding CNP in the CNS, there are limitations — some of which were inherent to 
the methods used here. 
Whilst the series of pilot studies described in 5.1.2 were successful in identifying a secretagogue 
for CNP in the CNS, they were by no means an exhaustive study designed to exclude the 
compounds previously described and the aim was to identify a potential candidate that could be 
examined more closely subsequent studies. Therefore, in the interest of time, cost and reduction 
of animal manipulations, study sizes were small (n = 4-6), and in some cases there were no 
secondary measures that could confirm the efficacy of the compound in question, e.g. l-deprenyl. 
In 5.2, ovine NTproCNP standards had to be used for the study of CNP in red deer stags, because 
the amino acid sequence of deer NTproCNP has not been characterised. However, a 5 kDa 
NTproCNP-immunoreactive product has been identified in deer plasma, which eluted where 
NTproCNP was expected to (Prickett et al. 2003). Overall, the separate temporal pattern and 
marked difference in CNP peptide concentrations between CSF and plasma that were recorded 
from the deer stags have provided relevant information to these studies. 
 
Profiles of CNP- and NTproCNP-immunoreactive fractions eluted by SE-HPLC suffered from poor 
resolution between peaks, in particular in CNP profiles of plasma and CSF, presumably where 
more peptide degradation had occurred — compared with profiles from tissue extracts. This is 
presumably due to the actions of C- and N-terminally directed exopeptidases in extracellular 
fluids. However, despite these limitations and the inherent time-consuming and laborious nature 
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of size-exclusion HPLC-RIA, multiple profiles were obtained (n = 2-4) and the results were highly 
reproducible — as demonstrated by one sample which was subject to two SE-HPLC runs and two 
separate CNP assays carried out in different weeks (see Appendix).  
 
It is relevant to note that the current understanding of the processing and release of proCNP can 
now be challenged, following the surprising finding that the large molecular weight form — 
presumably proCNP (1-103) is present in ovine plasma (Chapter 7). Very few previous reports 
have exposed plasma extracts to analysis by size-exclusion HPLC-RIA, largely due to the low 
concentration of CNP in plasma and consequently, the large amount of plasma required to 
generate HPLC data. The use of gel-permeation chromatography was used to identify the 
presence of CNP-22 in human plasma (Stingo et al. 1992), which contrasts to the virtual absence 
of CNP-22 in ovine plasma extracts reported in this thesis. Small amounts of CNP-22 were 
detected in plasma extracts containing higher concentrations of CNP (from dexamethasone-
treated sheep). This latter finding may reflect release from the anterior pituitary and/or minimal 
conversion from CNP-53 to CNP-22, or some level of sample degradation following collection. 
Determining how CNP-22 is generated may shed light here in the future. 
 
The studies described in Chapter 6 which examined the effect of dexamethasone administration 
to sheep on CNP peptide concentration in a selection of brain and pituitary gland tissues were not 
designed to identify either the mechanism behind dexamethasone-stimulated secretion or the 
regulation of specific CNS functions by CNP. Also, it is necessary to be cautious when 
extrapolating studies involving glucocorticoids, given that the down-stream effects vary widely 
depending on the dose, duration and target cell. For example, whereas repeat administration of 
dexamethasone reduces circulating concentrations of CNP peptides for several days in growing 
lambs (Prickett et al. 2009), these studies reveal that CNP concentration is acutely increased 
following a single dose. The effect of sustained dexamethasone administration on central levels of 
CNP remains unknown and will be necessary to resolve, in order to determine the relevance of 
CNP in settings of chronic stress and sustained exposure to high levels of glucocorticoids. In this 
context it will also be important to study the effects of cortisol and other glucocorticoids on CNP 
peptides in the CNS — although it is possible that other glucocorticoids stimulate CNP synthesis, 
this cannot be assumed. As circulating concentrations of cortisol exceed those of aldosterone by 
100-fold (free) to 1000-fold (bound), and the affinity of corticosteroids for the MR is 10-fold that 
of the GR (ter Heegde et al. 2015), most MR are occupied by glucocorticoids under non-stressful 
conditions — and it is during stress that GRs are activated by cortisol, when MR are saturated 
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(Gomez-Sanchez & Gomez-Sanchez 2014). As dexamethasone only binds to the GR, and has no 
affinity for the MR, it is likely that the action of dexamethasone on CNP synthesis reflects stressful 
conditions. Therefore, it may be worthwhile to consider basal levels of cortisol when studying 
dexamethasone actions on CNP, as high stress levels may lead to a higher GR occupancy, and less 
availability for binding with dexamethasone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.4 Conceptual model 
Conceptual model displaying the possible contribution of CNP from central and peripheral tissues to the blood, transfer of CNP between CSF and the 
circulation, and its potential mechanisms in the brain.  
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8.5 Implications 
The discovery of dexamethasone as a potent secretagogue in the CNS paves the way for many 
other future studies which should be aimed at identifying functions in the CNS regulated by CNP 
under normal physiological conditions, as well as under times of high stress and in 
neuropathological diseases. Furthermore, more questions have been raised that are particularly 
important to resolve given the high amount of glucocorticoid use, the known detrimental effects 
of chronic glucocorticoid exposure on brain function (including learning and memory; Conrad 
2010) which may be implicated with CNP (Telegdy et al. 1999), and the untapped potential of CNP 
as a diagnostic and/or therapeutic target for cognitive impairment pathophysiological disorders of 
the CNS. Dexamethasone can be used as a ‘tool’ to answer these new fundamental questions 
which include: Which cell type(s) secretes CNP in response to dexamethasone stimulation? Which 
signalling pathways lead to dexamethasone-induced CNP secretion in the brain? Can the 
dexamethasone-induced increase in CNP concentration be blocked? What are the downstream 
effects of such widespread increases in CNP secretion in the brain? The ultimate purpose for 
answering these questions is to determine whether there are neuropathological states that this is 
relevant to, and to establish how these new findings can be applied in clinical settings. 
 
These studies established CNP as a peptide derived from central sources, whereby concentrations 
are independent of those in the peripheral circulation and are remarkably stable in the face of 
changes in neuronal activity, consistent with a role for CNP in maintaining some essential, 
constitutive, aspect of normal brain health. The involvement of CNP in different forms of 
neurodegeneration such as in Alzheimer’s disease, Parkinson’s disease and multiple sclerosis 
deserves consideration, given that CNP has vasoactive effects on cerebral arterioles (Mori et al. 
1997), neuroprotective properties in vitro (Ma et al. 2010) and potentially in vivo (Espiner et al. 
2014), and the realisation that cerebrovascular dysfunction may precede cognitive decline and 
onset of neurodegenerative changes (Bell & Zlokovic 2009). It has been recognised that normal 
brain functioning requires communication between cells of the neurovascular unit — which 
involves all of the major cellular components of the brain including neurons, astrocytes, brain 
endothelium, pericytes, vascular smooth muscle cells, microglia and perivascular macrophages 
(Bell & Zlokovic 2009). Therefore, understanding how CNP sends signals within and between 
these cells will likely help us to understand mechanisms behind the onset and progression of 
neurodegeneration.  
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The possibility that changes in intracellular concentrations of Ca2+ in astrocytes constitutes an 
extraneuronal signalling system in the CNS has been a focus of research over recent years 
(reviewed by Bazargani & Attwell 2016). It is now recognised that Ca2+ transients exist with 
varying spatial and temporal patterns that differ between the cell soma and cell processes, but 
how these transients are communicated from a cell process across to the endfeet is unknown, as 
is the mechanism by which these transients are decoded and translated into functional effects 
(Bazargani & Attwell 2016). Investigating a role for CNP in this (and other) signalling system/s is 
certainly justified, particularly as cGMP is able to induce branching and elongation of astrocyte 
processes by redistributing GFAP filaments and depolymerising actin (Borán & García 2007). 
 
Findings arising from this thesis open up many avenues of study that have the potential to resolve 
not only questions surrounding the presence of CNP in the CNS, but the mechanism of action of 
many other functions in the CNS. The identification of dexamethasone as a secretagogue for CNP 
highlights the complex nature of the action of glucocorticoids, whereby effects depend on the 
dose, concentration and cellular target. Although there are many possible mechanisms for this 
glucocorticoid-induced increase in CNP secretion, many are testable and identifying the cell 
type(s) where CNP secretion is increased following dexamethasone stimulation is the most urgent 
next step that will certainly influence the direction of further investigation.  
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Appendix 
 
 
Size-exclusion HPLC profiles of CNP-immunoreactive fractions from one posterior pituitary extract 
of one dexamethasone-treated sheep. The extract was subject to two size-exclusion HPLC runs 
and two separate CNP assays carried out in different weeks. 
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A standard curve (human NTproCNP) and dilution curves of normal adult human plasma, pooled 
children (aged 5-18) plasma, pooled plasma from patients with heart failure and one sheep 
pituitary extract. Due to the slight divergence from parallelism of samples from sheep, (compared 
with human samples), ovine standards were introduced for the work produced in this thesis.  
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